Professor Phil Hansbro

Professor Phil Hansbro

Conjoint Professor

School of Biomedical Sciences and Pharmacy (Immunology and Microbiology)

Understanding respiratory disease to help us breathe easier

Professor Phil Hansbro is an internationally recognised researcher exploring the hallmark features of respiratory disease with an aim to improve global wellbeing.

Professor Phil Hansbro

Phil’s plan of attack on the diseases of our airways is quite simple – understand their pathogenesis to identify new avenues of therapy. His approach is recognised internationally as a valuable, ongoing contribution to the field, affording researchers the opportunity to dissect and study the intricate architecture of multiple chronic inflammation disorders.

As Deputy Director of the Priority Research Centre for Healthy Lungs, Phil leads a research team of around 30 researchers who are working to understand COPD/emphysema, asthma, infection and lung cancer. Using the integration of molecular biology theory and practice, Phil and his team use experimental models to explore respiratory disease and infection from several cellular angles.

A leader in the field, Phil has developed four ‘world first’ mouse models of COPD, asthma, infection and lung cancer, which have substantially furthered our understanding of these diseases. With particular emphasis on immunity, physiology and lung function analysis, their simulations of key pathogenic events excite those both in and out of the laboratory. “Our research outcomes have a translational goal,” Phil explains. “We need to first understand the pathogenesis in order to develop new therapies for these diseases.”

Based at the Hunter Medical Research Institute (HMRI), Phil employs both short-term and long-term studies in his research. “We’re focused on identifying potential treatments for severe asthma, chronic obstructive pulmonary disease (COPD), also known as emphysema, and lung cancer,” he says. “Existing treatments only partially suppress exacerbations and some don’t work at all.”

“People with existing conditions are more susceptible to respiratory infections too, so we need to work out why this is and find ways to manage them – or better yet – prevent this co-morbidity altogether.”

Dynamic networks

Taking a ‘very roundabout route’ to get to this point, Phil began his research career in organic chemistry. The English native completed a PhD in the discipline at the University of Leeds in the early 90s, principally using it to investigate intracellular signalling pathways relevant to cancer. “This involved isolating enzymes and using them to make compounds to produce biomembranes that release molecules, which when over-produced, are important in cancer,” he says.

Phil then headed across the ocean to Australia to undertake post-doctoral studies into protein biochemistry.  Also involving elements of microbiology and molecular biology, this endeavour inspired a widening of research fields and goals.

“This allowed us to explore the functions of these and other enzymes and molecules involved in muscle disease and respiration in some depth,” he states.

After these studies he moved back to England, taking up residency at the University of Cambridge in 1997 to design and test new vaccines against infection with the bacteria Streptococcus pneumoniae. The three-year appointment proved to be a mix of new and old for Phil, piquing his scientific curiosity in airway inflammation while also enabling him to continue using a range of microbiological and molecular techniques.

Streptococcus pneumoniae is a major respiratory pathogen,” he reveals. “It is the commonest cause of pneumonia and is also an important inducer of meningitis, blood and ear infections.”

Phil continued exploring the pathogenic bacterium after being recruited to the University of Newcastle, Australia, in the late 90s, impressively identifying several factors that protect against asthma. Developing them into therapeutic strategies over 15 years, Phil is currently leading clinical trials with promising results.

Gut reaction

In a simultaneous attempt to produce novel treatments for other respiratory diseases, Phil is conducting an extensive series of studies of the lower respiratory tract investigating the role of inflammatory features and immune cells involved in the disease and is hoping his studies will help firm up understanding of the pathogenesis of COPD.

“In some experiments we’re trying to determine the bacterial changes that occur in the lung and gut during the development of COPD,” he says. “So far we’ve found that smoking can alter the bacteria that make up the microbiome in the gut. It also might be possible to ‘drown out’ emphysema-related bacteria using faecal transplants.”

Comically labelled ‘transpoosion,’ the unsavoury science involves taking healthy faeces and putting them in the guts of those with COPD. It’s no laughing matter though as this ‘repoopulation’ remedy may treat the symptoms of the disorder and/or protect against its development.

“We’re in the process of studying bacteria that may be involved and discovering exactly what they do and what they are,” Phil adds. “The idea is that we’ll eventually be able to develop new antibiotics or other therapies against them.”

Damage control

A master of many disciplines, Phil is concurrently running an experimental trial of epigenetic inhibitors. Acknowledging the increased production of inflammatory genes when people are overexposed to smoke and air pollution, the esteemed educator and investigator is looking to find ways to prevent harmful DNA modifications from occurring.

“Nicotine-induced acetylation causes DNA to unravel, which means it opens up more and allows enzymes to generate greater amounts of these genes,” he explains. “We’re looking at ways of stopping this in animal modelling. Then we can try to work out precisely how the inhibitors suppress disease.”

Exploring the possibilities of therapeutic gene silencing inherent in another form of epigenetics, Phil is also in the middle of specifying the function of microRNAs. Once thought to be junk byproducts of RNA, these small pieces are now widely thought to serve as on/off switches for inflammation.

“Some of them potentially target and destroy anti-inflammatory factors,” he claims.

“Knowing exactly how and why they’re implicated in respiratory disease will help us to develop effective inhibitors.”

With oxidative stress from smoking similarly linked to pro-inflammatory environments, Phil is undertaking a research project on cellular respiration as well. “We need to work out how mitochondria become altered to produce it,” he says. “Then we can develop inhibitors.”

Two diseases, one knockout blow

Other new therapeutic targets for COPD are being imagined using a system of elimination, with Phil and his team ‘knocking out’ a number of genes in mast cells to infer probable function and identify novel roles. Their current research implicates mast cells as pathological mediators of several inflammatory conditions.

“Our recent studies show knocking out two different genes decreases the rate COPD,” he says. “This tells us how important they are in the disorder.”

The next phase

Set to translate this research into practice, Phil is looking forward to applying his therapies to improve health. “Proving their effectiveness takes a long time,” he admits.

“Once we’re sure, we can start exposing our own respiratory cells to allergens or cigarette smoke and using the treatments to suppress elevated inflammatory responses.”

With 29 HDR students under his supervision, and leading a team of young researchers, Phil is looking forward to celebrating the achievements of his young collaborators at UON and HMRI. “We really believe in our students and early career researchers,” he says. “They’re the next generation of scientists.”

Related links

Professor Phil Hansbro

Understanding respiratory disease to help us breathe easier

Professor Phil Hansbro is an internationally recognised researcher exploring the features of respiratory disease with an aim to improve global wellbeing

Read more

Career Summary

Biography

Professor Phil Hansbro is an internationally recognised research leader in the study of respiratory diseases, such as asthma, chronic obstructive airway disease (COPD, aka emphysema) and infections and is developing interests in lung cancer. His work is substantially contributing to understanding the pathogenesis and developing new therapies for these diseases. Indeed his work has made internationally important contributions and led to the identification of novel avenues for therapy that are under further study. This is achieved through the development of novel mouse models that recapitulate the hallmark features of human disease, including infections, asthma and COPD and now lung cancer. He employs these models in integrated approaches (infection, immunity & physiology with particular expertise in lung function analysis) to understand human diseases, and develop new treatment strategies. Research outcomes have a translational goal and his studies are conducted in parallel with collaborative human studies with clinical researchers. Major achievements:

1. Identified that the age, timing and nature of infection is critical in determining effects on asthma.

2. Determined that Chlamydia infection induces severe asthma in early life and adults.

3. Showed that combination of Haemophilus influenzae or Chlamydia respiratory infection and asthma drives a severe steroid-resistant asthma phenotype and chronic infection in adults.

4. Showed that Streptococcus pneumoniae exposure is protective against asthma.

5. Identified potential novel asthma therapeutic strategies that either target or utilise bacteria.

6. Created a short-term mouse model of COPD with the hallmark features of the human disease.

7. Identified novel roles for mast cell tryptases in experimental COPD.

8. Demonstrated critical roles for constitutive IFN responses and viral proteins in influenza.

9. Discovered that a new interferon, IFNε, protects against Chlamydia reproductive tract infection.

10. Developed a novel model of lung cancer that is induced by cigarette smoke.

11. He is also an expert in the study of avian influenza viruses (AIVs) in wild birds and to date his group has collected over 240,000 samples and identified ~250 AIVs.

His group has been recognized by the award of numerous nationally competitive grants, particularly from the NHMRC. Since 2004 he has published ~100 peer reviewed journal articles, with an average impact factor of 5+. These include publications in the leading general (Science [IF=31], Nature Immunology [IF=26]), respiratory (Am J Respir Crit Care Med [IF=12]), allergy (J Allergy Clin Immunol [IF=11]), infection (PLoS Pathog [IF=9]) and immunology journals (J Immunol [IF=6]). He is frequently invited to write reviews in prestigious journals (Pharmacol Ther [IF=8.0], Am J Respir Cell Mol Biol [IF=4.5], Immunology [IF=3.4]), which make substantial contributions to the fields. He is a regular reviewer for national granting bodies and leading international journals.

Prof Hansbro has a high level record of achievement & performance as a research leader recognised by high level appointments (Deputy director of the Centre for Asthma & Respiratory Disease (CARD) & the CRC for Asthma & Airways [CRCAA, UoN 2005-12], Head, Discipline of Immunology & Microbiology [2007-11], joint leader of Infection & Immunity Research Cluster, Director of School Research Committee). These Centres & Groups are internationally recognised for contributions to respiratory & infectious diseases. With Profs P. Foster & P. Gibson has built an internationally recognised, world leading research program with a reputation for excellence in respiratory research; CARD, with state-of-the-art facilities for the study of infection, immunity, histology, respiratory physiology & function.

Research Expertise
Expertise in the inevstigation of the relationship between bacterial and viral infections and obstructive airway diseases such as asthma and COPD. Expertise in the collection and analysis of avian influenza viruses from wild birds.

Teaching Expertise
Extensive undergraduate and postgraduate teaching experience into a wide variety of courses using teh full range of educational tools. Particular expertise in teaching Biomedical Sciences, Medicine, Nursing.

Administrative Expertise
Extensive expertise and experience in University administration and governance. head of Discipline of Immunology & Microbiology, Deputy Head of School of bIomedical Sciences Research Committee and various teaching administration bodies.



Qualifications

  • PhD, University of Leeds - UK
  • Bachelor of Science (Honours), Hallamshire University

Keywords

  • Allergy
  • Asthma
  • Avian influenza
  • Bacteriology
  • COPD
  • Epigenetics
  • Immunology
  • Infectious diseases
  • Inflammasome
  • Inflammation
  • Lung cancer
  • Microbiology
  • Microbiome
  • Reproductive tract diseases
  • Respiratory diseases
  • Virology

Fields of Research

Code Description Percentage
110799 Immunology not elsewhere classified 75
110299 Cardiorespiratory Medicine and Haematology not elsewhere classified 25

Professional Experience

Academic appointment

Dates Title Organisation / Department
Head - Discipline of Immunology & Microbiology University of Newcastle
Australia
Co-director Infection and Immunity Research Cluster University of Newcastle
School of Biomedical Sciences
Australia
Deputy Program Leader - Priority Research Centre for Asthma and Airways, UNEW University of Newcastle
Australia
1/07/2011 -  Professor University of Newcastle
Immunology & Microbiology
Australia
1/07/2007 - 1/06/2011 Associate Professor University of Newcastle
Immunology & Microbiology
Australia
1/01/2007 -  Head of Discipline of Immunology & Microbiology University of Newcastle
Australia
1/01/2005 - 1/06/2007 Senior Lecturer University of Newcastle
Immunology & Microbiology
Australia
1/01/2005 - 31/12/2007 Organiser and Convenor - Newcastle Asthma Meeting University of Newcastle
Australia
1/10/1999 - 1/12/2004 Lecturer University of Newcastle
Immunology & Microbiology
Australia
1/10/1999 -  Group leader Microbiology Research Group University of Newcastle
Australia
1/10/1999 - 1/12/2004 Lecturer in Microbiology University of Newcastle
Australia

Membership

Dates Title Organisation / Department
Membership - School of Biomedical Sciences Executive University of Newcastle
Australia
Member - Organising Committee of the International Symposium on Pneumococci and Pneumococcal Diseases Organising Committee of the International Symposium on Pneumococci and Pneumococcal Diseases
Australia
Invited Academic Member - Nuways Committee for Streamlining Research Processes University of Newcastle
Deputy Head School of Biomedical Sciences Research Committee
Australia
External Member - Mater Hospital Grant Review Panel Mater Hospital Grant Review Panel
Australia
Member - National Avian Influenza Stearing Committee National Avian Influenza Stearing Committee
Australia
Member - NHMRC Grant Review Panel (GRP2e inflammation) NHMRC Grant Review Panel
Australia
Associate Director - Priority Research Centre for Asthma and Airways, UNEW University of Newcastle
Australia
Representative of UNEW and HMRI nodes - CRC for Asthma and Airways Education Committee CRC for Asthma and Airways
Australia

Awards

Research Award

Year Award
2005 Brawn fellowship
University of Newcastle
2002 Leo Dintenfass Award
Rebecca L Cooper Medical Research Foundation Ltd

Invitations

External Reviewer - Programs

Year Title / Rationale
2006 research grants review panel
Organisation: Mater Hospital Description: research leader

Participant

Year Title / Rationale
2007 CRC for asthma and airways
Organisation: CRC for asthma and airways Description: Contribution to asthma research
2006 Influenza symposium
Organisation: Influenza symposium Description: Ledaer in bird flu research
2006 National avian influenza conference
Organisation: National avian influenza conference Description: Leader in influenza research
2006 Various including Asthma Think tank and a variety of other invited talks at departments and conferences
Organisation: Many Description: Resaerch leader in asthma
2006 CRC for asthma and airways
Organisation: CRC for asthma and airways Description: Contribution to asthma research
2005 CRC for asthma and airways
Organisation: CRC for asthma and airways Description: Contribution to asthma research
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Chapter (4 outputs)

Year Citation Altmetrics Link
2018 Awasthi R, Singh AK, Mishra G, Maurya A, Chellappan DK, Gupta G, et al., 'An Overview of Circular RNAs.', 3-14 (2018)
DOI 10.1007/978-981-13-1426-1_1
2014 Hsu A, Zhong H, Hansbro P, Wark P, 'Innate Immunity in the Airways to Respiratory Viruses', Virology II - Advanced Issues, iConcept Press, Hong Kong 1-32 (2014) [B1]
Co-authors Alan Hsu, Peter Wark
2014 Hsu A, Loo S, Fathi Aghdam F, Parsons K, Hansbro P, Wark P, 'Airway Epithelial and Early Innate Immune Responses to Virus Infections', Human Respiratory Viral Infections, CRC Press, Boca Raton, FL 29-44 (2014) [B1]
DOI 10.1201/b16778-5
Co-authors Peter Wark, Alan Hsu
2010 Hansbro PM, 'Migratory birds at Hunter Valley Gardens', Beautiful Birds: From Hunter Valley Gardens, Panographs Publishing, Wamberal, NSW 47 (2010) [B2]
Show 1 more chapter

Journal article (229 outputs)

Year Citation Altmetrics Link
2019 Ng SW, Chan Y, Chellappan DK, Madheswaran T, Zeeshan F, Chan YL, et al., 'Molecular modulators of celastrol as the keystones for its diverse pharmacological activities', Biomedicine and Pharmacotherapy, 109 1785-1792 (2019)

© 2018 The Authors In the recent years, much attention has been focused on identifying bioactive compounds from medicinal plants that could be employed in therapeutics, which is a... [more]

© 2018 The Authors In the recent years, much attention has been focused on identifying bioactive compounds from medicinal plants that could be employed in therapeutics, which is attributed to their potent pharmacological actions and better toxicological profile. One such example that has come into the light with considerable interest is the pentacyclic triterpenoid, celastrol, which has been found to provide substantial therapeutic properties in a variety of diseases. In an effort to further accelerate its potential to be utilized in clinical practice in the future; along with advancing technologies in the field of drug discovery and development, different researchers have been investigating on the various mechanisms and immunological targets of celastrol that underlie its broad spectrum of pharmacological properties. In this review, we have collated the various research findings related to the molecular modulators responsible for different pharmacological activities shown by celastrol. Our review will be of interest to the herbal, biological, molecular scientist and by providing a quick snapshot about celastrol giving a new direction in the area of herbal drug discovery and development.

DOI 10.1016/j.biopha.2018.11.051
Co-authors Peter Wark, Nicole Hansbro, Alan Hsu
2018 Nixon B, Johnston SD, Skerrett-Byrne DA, Anderson AL, Stanger SJ, Bromfield EG, et al., 'Proteomic profiling of crocodile spermatozoa refutes the tenet that post-testicular maturation is restricted to mammals.', Mol Cell Proteomics, (2018)
DOI 10.1074/mcp.RA118.000904
Co-authors Elizabeth Bromfield, Brett Nixon, Matt Dun
2018 Donovan C, Starkey MR, Kim RY, Rana BMJ, Barlow JL, Jones B, et al., 'Roles for T/B lymphocytes and ILC2s in experimental chronic obstructive pulmonary disease.', J Leukoc Biol, (2018)
DOI 10.1002/JLB.3AB0518-178R
Co-authors Jay Horvat, Malcolm Starkey, Peter Wark, Paul Foster, Chantal Donovan
2018 Stifter SA, Matthews AY, Mangan NE, Fung KY, Drew A, Tate MD, et al., 'Defining the distinct, intrinsic properties of the novel type I interferon, IFN¿.', The Journal of biological chemistry, 293 3168-3179 (2018) [C1]
DOI 10.1074/jbc.m117.800755
Citations Scopus - 3Web of Science - 3
2018 McIlroy DJ, Minahan K, Keely S, Lott N, Hansbro P, Smith DW, Balogh ZJ, 'Reduced deoxyribonuclease enzyme activity in response to high postinjury mitochondrial DNA concentration provides a therapeutic target for Systemic Inflammatory Response Syndrome', Journal of Trauma and Acute Care Surgery, 85 354-358 (2018) [C1]

© 2018 Wolters Kluwer Health, Inc. All rights reserved. BACKGROUND Cell-free mitochondrial DNA (mtDNA) is proinflammatory and has been detected in high concentrations in trauma pa... [more]

© 2018 Wolters Kluwer Health, Inc. All rights reserved. BACKGROUND Cell-free mitochondrial DNA (mtDNA) is proinflammatory and has been detected in high concentrations in trauma patients' plasma. Deoxyribonuclease (DNAse) is the free plasma enzyme responsible for the digestion of extracellular DNA. The relationship between mtDNA and DNAse after major trauma is unknown. We hypothesized that DNAse activity would be elevated after injury and trauma surgery and would be associated with high concentrations of extracellular DNA. METHODS Two-year prospective study was performed on 103 consecutive trauma patients (male, 81%; age, 38 years [interquartile range, 30-59 years]; injury severity score, 18 [interquartile range, 12-26 years]) who underwent standardized major orthopedic trauma surgical interventions. Blood was collected at five perioperative time points (preoperative, postoperative, 7 hours, 24 hours, and 3 days postoperatively). Healthy control subjects (n = 20) were also sampled. Cell-free mtDNA and nuclear DNA (nDNA) were measured using quantitative polymerase chain reaction. Deoxyribonuclease was also assayed in the same plasma samples. RESULTS Increased levels of mtDNA (from preoperative 163 ± 86 ng/mL to 3 days 282 ± 201 ng/mL, p < 0.0001) and nDNA (from preoperative 28 ± 20 ng/mL to 3 days 37 ± 27 ng/mL, p < 0.05) were present in trauma patients at all perioperative time points compared with healthy controls (mtDNA: 4 ± 2 ng/mL; nDNA: 10 ± 5 ng/mL). Deoxyribonuclease activity was lower in the trauma cohort (from preoperative 0.06 ± 0.04U/mL to 3 days 0.08 ± 0.04U/mL, p < 0.0001) compared with healthy controls (DNAse: 0.17 ± 0.03U/mL). There was no correlation between DNAse and perioperative DNA concentrations. Elevated mtDNA (but not nDNA) correlated with the development of systemic inflammatory response syndrome (SIRS) (p = 0.026) but not multiple organ failure. CONCLUSIONS The significant perioperative elevation in plasma-free mtDNA concentration is associated with the development of SIRS. The fact that increased cell-free DNA concentrations present with significantly lower than healthy control DNAse activity suggests a potential therapeutic opportunity with DNAse administration to modulate postinjury severe SIRS. LEVEL OF EVIDENCE Prognostic/Epidemiological, level II.

DOI 10.1097/TA.0000000000001919
Co-authors Douglas Smith, Zsolt Balogh, Simon Keely
2018 Shastri MD, Shukla SD, Chong WC, Dua K, Peterson GM, Patel RP, et al., 'Role of Oxidative Stress in the Pathology and Management of Human Tuberculosis', OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2018 (2018) [C1]
DOI 10.1155/2018/7695364
Co-authors Nicole Hansbro
2018 Reid AT, Veerati PC, Gosens R, Bartlett NW, Wark PA, Grainge CL, et al., 'Persistent induction of goblet cell differentiation in the airways: Therapeutic approaches', Pharmacology and Therapeutics, 185 155-169 (2018) [C1]

© 2017 Dysregulated induction of goblet cell differentiation results in excessive production and retention of mucus and is a common feature of several chronic airways diseases. To... [more]

© 2017 Dysregulated induction of goblet cell differentiation results in excessive production and retention of mucus and is a common feature of several chronic airways diseases. To date, therapeutic strategies to reduce mucus accumulation have focused primarily on altering the properties of the mucus itself, or have aimed to limit the production of mucus-stimulating cytokines. Here we review the current knowledge of key molecular pathways that are dysregulated during persistent goblet cell differentiation and highlights both pre-existing and novel therapeutic strategies to combat this pathology.

DOI 10.1016/j.pharmthera.2017.12.009
Citations Scopus - 1Web of Science - 1
Co-authors Nathan Bartlett, Fatemeh Moheimani, Darryl Knight, Christopher Grainge, Peter Wark, Andrew Reid
2018 Eapen MS, Hansbro PM, Larsson-Callerfelt A-K, Jolly MK, Myers S, Sharma P, et al., 'Chronic Obstructive Pulmonary Disease and Lung Cancer: Underlying Pathophysiology and New Therapeutic Modalities.', Drugs, 78 1717-1740 (2018) [C1]
DOI 10.1007/s40265-018-1001-8
2018 Eapen MS, Sharma P, Moodley YP, Hansbro PM, Sohal SS, 'Dysfunctional Immunity and Microbial Adhesion Molecules in Smoking-Induced Pneumonia.', Am J Respir Crit Care Med, (2018)
DOI 10.1164/rccm.201808-1553LE
2018 Dua K, Gupta G, Chellappan DK, Shukla S, Hansbro PM, 'Targeting bacterial biofilms in pulmonary diseases in pediatric population.', Minerva Pediatr, (2018)
DOI 10.23736/S0026-4946.18.05256-8
2018 Wood LG, Li Q, Scott HA, Rutting S, Berthon BS, Gibson PG, et al., 'Saturated fatty acids, obesity, and the nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome in asthmatic patients.', J Allergy Clin Immunol, (2018)
DOI 10.1016/j.jaci.2018.04.037
Co-authors Jay Horvat, Peter Gibson, Katherine Baines, Lisa Wood, Hayley Scott, Jodie Simpson
2018 Sunkara KP, Gupta G, Hansbro PM, Dua K, Bebawy M, 'Functional relevance of SATB1 in immune regulation and tumorigenesis', Biomedicine and Pharmacotherapy, 104 87-93 (2018) [C1]

© 2018 The Special AT-rich Sequence Binding Protein 1 (SATB1) is a chromatin organiser and transcription factor which regulates numerous cellular processes such as differentiation... [more]

© 2018 The Special AT-rich Sequence Binding Protein 1 (SATB1) is a chromatin organiser and transcription factor which regulates numerous cellular processes such as differentiation, proliferation and apoptosis through effects on gene expression. SATB1 undergoes various post-translational modifications, which determine its interaction with co-activators and co-repressors to induce regulation of gene transcription. SATB1 is an identified oncogene, its increased expression is associated with poor prognosis in many cancers. This paper provides a review on SATB1-mediated immune responses and on its target genes in the context of tumorigenesis and tumour progression. Specifically, we discuss the role of SATB1 in tumour immunity, Epithelial to Mesenchymal Transition (EMT), metastasis and multidrug resistance. Therapeutic targeting of aberrant SATB1 may be an important strategy in the treatment of cancer.

DOI 10.1016/j.biopha.2018.05.045
2018 Nair PM, Starkey MR, Haw TJ, Ruscher R, Liu G, Maradana MR, et al., 'RelB-deficient Dendritic Cells Promote the Development of Spontaneous Allergic Airway Inflammation.', American journal of respiratory cell and molecular biology, (2018) [C1]
DOI 10.1165/rcmb.2017-0242oc
Citations Scopus - 1Web of Science - 1
Co-authors Gang Liu, Malcolm Starkey
2018 Knight DA, Hansbro PM, 'Restricted access or access all areas?: a new cadherin-like protein upregulated in the inflamed esophagus', MUCOSAL IMMUNOLOGY, 11 1-2 (2018)
DOI 10.1038/mi.2017.56
Co-authors Darryl Knight
2018 Dua K, Rapalli VK, Shukla SD, Singhvi G, Shastri MD, Chellappan DK, et al., 'Multi-drug resistant Mycobacterium tuberculosis & oxidative stress complexity: Emerging need for novel drug delivery approaches', Biomedicine and Pharmacotherapy, 107 1218-1229 (2018) [C1]

© 2018 Elsevier Masson SAS Tuberculosis (caused by Mycobacterium tuberculosis, Mtb) treatment involves multiple drug regimens for a prolonged period. However, the therapeutic bene... [more]

© 2018 Elsevier Masson SAS Tuberculosis (caused by Mycobacterium tuberculosis, Mtb) treatment involves multiple drug regimens for a prolonged period. However, the therapeutic benefit is often limited by poor patient compliance, subsequently leading to treatment failure and development of antibiotic resistance. Notably, oxidative stress is a crucial underlying factor that adversely influences the various treatment regimens in tuberculosis. Little information is available with advanced drug delivery systems that could be effectively utilized, in particular, for targeting the oxidative stress in tuberculosis. Thus, this presents an opportunity to review the utility of various available, controlled-release drug delivery systems (e.g., microspheres, liposomes, niosomes, solid lipid nanoparticles, dendrimers) that could be beneficial in tuberculosis treatments. This will help the biological and formulation scientists to pave a new path in formulating a treatment regimen for multi-drug resistant Mtb.

DOI 10.1016/j.biopha.2018.08.101
2018 Dua K, Hansbro NG, Foster PS, Hansbro PM, 'Targeting MicroRNAs: Promising Future Therapeutics in the Treatment of Allergic Airway Disease', CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 28 125-127 (2018)
DOI 10.1615/CritRevEukaryotGeneExpr.2018022218
Co-authors Paul Foster, Nicole Hansbro
2018 Mateer SW, Mathe A, Bruce J, Liu G, Maltby S, Fricker M, et al., 'IL-6 Drives Neutrophil-Mediated Pulmonary Inflammation Associated with Bacteremia in Murine Models of Colitis', American Journal of Pathology, 188 1625-1639 (2018) [C1]

© 2018 American Society for Investigative Pathology Inflammatory bowel disease (IBD) is associated with several immune-mediated extraintestinal manifestations. More than half of a... [more]

© 2018 American Society for Investigative Pathology Inflammatory bowel disease (IBD) is associated with several immune-mediated extraintestinal manifestations. More than half of all IBD patients have some form of respiratory pathology, most commonly neutrophil-mediated diseases, such as bronchiectasis and chronic bronchitis. Using murine models of colitis, we aimed to identify the immune mechanisms driving pulmonary manifestations of IBD. We found increased neutrophil numbers in lung tissue associated with the pulmonary vasculature in both trinitrobenzenesulfonic acid¿ and dextran sulfate sodium¿induced models of colitis. Analysis of systemic inflammation identified that neutrophilia was associated with bacteremia and pyrexia in animal models of colitis. We further identified IL-6 as a systemic mediator of neutrophil recruitment from the bone marrow of dextran sulfate sodium animals. Functional inhibition of IL-6 led to reduced systemic and pulmonary neutrophilia, but it did not attenuate established colitis pathology. These data suggest that systemic bacteremia and pyrexia drive IL-6 secretion, which is a critical driver for pulmonary manifestation of IBD. Targeting IL-6 may reduce neutrophil-associated extraintestinal manifestations in IBD patients.

DOI 10.1016/j.ajpath.2018.03.016
Co-authors Steven Maltby, Marjorie Walker, Jay Horvat, Paul Foster, Michael Fricker, Hock Tay, Gang Liu, Andrea Mathe, Simon Keely, Robert Callister
2018 Dua K, de Jesus Andreoli Pinto T, Chellappan DK, Gupta G, Bebawy M, Hansbro PM, 'Advancements in nano drug delivery systems: a challenge for biofilms in respiratory diseases', PANMINERVA MEDICA, 60 35-36 (2018)
DOI 10.23736/S0031-0808.18.03402-X
Citations Scopus - 2Web of Science - 1
2018 Terlizzi M, Molino A, Colarusso C, Donovan C, Imitazione P, Somma P, et al., 'Activation of the Absent in Melanoma 2 Inflammasome in Peripheral Blood Mononuclear Cells From Idiopathic Pulmonary Fibrosis Patients Leads to the Release of Pro-Fibrotic Mediators', FRONTIERS IN IMMUNOLOGY, 9 (2018) [C1]
DOI 10.3389/fimmu.2018.00670
Co-authors Chantal Donovan
2018 Gupta G, Chellappan DK, de Jesus Andreoli Pinto T, Hansbro PM, Bebawy M, Dua K, 'Tumor suppressor role of miR-503.', Panminerva Medica, 60 17-24 (2018) [C1]
DOI 10.23736/s0031-0808.17.03386-9
2018 Dua K, Awasthi R, Madan JR, Chellappan DK, Nalluri BN, Gupta G, et al., 'Novel drug delivery approaches in treating pulmonary fibrosis.', Panminerva Med, (2018)
DOI 10.23736/S0031-0808.18.03428-6
2018 Chellappan DK, Sivam NS, Teoh KX, Leong WP, Fui TZ, Chooi K, et al., 'Gene therapy and type 1 diabetes mellitus', Biomedicine and Pharmacotherapy, 108 1188-1200 (2018) [C1]

© 2018 Elsevier Masson SAS Background: Type 1 diabetes mellitus (T1DM) is an autoimmune disorder characterized by T cell-mediated self-destruction of insulin-secreting islet ß cel... [more]

© 2018 Elsevier Masson SAS Background: Type 1 diabetes mellitus (T1DM) is an autoimmune disorder characterized by T cell-mediated self-destruction of insulin-secreting islet ß cells. Management of T1DM is challenging and complicated especially with conventional medications. Gene therapy has emerged as one of the potential therapeutic alternatives to treat T1DM. This review primarily focuses on the current status and the future perspectives of gene therapy in the management of T1DM. A vast number of the studies which are reported on gene therapy for the management of T1DM are done in animal models and in preclinical studies. In addition, the safety of such therapies is yet to be established in humans. Currently, there are several gene level interventions that are being investigated, notably, overexpression of genes and proteins needed against T1DM, transplantation of cells that express the genes against T1DM, stem-cells mediated gene therapy, genetic vaccination, immunological precursor cell-mediated gene therapy and vectors. Methods: We searched the current literature through searchable online databases, journals and other library sources using relevant keywords and search parameters. Only relevant publications in English, between the years 2000 and 2018, with evidences and proper citations, were considered. The publications were then analyzed and segregated into several subtopics based on common words and content. A total of 126 studies were found suitable for this review. Findings: Generally, the pros and cons of each of the gene-based therapies have been discussed based on the results collected from the literature. However, there are certain interventions that require further detailed studies to ensure their effectiveness. We have also highlighted the future direction and perspectives in gene therapy, which, researchers could benefit from.

DOI 10.1016/j.biopha.2018.09.138
2018 Ng ZY, Wong JY, Panneerselvam J, Madheswaran T, Kumar P, Pillay V, et al., 'Assessing the potential of liposomes loaded with curcumin as a therapeutic intervention in asthma', Colloids and Surfaces B: Biointerfaces, 172 51-59 (2018) [C1]

© 2018 Elsevier B.V. Curcumin a component of turmeric, which is derived from Curcuma longa is used as a colouring agent and as a dietary spice for centuries. Extensive studies hav... [more]

© 2018 Elsevier B.V. Curcumin a component of turmeric, which is derived from Curcuma longa is used as a colouring agent and as a dietary spice for centuries. Extensive studies have been done on the anti-inflammatory activity of curcumin along with its molecular mechanism involving different signalling pathways. However, the physicochemical and biological properties such as poor solubility and rapid metabolism of curcumin have led to low bioavailability and hence limits its application. Current therapies for asthma such as bronchodilators and inhaled corticosteroids (ICS) are aimed at controlling disease symptoms and prevent asthma exacerbation. However, this approach requires lifetime therapy and is associated with a constellation of side effects. This creates a clear unmet medical need and there is an urgent demand for new and more-effective treatments. The present study is aimed to formulate liposomes containing curcumin and evaluate for its anti-inflammatory effects on lipopolysaccharide (LPS)-induced inflammation on BCi-NS1.1 cell line. Curcumin and salbutamol liposomes were formulated using lipid hydration method. The prepared liposomes were characterized in terms of particle size, zeta potential, encapsulation efficiency and in-vitro release profile. The liposomes were tested on BCI-NS1.1 cell line to evaluate its anti-inflammatory properties. The various pro-inflammatory markers studied were Interleukin-6 (IL-6), Interleukin-8 (IL-8), Interleukin-1ß (IL-1ß) and Tumour Necrosis Factor-a (TNF-a). Additionally, molecular mechanics simulations were used to elucidate the positioning, energy minimization, and aqueous dispersion of the liposomal architecture involving lecithin and curcumin. The prepared curcumin formulation showed an average size and zeta potential of 271.3 ± 3.06 nm and -61.0 mV, respectively. The drug encapsulation efficiency of liposomal curcumin is 81.1%. Both curcumin-loaded liposomes formulation (1 µg/mL, 5 µg/mL) resulted in significant (p < 0.05) reduction in the level of pro-inflammatory marker expression such as IL-6, IL-8, IL-1ß and TNF-a compared to positive control group. Liposomal curcumin with the dose of 1 µg/mL reduced the inflammatory markers more effectively compared to that of 5 µg/mL. Liposomal curcumin could be a promising intervention for asthma therapy showing their efficacy in suppressing the important pro-inflammatory markers involved in the pathogenesis of asthma.

DOI 10.1016/j.colsurfb.2018.08.027
Citations Scopus - 1
Co-authors Peter Wark, Nicole Hansbro, Alan Hsu
2018 Kc R, Shukla SD, Gautam SS, Hansbro PM, O'Toole RF, 'The role of environmental exposure to non-cigarette smoke in lung disease.', Clin Transl Med, 7 39 (2018)
DOI 10.1186/s40169-018-0217-2
2018 Loering S, Cameron GJM, Starkey MR, Hansbro PM, 'Lung development and emerging roles for type 2 immunity.', J Pathol, (2018)
DOI 10.1002/path.5211
2018 Fricker M, Goggins BJ, Mateer S, Jones B, Kim RY, Gellatly SL, et al., 'Chronic cigarette smoke exposure induces systemic hypoxia that drives intestinal dysfunction.', JCI insight, 3 1-19 (2018) [C1]
DOI 10.1172/jci.insight.94040
Citations Web of Science - 4
Co-authors Nicholas Talley, Michael Fricker, Marjorie Walker, Simon Keely
2018 Awasthi R, Roseblade A, Hansbro PM, Rathbone MJ, Dua K, Bebawy M, 'Nanoparticles in Cancer Treatment: Opportunities and Obstacles', CURRENT DRUG TARGETS, 19 1696-1709 (2018)
DOI 10.2174/1389450119666180326122831
Citations Scopus - 2Web of Science - 2
2018 Baines KJ, Wright TK, Gibson PG, Powell H, Hansbro PM, Simpson JL, 'Azithromycin treatment modifies airway and blood gene expression networks in neutrophilic COPD.', ERJ open research, 4 (2018) [C1]
DOI 10.1183/23120541.00031-2018
Co-authors Peter Gibson, Jodie Simpson, Katherine Baines
2018 Haw TJ, Starkey MR, Pavlidis S, Fricker M, Arthurs AL, Nair PM, et al., 'Toll-like receptor 2 and 4 have opposing roles in the pathogenesis of cigarette smoke-induced chronic obstructive pulmonary disease.', American journal of physiology. Lung cellular and molecular physiology, 314 L298-L317 (2018) [C1]
DOI 10.1152/ajplung.00154.2017
Citations Scopus - 3Web of Science - 1
Co-authors Malcolm Starkey, Gang Liu, Michael Fricker, Jay Horvat, Paul Foster
2018 Singhvi G, Girdhar V, Patil S, Gupta G, Hansbro PM, Dua K, 'Microbiome as therapeutics in vesicular delivery', Biomedicine and Pharmacotherapy, 104 738-741 (2018) [C1]

© 2018 Elsevier Masson SAS Microbiome refers to an ecological community of various symbiotic and pathogenic microorganisms, which plays a crucial role in human health and disease.... [more]

© 2018 Elsevier Masson SAS Microbiome refers to an ecological community of various symbiotic and pathogenic microorganisms, which plays a crucial role in human health and disease. The concept of novel drug delivery systems particularly the vesicular drug delivery systems is gaining massive attention. This emerging technology has started expanding its horizons in the area of microbiome delivery. This mini-review highlights the role of vesicular systems such as nanoparticles, liposomes etc. as a host/carrier for the microbiome in targeting various diseases. This review will be of interest for both the biological and formulation scientists to understand and explore the new vistas in the area of vesicular delivery system as carrier for microbiome delivery.

DOI 10.1016/j.biopha.2018.05.099
Citations Scopus - 1Web of Science - 1
2018 Rutting S, Xenaki D, Lau E, Horvat J, Wood LG, Hansbro PM, Oliver BG, 'Dietary omega-6, but not omega-3, polyunsaturated or saturated fatty acids increase inflammation in primary lung mesenchymal cells', American Journal of Physiology - Lung Cellular and Molecular Physiology, 314 L922-L935 (2018) [C1]

© 2018 American Physiological Society. All rights reserved. Obesity is an important risk factor for developing severe asthma. Dietary fatty acids, which are increased in sera of o... [more]

© 2018 American Physiological Society. All rights reserved. Obesity is an important risk factor for developing severe asthma. Dietary fatty acids, which are increased in sera of obese individuals and after high-fat meals, activate the innate immune system and induce inflammation. This study investigated whether dietary fatty acids directly cause inflammation and/or synergize with obesity-induced cytokines in primary human pulmonary fibroblasts in vitro. Fibroblasts were challenged with BSA-conjugated fatty acids [¿-6 polyunsaturated fatty acids (PUFAs) and ¿-3 PUFAs or saturated fatty acids (SFAs)], with or without TNF-a, and release of the proinflammatory cytokines, IL-6 and CXCL8, was measured. We found that the ¿-6 PUFA arachidonic acid (AA), but not ¿-3 PUFAs or SFAs, upregulates IL-6 and CXCL8 release. Combined AA and TNF-a challenge resulted in substantially greater cytokine release than either alone, demonstrating synergy. Synergistic upregulation of IL-6, but not CXCL8, was mainly mediated via cyclooxygenase (COX). Inhibition of p38 MAPK reduced CXCL8 release, induced by AA and TNF-a alone, but not in combination. Synergistic CXCL8 release, following AA and TNF-a challenge, was not medicated via a single signaling pathway (MEK1, JNK, phosphoinositide 3-kinase, and NF-¿B) nor by hyperactivation of NF-¿B or p38. To investigate if these findings occur in other airway cells, effects of AA in primary human airway smooth muscle (ASM) cells and human bronchial epithelial cells were also investigated. We found proinflammatory effects in ASM cells but not epithelial cells. This study suggests that diets rich in ¿-6 PUFAs might promote airway inflammation via multiple pathways, including COX-depen-dent and-independent pathways, and in an obese person, may lead to more severe airway inflammation.

DOI 10.1152/ajplung.00438.2017
Citations Scopus - 1
Co-authors Jay Horvat, Lisa Wood
2018 Rutting S, Xenaki D, Malouf M, Horvat JC, Wood LG, Hansbro PM, Oliver BG, 'Short chain fatty acids increase TNFa-induced inflammation in primary human lung mesenchymal cells through the activation of p38 MAP kinase.', Am J Physiol Lung Cell Mol Physiol, (2018)
DOI 10.1152/ajplung.00306.2018
Co-authors Lisa Wood
2018 Obeidat M, Dvorkin-Gheva A, Li X, Bosse Y, Brandsma C-A, Nickle DC, et al., 'The Overlap of Lung Tissue Transcriptome of Smoke Exposed Mice with Human Smoking and COPD', SCIENTIFIC REPORTS, 8 (2018) [C1]
DOI 10.1038/s41598-018-30313-z
2018 Rutting S, Papanicolaou M, Xenaki D, Wood LG, Mullin AM, Hansbro PM, Oliver BG, 'Dietary ¿-6 polyunsaturated fatty acid arachidonic acid increases inflammation, but inhibits ECM protein expression in COPD.', Respiratory research, 19 (2018) [C1]
DOI 10.1186/s12931-018-0919-4
Co-authors Lisa Wood
2018 Eapen MS, Sharma P, Thompson IE, Lu W, Myers S, Hansbro PM, Sohal SS, 'Heparin-binding epidermal growth factor (HB-EGF) drives EMT in patients with COPD: implications for disease pathogenesis and novel therapies.', Lab Invest, (2018)
DOI 10.1038/s41374-018-0146-0
2018 Pathinayake PS, Hsu AC-Y, Waters DW, Hansbro PM, Wood LG, Wark PAB, 'Understanding the Unfolded Protein Response in the Pathogenesis of Asthma', FRONTIERS IN IMMUNOLOGY, 9 (2018) [C1]
DOI 10.3389/fimmu.2018.00175
Co-authors Lisa Wood, Peter Wark, Alan Hsu
2018 Moheimani F, Koops J, Williams T, Reid AT, Hansbro PM, Wark PA, Knight DA, 'Influenza A virus infection dysregulates the expression of microRNA-22 and its targets; CD147 and HDAC4, in epithelium of asthmatics', Respiratory Research, 19 (2018) [C1]
DOI 10.1186/s12931-018-0851-7
Co-authors Andrew Reid, Peter Wark, Darryl Knight, Fatemeh Moheimani
2018 Awasthi R, Rathbone MJ, Hansbro PM, Bebawy M, Dua K, 'Therapeutic prospects of microRNAs in cancer treatment through nanotechnology', Drug Delivery and Translational Research, 8 97-110 (2018) [C1]

© 2017, Controlled Release Society. MicroRNAs (miRNAs) represent a new class of diagnostic and prognostic biomarker as well as new therapeutic targets in cancer therapy. miRNAs ar... [more]

© 2017, Controlled Release Society. MicroRNAs (miRNAs) represent a new class of diagnostic and prognostic biomarker as well as new therapeutic targets in cancer therapy. miRNAs are gaining significant interest due to extensive advancements in knowledge since their discovery and, more recently, their translational application as therapeutic moieties and targets in the management of disease. miRNAs used in the treatment of cancer would position them as a new class of emerging therapeutic agents. Indeed, numerous candidate miRNAs have been identified as having therapeutic application in the treatment of cancer, but there is still much to learn about how to transform these into effective, patient-compliant, and targeted drug delivery systems. In this mini review, we discuss the utility and potential of nanotechnology in miRNA formulation and delivery with particular emphasis on cancer, including their role in conferring multidrug resistance and metastatic capacity. This review benefits both the formulation and biological scientists in understanding and exploring the new vistas of miRNA delivery using nanotechnology in the cancer clinically.

DOI 10.1007/s13346-017-0440-1
Citations Web of Science - 1
2018 Chellappan DK, Ng ZY, Wong JY, Hsu A, Wark P, Hansbro N, et al., 'Immunological axis of curcumin-loaded vesicular drug delivery systems', Future Medicinal Chemistry, 10 839-844 (2018) [C1]

© 2018 Newlands Press. Several vesicular systems loaded with curcumin have found their way in the therapeutic applications of several diseases, primarily acting through their immu... [more]

© 2018 Newlands Press. Several vesicular systems loaded with curcumin have found their way in the therapeutic applications of several diseases, primarily acting through their immunological pathways. Such systems use particles at a nanoscale range, bringing about their intended use through a range of complex mechanisms. Apart from delivering drug substances into target tissues, these vesicular systems also effectively overcome problems like insolubility and unequal drug distribution. Several mechanisms are explored lately by different workers, and interest over vesicular curcumin has been renewed in the past decade. This commentary discusses several immunological targets in which curcumin is employed in a vesicular form.

DOI 10.4155/fmc-2017-0245
Citations Scopus - 3Web of Science - 1
Co-authors Nicole Hansbro, Alan Hsu, Peter Wark
2017 Foster PS, Maltby S, Rosenberg HF, Tay HL, Hogan SP, Collison AM, et al., 'Modeling T

© 2017 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd In this review, we highlight experiments conducted in our laboratories that have elucidated functional... [more]

© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd In this review, we highlight experiments conducted in our laboratories that have elucidated functional roles for CD4+ T-helper type-2 lymphocytes (TH2 cells), their associated cytokines, and eosinophils in the regulation of hallmark features of allergic asthma. Notably, we consider the complexity of type-2 responses and studies that have explored integrated signaling among classical TH2 cytokines (IL-4, IL-5, and IL-13), which together with CCL11 (eotaxin-1) regulate critical aspects of eosinophil recruitment, allergic inflammation, and airway hyper-responsiveness (AHR). Among our most important findings, we have provided evidence that the initiation of TH2 responses is regulated by airway epithelial cell-derived factors, including TRAIL and MID1, which promote TH2 cell development via STAT6-dependent pathways. Further, we highlight studies demonstrating that microRNAs are key regulators of allergic inflammation and potential targets for anti-inflammatory therapy. On the background of TH2 inflammation, we have demonstrated that innate immune cells (notably, airway macrophages) play essential roles in the generation of steroid-resistant inflammation and AHR secondary to allergen- and pathogen-induced exacerbations. Our work clearly indicates that understanding the diversity and spatiotemporal role of the inflammatory response and its interactions with resident airway cells is critical to advancing knowledge on asthma pathogenesis and the development of new therapeutic approaches.

DOI 10.1111/imr.12549
Citations Scopus - 12Web of Science - 7
Co-authors Joerg Mattes, Paul Foster, Gerard Kaiko, Adam Collison, Steven Maltby, Nicole Hansbro, Hock Tay, Ming Yang
2017 Hansbro PM, Kim RY, Starkey MR, Donovan C, Dua K, Mayall JR, et al., 'Mechanisms and treatments for severe, steroid-resistant allergic airway disease and asthma', Immunological Reviews, 278 41-62 (2017) [C1]

© 2017 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd Severe, steroid-resistant asthma is clinically and economically important since affected individuals d... [more]

© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd Severe, steroid-resistant asthma is clinically and economically important since affected individuals do not respond to mainstay corticosteroid treatments for asthma. Patients with this disease experience more frequent exacerbations of asthma, are more likely to be hospitalized, and have a poorer quality of life. Effective therapies are urgently required, however, their development has been hampered by a lack of understanding of the pathological processes that underpin disease. A major obstacle to understanding the processes that drive severe, steroid-resistant asthma is that the several endotypes of the disease have been described that are characterized by different inflammatory and immunological phenotypes. This heterogeneity makes pinpointing processes that drive disease difficult in humans. Clinical studies strongly associate specific respiratory infections with severe, steroid-resistant asthma. In this review, we discuss key findings from our studies where we describe the development of representative experimental models to improve our understanding of the links between infection and severe, steroid-resistant forms of this disease. We also discuss their use in elucidating the mechanisms, and their potential for developing effective therapeutic strategies, for severe, steroid-resistant asthma. Finally, we highlight how the immune mechanisms and therapeutic targets we have identified may be applicable to obesity-or pollution-associated asthma.

DOI 10.1111/imr.12543
Citations Scopus - 10Web of Science - 7
Co-authors Lisa Wood, Gang Liu, Malcolm Starkey, Paul Foster, Jay Horvat, Darryl Knight, Chantal Donovan, Jodie Simpson, Nicole Hansbro
2017 Conickx G, Mestdagh P, Cobos FA, Verhamme FM, Maes T, Vanaudenaerde BM, et al., 'MicroRNA profiling reveals a role for MicroRNA-218-5p in the pathogenesis of chronic obstructive pulmonary disease', American Journal of Respiratory and Critical Care Medicine, 195 43-56 (2017) [C1]

Rationale: Aberrant expression of microRNAs (miRNAs) can have a detrimental role in disease pathogenesis. Objectives: To identify dysregulated miRNAs in lung tissue of patients wi... [more]

Rationale: Aberrant expression of microRNAs (miRNAs) can have a detrimental role in disease pathogenesis. Objectives: To identify dysregulated miRNAs in lung tissue of patients with chronic obstructive pulmonary disease (COPD). Methods: We performed miRNA and mRNA profiling using high throughput stem-loop reverse-transcriptase quantitative polymerase chain reaction and mRNA microarray, respectively, on lung tissue of 30 patients (screening cohort) encompassing 8 never-smokers, 10 smokers without airflow limitation, and 12 smokers with COPD. Differential expression of miRNA-218-5p (miR-218-5p) was validated by reverse-transcriptase quantitative polymerase chain reaction in an independent cohort of 71 patients, an in vivo murine model of COPD, and primary human bronchial epithelial cells. Localization of miR-218-5p was assessed by in situ hybridization. In vitro and in vivo perturbation of miR-218-5p combined with RNA sequencing and gene set enrichment analysis was used to elucidate its functional role in COPD pathogenesis. Measurements and Main Results: Several miRNAs were differentially expressed among the different patient groups. Interestingly, miR-218-5p was significantly down-regulated in smokers without airflow limitation and in patients with COPD compared with never-smokers. Decreased pulmonary expression of miR-218-5p was validated in an independent validation cohort, in cigarette smoke-exposed mice, and in human bronchial epithelial cells. Importantly, expression of miR-218-5p strongly correlated with airway obstruction. Furthermore, cellular localization of miR-218-5p in human and murine lung revealed highest expression of miR-218-5p in the bronchial airway epithelium. Perturbation experiments with a miR-218-5p mimic or inhibitor demonstrated a protective role of miR-218-5p in cigarette smoke-induced inflammation and COPD. Conclusions: We highlight a role for miR-218-5p in the pathogenesis of COPD.

DOI 10.1164/rccm.201506-1182OC
Citations Scopus - 24Web of Science - 24
Co-authors Peter Wark, Alan Hsu
2017 Maheshwari R, Sharma P, Tekade M, Atneriya U, Dua K, Hansbro PM, Tekade RK, 'Microsponge Embedded Tablets for Sustained Delivery of Nifedipine.', Pharmaceutical nanotechnology, 5 192-202 (2017) [C1]
DOI 10.2174/2211738505666170921125549
2017 Ng Kee Kwong F, Nicholson AG, Harrison CL, Hansbro PM, Adcock IM, Chung KF, 'Is mitochondrial dysfunction a driving mechanism linking COPD to nonsmall cell lung carcinoma?', European Respiratory Review, 26 (2017) [C1]

© ERS 2017. Chronic obstructive pulmonary disease (COPD) patients are at increased risk of developing nonsmall cell lung carcinoma, irrespective of their smoking history. Although... [more]

© ERS 2017. Chronic obstructive pulmonary disease (COPD) patients are at increased risk of developing nonsmall cell lung carcinoma, irrespective of their smoking history. Although the mechanisms behind this observation are not clear, established drivers of carcinogenesis in COPD include oxidative stress and sustained chronic inflammation. Mitochondria are critical in these two processes and recent evidence links increased oxidative stress in COPD patients to mitochondrial damage. We therefore postulate that mitochondrial damage in COPD patients leads to increased oxidative stress and chronic inflammation, thereby increasing the risk of carcinogenesis. The functional state of the mitochondrion is dependent on the balance between its biogenesis and degradation (mitophagy). Dysfunctional mitochondria are a source of oxidative stress and inflammasome activation. In COPD, there is impaired translocation of the ubiquitin-related degradation molecule Parkin following activation of the Pink1 mitophagy pathway, resulting in excessive dysfunctional mitochondria. We hypothesise that deranged pathways in mitochondrial biogenesis and mitophagy in COPD can account for the increased risk in carcinogenesis. To test this hypothesis, animal models exposed to cigarette smoke and developing emphysema and lung cancer should be developed. In the future, the use of mitochondria-based antioxidants should be studied as an adjunct with the aim of reducing the risk of COPD-associated cancer.

DOI 10.1183/16000617.0040-2017
Citations Scopus - 3
2017 Dua K, Bebawy M, Awasthi R, Tekade RK, Tekade M, Gupta G, et al., 'Application of Chitosan and its Derivatives in Nanocarrier Based Pulmonary Drug Delivery Systems.', Pharmaceutical nanotechnology, 5 243-249 (2017) [C1]
DOI 10.2174/2211738505666170808095258
2017 Chotirmall SH, Gellatly SL, Budden KF, Mac Aogain M, Shukla SD, Wood DLA, et al., 'Microbiomes in respiratory health and disease: An Asia-Pacific perspective', Respirology, 22 240-250 (2017) [C1]

© 2017 Asian Pacific Society of Respirology There is currently enormous interest in studying the role of the microbiome in health and disease. Microbiome&apos;s role is increasing... [more]

© 2017 Asian Pacific Society of Respirology There is currently enormous interest in studying the role of the microbiome in health and disease. Microbiome's role is increasingly being applied to respiratory diseases, in particular COPD, asthma, cystic fibrosis and bronchiectasis. The changes in respiratory microbiomes that occur in these diseases and how they are modified by environmental challenges such as cigarette smoke, air pollution and infection are being elucidated. There is also emerging evidence that gut microbiomes play a role in lung diseases through the modulation of systemic immune responses and can be modified by diet and antibiotic treatment. There are issues that are particular to the Asia-Pacific region involving diet and prevalence of specific respiratory diseases. Each of these issues is further complicated by the effects of ageing. The challenges now are to elucidate the cause and effect relationships between changes in microbiomes and respiratory diseases and how to translate these into new treatments and clinical care. Here we review the current understanding and progression in these areas.

DOI 10.1111/resp.12971
Citations Scopus - 9Web of Science - 13
2017 Camlin NJ, Jarnicki AG, Vanders RL, Walters KA, Hansbro PM, McLaughlin EA, Holt JE, 'Grandmaternal smoke exposure reduces female fertility in a murine model, with great-grandmaternal smoke exposure unlikely to have an effect', HUMAN REPRODUCTION, 32 1270-1281 (2017) [C1]
DOI 10.1093/humrep/dex073
Citations Scopus - 4Web of Science - 2
Co-authors Janet Bristow, Eileen Mclaughlin
2017 Leung JM, Tiew PY, Mac Aogáin M, Budden KF, Yong VFL, Thomas SS, et al., 'The role of acute and chronic respiratory colonization and infections in the pathogenesis of COPD', Respirology, 22 634-650 (2017) [C1]
DOI 10.1111/resp.13032
Citations Scopus - 12Web of Science - 12
2017 Hansbro PM, Haw TJ, Starkey MR, Miyake K, 'Toll-like receptors in COPD', EUROPEAN RESPIRATORY JOURNAL, 49 (2017) [C1]
DOI 10.1183/13993003.00739-2017
Co-authors Malcolm Starkey
2017 Budden KF, Gellatly SL, Wood DLA, Cooper MA, Morrison M, Hugenholtz P, Hansbro PM, 'Emerging pathogenic links between microbiota and the gut-lung axis', Nature Reviews Microbiology, 15 55-63 (2017) [C1]

© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. The microbiota is vital for the development of the immune system and homeostasis. Changes in mic... [more]

© 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. The microbiota is vital for the development of the immune system and homeostasis. Changes in microbial composition and function, termed dysbiosis, in the respiratory tract and the gut have recently been linked to alterations in immune responses and to disease development in the lungs. In this Opinion article, we review the microbial species that are usually found in healthy gastrointestinal and respiratory tracts, their dysbiosis in disease and interactions with the gut-lung axis. Although the gut-lung axis is only beginning to be understood, emerging evidence indicates that there is potential for manipulation of the gut microbiota in the treatment of lung diseases.

DOI 10.1038/nrmicro.2016.142
Citations Scopus - 91Web of Science - 84
2017 Nair PM, Starkey MR, Haw TJ, Liu G, Horvat JC, Morris JC, et al., 'Targeting PP2A and proteasome activity ameliorates features of allergic airway disease in mice', Allergy: European Journal of Allergy and Clinical Immunology, 72 1891-1903 (2017) [C1]

© 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd. Background: Asthma is an allergic airway disease (AAD) caused by aberrant immune responses to aller... [more]

© 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd. Background: Asthma is an allergic airway disease (AAD) caused by aberrant immune responses to allergens. Protein phosphatase-2A (PP2A) is an abundant serine/threonine phosphatase with anti-inflammatory activity. The ubiquitin proteasome system (UPS) controls many cellular processes, including the initiation of inflammatory responses by protein degradation. We assessed whether enhancing PP2A activity with fingolimod (FTY720) or 2-amino-4-(4-(heptyloxy) phenyl)-2-methylbutan-1-ol (AAL(S)), or inhibiting proteasome activity with bortezomib (BORT), could suppress experimental AAD. Methods: Acute AAD was induced in C57BL/6 mice by intraperitoneal sensitization with ovalbumin (OVA) in combination with intranasal (i.n) exposure to OVA. Chronic AAD was induced in mice with prolonged i.n exposure to crude house dust mite (HDM) extract. Mice were treated with vehicle, FTY720, AAL(S), BORT or AAL(S)+BORT and hallmark features of AAD assessed. Results: AAL(S) reduced the severity of acute AAD by suppressing tissue eosinophils and inflammation, mucus-secreting cell (MSC) numbers, type 2-associated cytokines (interleukin (IL)-33, thymic stromal lymphopoietin, IL-5 and IL-13), serum immunoglobulin (Ig)E and airway hyper-responsiveness (AHR). FTY720 only suppressed tissue inflammation and IgE. BORT reduced bronchoalveolar lavage fluid (BALF) and tissue eosinophils and inflammation, IL-5, IL-13 and AHR. Combined treatment with AAL(S)+BORT had complementary effects and suppressed BALF and tissue eosinophils and inflammation, MSC numbers, reduced the production of type 2 cytokines and AHR. AAL(S), BORT and AAL(S)+BORT also reduced airway remodelling in chronic AAD. Conclusion: These findings highlight the potential of combination therapies that enhance PP2A and inhibit proteasome activity as novel therapeutic strategies for asthma.

DOI 10.1111/all.13212
Citations Scopus - 2Web of Science - 2
Co-authors Nicole Hansbro, Malcolm Starkey, Gang Liu, Nikki Verrills, Jay Horvat
2017 Dua K, Hansbro NG, Hansbro PM, 'STEROID RESISTANCE AND CONCOMITANT RESPIRATORY INFECTIONS: A CHALLENGING BATTLE IN PULMONARY CLINIC', EXCLI JOURNAL, 16 981-985 (2017)
DOI 10.17179/excli2017-425
Co-authors Nicole Hansbro
2017 Chellappan DK, Hansbro PM, Dua K, Hsu A, Gupta G, Ng ZY, et al., 'Vesicular Systems Containing Curcumin and Their Applications in Respiratory Disorders - A Mini Review.', Pharmaceutical nanotechnology, 5 250-254 (2017)
DOI 10.2174/2211738505666170808094635
Co-authors Alan Hsu
2017 Sohal SS, Hansbro PM, Shukla SD, Eapen MS, Walters EH, 'Potential Mechanisms of Microbial Pathogens in Idiopathic Interstitial Lung Disease', CHEST, 152 899-900 (2017)
DOI 10.1016/j.chest.2017.05.024
Citations Scopus - 3Web of Science - 3
2017 Pinkerton JW, Kim RY, Robertson AAB, Hirota JA, Wood LG, Knight DA, et al., 'Inflammasomes in the lung', Molecular Immunology, 86 44-55 (2017) [C1]

© 2017 Elsevier Ltd Innate immune responses act as first line defences upon exposure to potentially noxious stimuli. The innate immune system has evolved numerous intracellular an... [more]

© 2017 Elsevier Ltd Innate immune responses act as first line defences upon exposure to potentially noxious stimuli. The innate immune system has evolved numerous intracellular and extracellular receptors that undertake surveillance for potentially damaging particulates. Inflammasomes are intracellular innate immune multiprotein complexes that form and are activated following interaction with these stimuli. Inflammasome activation leads to the cleavage of pro-IL-1ß and release of the pro-inflammatory cytokine, IL-1ß, which initiates acute phase pro-inflammatory responses, and other responses are also involved (IL-18, pyroptosis). However, excessive activation of inflammasomes can result in chronic inflammation, which has been implicated in a range of chronic inflammatory diseases. The airways are constantly exposed to a wide variety of stimuli. Inflammasome activation and downstream responses clears these stimuli. However, excessive activation may drive the pathogenesis of chronic respiratory diseases such as severe asthma and chronic obstructive pulmonary disease. Thus, there is currently intense interest in the role of inflammasomes in chronic inflammatory lung diseases and in their potential for therapeutic targeting. Here we review the known associations between inflammasome-mediated responses and the development and exacerbation of chronic lung diseases.

DOI 10.1016/j.molimm.2017.01.014
Citations Scopus - 10Web of Science - 10
Co-authors Darryl Knight, Lisa Wood, Jay Horvat
2017 Bazett M, Biala A, Huff RD, Zeglinksi MR, Hansbro PM, Bosiljcic M, et al., 'Attenuating immune pathology using a microbial-based intervention in a mouse model of cigarette smoke-induced lung inflammation', RESPIRATORY RESEARCH, 18 (2017) [C1]
DOI 10.1186/s12931-017-0577-y
Citations Scopus - 7Web of Science - 7
2017 Kim RY, Horvat JC, Pinkerton JW, Starkey MR, Essilfie AT, Mayall JR, et al., 'MicroRNA-21 drives severe, steroid-insensitive experimental asthma by amplifying phosphoinositide 3-kinase¿mediated suppression of histone deacetylase 2', Journal of Allergy and Clinical Immunology, 139 519-532 (2017) [C1]

© 2016 American Academy of Allergy, Asthma &amp; Immunology Background Severe steroid-insensitive asthma is a substantial clinical problem. Effective treatments are urgently req... [more]

© 2016 American Academy of Allergy, Asthma & Immunology Background Severe steroid-insensitive asthma is a substantial clinical problem. Effective treatments are urgently required, however, their development is hampered by a lack of understanding of the mechanisms of disease pathogenesis. Steroid-insensitive asthma is associated with respiratory tract infections and noneosinophilic endotypes, including neutrophilic forms of disease. However, steroid-insensitive patients with eosinophil-enriched inflammation have also been described. The¿mechanisms that underpin infection-induced, severe steroid-insensitive asthma can be elucidated by using mouse models of disease. Objective We sought to develop representative mouse models of severe, steroid-insensitive asthma and to use them to identify pathogenic mechanisms and investigate new treatment approaches. Methods Novel mouse models of Chlamydia, Haemophilus influenzae, influenza, and respiratory syncytial virus respiratory¿tract infections and ovalbumin-induced, severe, steroid-insensitive allergic airway disease (SSIAAD) in BALB/c mice were developed and interrogated. Results Infection induced increases in the levels of microRNA (miRNA)-21 (miR-21) expression in the lung during SSIAAD, whereas expression of the miR-21 target phosphatase and tensin homolog was reduced. This was associated with an increase in levels of phosphorylated Akt, an indicator of phosphoinositide 3-kinase (PI3K) activity, and decreased nuclear histone deacetylase (HDAC)2 levels. Treatment with an miR-21¿specific antagomir (Ant-21) increased phosphatase and tensin homolog levels. Treatment with Ant-21, or the pan-PI3K inhibitor LY294002, reduced PI3K activity and restored HDAC2 levels. This led to suppression of airway hyperresponsiveness and restored steroid sensitivity to allergic airway disease. These observations were replicated with SSIAAD associated with 4 different pathogens. Conclusion We identify a previously unrecognized role for an¿miR-21/PI3K/HDAC2 axis in SSIAAD. Our data highlight miR-21 as a novel therapeutic target for the treatment of this form of asthma.

DOI 10.1016/j.jaci.2016.04.038
Citations Scopus - 28Web of Science - 28
Co-authors Joerg Mattes, Paul Foster, Nicole Hansbro, Jay Horvat, Malcolm Starkey, Simon Keely
2017 Huff RD, Hsu ACY, Nichol KS, Jones B, Knight DA, Wark PAB, et al., 'Regulation of xanthine dehydrogensase gene expression and uric acid production in human airway epithelial cells', PLoS ONE, 12 1-17 (2017) [C1]
DOI 10.1371/journal.pone.0184260
Citations Scopus - 1
Co-authors Peter Wark, Alan Hsu, Darryl Knight
2017 Jones B, Donovan C, Liu G, Gomez HM, Chimankar V, Harrison CL, et al., 'Animal models of COPD: What do they tell us?', Respirology, 22 21-32 (2017) [C1]

© 2016 Asian Pacific Society of Respirology COPD is a major cause of global mortality and morbidity but current treatments are poorly effective. This is because the underlying mec... [more]

© 2016 Asian Pacific Society of Respirology COPD is a major cause of global mortality and morbidity but current treatments are poorly effective. This is because the underlying mechanisms that drive the development and progression of COPD are incompletely understood. Animal models of disease provide a valuable, ethically and economically viable experimental platform to examine these mechanisms and identify biomarkers that may be therapeutic targets that would facilitate the development of improved standard of care. Here, we review the different established animal models of COPD and the various aspects of disease pathophysiology that have been successfully recapitulated in these models including chronic lung inflammation, airway remodelling, emphysema and impaired lung function. Furthermore, some of the mechanistic features, and thus biomarkers and therapeutic targets of COPD identified in animal models are outlined. Some of the existing therapies that suppress some disease symptoms that were identified in animal models and are progressing towards therapeutic development have been outlined. Further studies of representative animal models of human COPD have the strong potential to identify new and effective therapeutic approaches for COPD.

DOI 10.1111/resp.12908
Citations Scopus - 22Web of Science - 19
Co-authors Chantal Donovan, Darryl Knight, Gang Liu
2017 Girkin JL, Hatchwell LM, Collison AM, Starkey MR, Hansbro PM, Yagita H, et al., 'TRAIL signaling is proinflammatory and proviral in a murine model of rhinovirus 1B infection', American Journal of Physiology - Lung Cellular and Molecular Physiology, 312 L89-L99 (2017) [C1]

© 2017 the American Physiological Society. The aim of this study is to elucidate the role of TRAIL during rhinovirus (RV) infection in vivo. Naïve wild-type and tumor necrosis fac... [more]

© 2017 the American Physiological Society. The aim of this study is to elucidate the role of TRAIL during rhinovirus (RV) infection in vivo. Naïve wild-type and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-deficient (Tnfsf10-/-) BALB/c mice were infected intranasally with RV1B. In separate experiments, Tnfsf10-/-mice were sensitized and challenged via the airway route with house dust mite (HDM) to induce allergic airways disease and then challenged with RVIB or UV-RVIB. Airway hyperreactivity (AHR) was invasively assessed as total airways resistance in response to increasing methacholine challenge and inflammation was assessed in bronchoalveolar lavage fluid at multiple time points postinfection. Chemokines were quantified by ELISA of whole lung lysates and viral load was determined by quantitative RT-PCR and tissue culture infective dose (TCID50). Human airway epithelial cells (BEAS2B) were infected with RV1B and stimulated with recombinant TRAIL or neutralizing anti-TRAIL antibodies and viral titer assessed by TCID50. HDM-challenged Tnfsf10-/-mice were protected against RV-induced AHR and had suppressed cellular infiltration in the airways upon RV infection. Chemokine C-X-C-motif ligand 2 (CXCL2) production was suppressed in naïve Tnfsf10-/-mice infected with RV1B, with less RV1B detected 24 h postinfection. This was associated with reduced apoptotic cell death and a reduction of interferon (IFN)-¿2/3 but not IFN-a or IFN-ß. TRAIL stimulation increased, whereas anti-TRAIL antibodies reduced viral replication in RV1B-infected BEAS2B cells in vitro. In conclusion, TRAIL promotes RV-induced AHR, inflammation and RV1B replication, implicating this molecule and its downstream signaling pathways as a possible target for the amelioration of RV1B-induced allergic and nonallergic lung inflammation and AHR.

DOI 10.1152/ajplung.00200.2016
Citations Scopus - 2Web of Science - 3
Co-authors Adam Collison, Malcolm Starkey, Joerg Mattes, Paul Foster
2017 Ali MK, Kim RY, Karim R, Mayall JR, Martin KL, Shahandeh A, et al., 'Role of iron in the pathogenesis of respiratory disease', INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 88 181-195 (2017) [C1]
DOI 10.1016/j.biocel.2017.05.003
Citations Scopus - 3Web of Science - 4
Co-authors Malcolm Starkey, Liz Milward, Jay Horvat
2017 Al-Kouba J, Wilkinson AN, Starkey MR, Rudraraju R, Werder RB, Liu X, et al., 'Allergen-encoding bone marrow transfer inactivates allergic T cell responses, alleviating airway inflammation', JCI INSIGHT, 2 (2017) [C1]
DOI 10.1172/jci.insight.85742
Citations Web of Science - 6
Co-authors Malcolm Starkey, Jay Horvat
2017 Liu G, Cooley MA, Nair PM, Donovan C, Hsu AC, Jarnicki AG, et al., 'Airway remodelling and inflammation in asthma are dependent on the extracellular matrix protein fibulin-1c', JOURNAL OF PATHOLOGY, 243 510-523 (2017) [C1]
DOI 10.1002/path.4979
Citations Scopus - 5Web of Science - 5
Co-authors Paul Foster, Nicole Hansbro, Peter Wark, Gang Liu, Alan Hsu, Christopher Grainge, Jay Horvat, Hock Tay, Darryl Knight, Chantal Donovan
2017 Sohal SS, Hansbro PM, Walters EH, 'Epithelial Mesenchymal Transition in Chronic Obstructive Pulmonary Disease, a Precursor for Epithelial Cancers: Understanding and Translation to Early Therapy', ANNALS OF THE AMERICAN THORACIC SOCIETY, 14 1491-1492 (2017)
DOI 10.1513/AnnalsATS.201705-387LE
Citations Scopus - 6Web of Science - 3
2017 Dua K, Hansbro NG, Foster PS, Hansbro PM, 'MicroRNAs as therapeutics for future drug delivery systems in treatment of lung diseases', Drug Delivery and Translational Research, 7 168-178 (2017) [C1]

© 2016, Controlled Release Society. The rapid advancement in the area of microRNAs (miRNAs) from discovery to their translation into therapeutic moieties reflects their significan... [more]

© 2016, Controlled Release Society. The rapid advancement in the area of microRNAs (miRNAs) from discovery to their translation into therapeutic moieties reflects their significance as important regulators in the management of disease pathology. The miRNAs can potentially be a new class of drugs in the near future for the treatment of various lung diseases, but it lacks the current knowledge how these identified therapeutic moieties can be designed into an effective, patient complaint and targeted drug delivery system. miRNAs have characteristic features like small size and low molecular weight which makes them easily translated into an effective drug delivery system. In this review, we have summarised the concept of miRNAs and different approaches which can be employed to deliver miRNAs effectively and safely to the target cells including the challenges associated with their development in particular emphasis on pulmonary diseases. Such approaches will be of interest for both the biological and formulation scientists to understand and explore the new vistas in the area of miRNA delivery for pulmonary inflammatory diseases.

DOI 10.1007/s13346-016-0343-6
Citations Scopus - 13Web of Science - 12
Co-authors Nicole Hansbro, Paul Foster
2017 Dua K, Shukla SD, Tekade RK, Hansbro PM, 'Whether a novel drug delivery system can overcome the problem of biofilms in respiratory diseases?', Drug Delivery and Translational Research, 7 179-187 (2017) [C1]

© 2016, Controlled Release Society. Biofilm comprises a community of microorganisms which form on medical devices and can lead to various threatening infections. It is a major con... [more]

© 2016, Controlled Release Society. Biofilm comprises a community of microorganisms which form on medical devices and can lead to various threatening infections. It is a major concern in various respiratory diseases like cystic fibrosis, chronic obstructive pulmonary disease, etc. The treatment strategies for such infections are difficult due to the resistance of the microflora existing in the biofilms against various antimicrobial agents, thus posing threats to the patient population. The present era witnesses the beginning of research to understand the biofilm physiology and the associated microfloral diversity by applying -omics approaches. There is very limited information about how the deposition of biofilm on the respiratory devices and lung itself affects the drug delivered, the delivery system, and other implications. The present mini review summarizes the basic introduction to the biofilms and its avoidance using various drug delivery systems with special emphasis on the respiratory diseases. Understanding the approaches, principles, and modes of drug delivery involved in preventing biofilm deposition will be of interest to both biological and formulation scientists, thereby opening avenues to explore the new vistas in biofilm research for identifying better treatments for pulmonary infectious diseases.

DOI 10.1007/s13346-016-0349-0
Citations Scopus - 10Web of Science - 9
2017 Eapen MS, Hansbro PM, McAlinden K, Kim RY, Ward C, Hackett T-L, et al., 'Abnormal M1/M2 macrophage phenotype profiles in the small airway wall and lumen in smokers and chronic obstructive pulmonary disease (COPD).', Scientific Reports, 7 (2017) [C1]
DOI 10.1038/s41598-017-13888-x
Citations Scopus - 10Web of Science - 8
2017 Sohal SS, Hansbro PM, Walters EH, 'Epithelial Mesenchymal Transition in Chronic Obstructive Pulmonary Disease, a Precursor for Epithelial Cancers: Understanding and Translation to Early Therapy.', Annals of the American Thoracic Society, 14 1491-1492 (2017)
DOI 10.1513/annalsats.201705-387le
2017 Stevens RL, McNeil HP, Wensing LA, Shin K, Wong GW, Hansbro PM, Krilis SA, 'Experimental arthritis is dependent on mouse mast cell protease-5', Journal of Biological Chemistry, 292 5392-5404 (2017) [C1]

© 2017 by The American Society for Biochemistry and Molecular Biology, Inc. The constitutive heparin+ (HP) mast cells (MCs) in mice express mouseMCprotease (mMCP)-5 and carboxypep... [more]

© 2017 by The American Society for Biochemistry and Molecular Biology, Inc. The constitutive heparin+ (HP) mast cells (MCs) in mice express mouseMCprotease (mMCP)-5 and carboxypeptidaseA (mMC-CPA). The amino acid sequence ofmMCP-5is most similar to that of human chymase-1, as are the nucleotide sequences of their genes and transcripts. Using a homologous recombination approach, a C57BL/6 mouse line was created that possessed a disrupted mMCP-5 gene. The resulting mice were fertile and had no obvious developmental abnormality. Lack of mMCP-5 protein did not alter the granulation of the IL-3/IL-9-dependent mMCP-2+ MCs in the jejunal mucosa of Trichinella spiralisinfected mice. In contrast, the constitutive HP+ MCs in the tongues of mMCP-5-null mice were poorly granulated and lacked mMC-CPA protein. Bone marrow-derived MCs were readily developed from the transgenic mice using IL-3. Although these MCs contained high levels of mMC-CPA mRNA, they also lacked the latter exopeptidase. mMCP-5 protein is therefore needed to target translated mMC-CPA to the secretory granule along with HP-containing serglycin proteoglycans. Alternately, mMCP-5 is needed to protect mMC-CPA from autolysis in the cell's granules. Fibronectin was identified as a target of mMCP-5, and the exocytosis ofmMCP-5from theMCs in the mouse's peritoneal cavity resulted in the expression of metalloproteinase protease-9, which has been implicated in arthritis. In support of the latter finding, experimental arthritis was markedly reduced in mMCP-5-null mice relative to wildtype mice in two disease models.

DOI 10.1074/jbc.M116.773416
Citations Scopus - 2Web of Science - 2
2017 Kim RY, Pinkerton JW, Essilfie AT, Robertson AAB, Baines KJ, Brown AC, et al., 'Role for NLRP3 inflammasome-mediated, IL-1ß-dependent responses in severe, steroid-resistant asthma', American Journal of Respiratory and Critical Care Medicine, 196 283-297 (2017) [C1]

© 2017 by the American Thoracic Society. Rationale: Severe, steroid-resistant asthma is the major unmet need in asthma therapy. Disease heterogeneity and poor understanding of pat... [more]

© 2017 by the American Thoracic Society. Rationale: Severe, steroid-resistant asthma is the major unmet need in asthma therapy. Disease heterogeneity and poor understanding of pathogenic mechanisms hampers the identification of therapeutic targets. Excessive nucleotide-binding oligomerization domain-like receptor family, pyrin domain-containing 3 (NLRP3) inflammasome and concomitant IL-1ß responses occur in chronic obstructive pulmonary disease, respiratory infections, and neutrophilic asthma. However, the direct contributions to pathogenesis, mechanisms involved, and potential for therapeutic targeting remain poorly understood, and are unknown in severe, steroid-resistant asthma. Objectives: To investigate the roles and therapeutic targeting of the NLRP3 inflammasome and IL-1ß in severe, steroid-resistant asthma. Methods: We developed mouse models of Chlamydia and Haemophilus respiratory infection-mediated, ovalbumin-induced severe, steroid-resistant allergic airway disease. These models share the hallmark features of human disease, including elevated airway neutrophils, and NLRP3 inflammasome and IL-1ß responses. The roles and potential for targeting of NLRP3 inflammasome, caspase-1, and IL-1ß responses in experimental severe, steroid-resistant asthma were examined using a highly selective NLRP3 inhibitor, MCC950; the specific caspase-1 inhibitor Ac-YVAD-cho; and neutralizing anti-IL-1ß antibody. Roles for IL-1ß-induced neutrophilic inflammation were examined using IL-1ß and anti-Ly6G. Measurements and Main Results: Chlamydia and Haemophilus infections increase NLRP3, caspase-1, IL-1ß responses that drive steroid-resistant neutrophilic inflammation and airway hyperresponsiveness. Neutrophilic airway inflammation, disease severity, and steroid resistance in human asthma correlate with NLRP3 and IL-1ß expression. Treatment with anti-IL-1ß, Ac- YVAD-cho, and MCC950 suppressed IL-1ß responses and the important steroid-resistant features of disease in mice, whereas IL-1ß administration recapitulated these features. Neutrophil depletion suppressed IL-1ß-induced steroid-resistant airway hyperresponsiveness. Conclusions: NLRP3 inflammasome responses drive experimental severe, steroid-resistant asthma and are potential therapeutic targets in this disease.

DOI 10.1164/rccm.201609-1830OC
Citations Scopus - 26Web of Science - 22
Co-authors Katherine Baines, Peter Gibson, Peter Wark, Malcolm Starkey, Lisa Wood, Jay Horvat, Darryl Knight, Jodie Simpson, Nicole Hansbro
2017 Kedzierski L, Tate MD, Hsu AC, Kolesnik TB, Linossi EM, Dagley L, et al., 'Suppressor of cytokine signaling (SOCS)5 ameliorates influenza infection via inhibition of EGFR signaling', eLife, 6 1-27 (2017) [C1]
DOI 10.7554/eLife.20444
Citations Scopus - 10Web of Science - 6
Co-authors Malcolm Starkey, Alan Hsu, Peter Wark
2017 Soni N, Tekade M, Kesharwani P, Bhattacharya P, Maheshwari R, Dua K, et al., 'Recent advances in oncological submissions of dendrimer', Current Pharmaceutical Design, 23 3084-3098 (2017) [C1]

© 2017 Bentham Science Publishers. Background: Disseminated metastatic cancer requires insistent management owing to its reduced responsiveness for chemotherapeutic agents, toxici... [more]

© 2017 Bentham Science Publishers. Background: Disseminated metastatic cancer requires insistent management owing to its reduced responsiveness for chemotherapeutic agents, toxicity to normal cells consequently lower survival rate and hampered quality of life of patients. Methods: Dendrimer mediated cancer therapy is advantageous over conventional chemotherapy, radiotherapy and surgical resection due to reduced systemic toxicity, and molecular level cell injury to cancerous mass, for an appreciable survival of the subject. Recently used dendrimer mediated nanotechnology for oncology aims to conquer these challenges. Dendrimers based nano-constructs are having architectures comparable to that of biological vesicles present in the human body. Results: Operating with dendrimer technology, proffers the exclusive and novel strategies with numerous applications in cancer management involving diagnostics, therapeutics, imaging, and prognostics by sub-molecular interactions. Dendrimers are designed to acquire the benefits of the malignant tumor morphology and characteristics, i.e. leaky vasculature of tumor, expression of specific cell surface antigen, and rapid proliferation. Conclusion: Dendrimers mediated targeted therapy recommends innovatory function equally in diagnostics (imaging, immune-detection) as well as chemotherapy. Currently, dendrimers as nanomedicine has offered a strong assurance and advancement in drastically varying approaches towards cancer imaging and treatment. The present review discusses different approaches for cancer diagnosis and treatment such as, targeted and control therapy, photodynamic therapy, photo-thermal therapy, gene therapy, antiangiogenics therapy, radiotherapy etc.

DOI 10.2174/1381612823666170329150201
Citations Scopus - 6Web of Science - 3
2017 Shukla SD, Budden KF, Neal R, Hansbro PM, 'Microbiome effects on immunity, health and disease in the lung', CLINICAL & TRANSLATIONAL IMMUNOLOGY, 6 (2017) [C1]
DOI 10.1038/cti.2017.6
Citations Scopus - 33Web of Science - 27
2017 Dua K, Shukla SD, Andreoli Pinto TDJ, Hansbro PM, 'Nanotechnology: Advancing the translational respiratory research', INTERVENTIONAL MEDICINE AND APPLIED SCIENCE, 9 39-41 (2017)
DOI 10.1556/1646.9.2017.02
Citations Scopus - 2Web of Science - 2
2017 Shukla SD, Hansbro PM, Walters EH, 'Blocking rhinoviral adhesion molecule (ICAM-1): potential to prevent COPD exacerbations', INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 12 1413-1414 (2017)
DOI 10.2147/COPD.S138612
2017 Shukla SD, Hansbro PM, Walters EH, 'Upregulated pneumococcal adhesion molecule (platelet-activating factor receptor) may predispose COPD patients to community-acquired pneumonia', INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 12 3111-3112 (2017)
DOI 10.2147/COPD.S151142
2017 Hsu AC-Y, Dua K, Starkey MR, Haw T-J, Nair PM, Nichol K, et al., 'MicroRNA-125a and -b inhibit A20 and MAVS to promote inflammation and impair antiviral response in COPD', JCI INSIGHT, 2 (2017) [C1]
DOI 10.1172/jci.insight.90443
Citations Web of Science - 9
Co-authors Paul Foster, Katherine Baines, Peter Wark, Alan Hsu, Malcolm Starkey
2016 Kim RY, Rae B, Neal R, Donovan C, Pinkerton J, Balachandran L, et al., 'Elucidating novel disease mechanisms in severe asthma', CLINICAL & TRANSLATIONAL IMMUNOLOGY, 5 (2016) [C1]
DOI 10.1038/cti.2016.37
Citations Web of Science - 8
Co-authors Jay Horvat, Darryl Knight, Malcolm Starkey, Chantal Donovan
2016 Sokulsky LA, Collison AM, Nightingale S, Le Fevre A, Percival E, Starkey MR, et al., 'TRAIL deficiency and PP2A activation with salmeterol ameliorates egg allergen-driven eosinophilic esophagitis', American Journal of Physiology - Gastrointestinal and Liver Physiology, 311 G998-G1008 (2016) [C1]

© 2016 the American Physiological Society. Food antigens are common inflammatory triggers in pediatric eosinophilic esophagitis (EoE). TNFrelated apoptosis-inducing ligand (TRAIL)... [more]

© 2016 the American Physiological Society. Food antigens are common inflammatory triggers in pediatric eosinophilic esophagitis (EoE). TNFrelated apoptosis-inducing ligand (TRAIL) promotes eosinophilic inflammation through the upregulation of the E3 ubiquitin ligase Midline (MID)-1 and subsequent downregulation of protein phosphatase 2A (PP2A), but the role of this pathway in EoE that is experimentally induced by repeated food antigen challenges has not been investigated. Esophageal mucosal biopsies were collected from children with EoE and controls and assessed for TRAIL and MID-1 protein and mRNA transcript levels. Wild-type and TRAIL-deficient (Tnfsf10-/-) mice were administered subcutaneous ovalbumin (OVA) followed by oral OVA challenges. In separate experiments, OVA-challenged mice were intraperitoneally administered salmeterol or dexamethasone. Esophageal biopsies from children with EoE revealed increased levels of TRAIL and MID-1 and reduced PP2A activation compared with controls. Tnfsf10-/- mice were largely protected from esophageal fibrosis, eosinophilic inflammation, and the upregulation of TSLP, IL-5, IL-13, and CCL11 when compared with wild-type mice. Salmeterol administration to wild-type mice with experimental EoE restored PP2A activity and also prevented esophageal eosinophilia, inflammatory cytokine expression, and remodeling, which was comparable to the treatment effect of dexamethasone. TRAIL and PP2A regulate inflammation and fibrosis in experimental EoE, which can be therapeutically modulated by salmeterol.

DOI 10.1152/ajpgi.00151.2016
Citations Scopus - 1Web of Science - 1
Co-authors Malcolm Starkey, Paul Foster, Joerg Mattes, Adam Collison
2016 Russell KE, Chung KF, Clarke CJ, Durham AL, Mallia P, Footitt J, et al., 'The MIF antagonist ISO-1 attenuates corticosteroid-insensitive inflammation and airways hyperresponsiveness in an ozone-induced model of COPD', PLoS ONE, 11 (2016) [C1]

Copyright © 2016 Russell et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distributio... [more]

Copyright © 2016 Russell et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Introduction. Macrophage migration inhibitory factor (MIF) is an inflammatory cytokine associated with acute and chronic inflammatory disorders and corticosteroid insensitivity. Its expression in the airways of patients with chronic obstructive pulmonary disease (COPD), a relatively steroid insensitive inflammatory disease is unclear, however. Methods. Sputum, bronchoalveolar lavage (BAL) macrophages and serum were obtained from nonsmokers, smokers and COPD patients. To mimic oxidative stress-induced COPD, mice were exposed to ozone for six-weeks and treated with ISO-1, a MIF inhibitor, and/or dexamethasone before each exposure. BAL fluid and lung tissue were collected after the final exposure. Airway hyperresponsiveness (AHR) and lung function were measured using whole body plethysmography. HIF-1a binding to the Mif promoter was determined by Chromatin Immunoprecipitation assays. Results. MIF levels in sputum and BAL macrophages from COPD patients were higher than those from non-smokers, with healthy smokers having intermediate levels. MIF expression correlated with that of HIF-1a in all patients groups and in ozone-exposed mice. BAL cell counts, cytokine mRNA and protein expression in lungs and BAL, including MIF, were elevated in ozone-exposed mice and had increased AHR. Dexamethasone had no effect on these parameters in the mouse but ISO-1 attenuated cell recruitment, cytokine release and AHR. Conclusion MIF and HIF-1a levels are elevated in COPD BAL macrophages and inhibition of MIF function blocks corticosteroid-insensitive lung inflammation and AHR. Inhibition of MIF may provide a novel anti-inflammatory approach in COPD.

DOI 10.1371/journal.pone.0146102
Citations Scopus - 16Web of Science - 10
Co-authors Malcolm Starkey
2016 Simpson JL, Baines KJ, Horvat JC, Essilfie AT, Brown AC, Tooze M, et al., 'COPD is characterized by increased detection of Haemophilus influenzae, Streptococcus pneumoniae and a deficiency of Bacillus species', Respirology, 21 697-704 (2016) [C1]

© 2016 Asian Pacific Society of Respirology. Background and objective Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation and inflammat... [more]

© 2016 Asian Pacific Society of Respirology. Background and objective Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow limitation and inflammation. Airway bacterial colonization is increased in COPD; however, the role of potentially pathogenic and non-pathogenic bacteria in the pathogenesis of disease is unclear. This study characterized the presence of bacteria in a well-characterized cohort of adults with COPD and healthy controls. Methods Adults with COPD (n = 70) and healthy controls (n = 51) underwent clinical assessment and sputum induction. Sputum was dispersed, and total and differential cell counts were performed. Bacteria were cultured, identified and enumerated. Supernatants were assessed for neutrophil elastase (NE) and IL-1ß. Common respiratory pathogens were also determined using real-time PCR. Results Participants with COPD had a typical neutrophilic inflammatory profile. The total load of bacteria was increased in COPD and was associated with poorer respiratory health status, as measured by the St George's Respiratory Questionnaire (Spearman's r = 0.336, P = 0.013). Significantly lower levels of culturable Bacillus species were identified compared with healthy controls. PCR analyses revealed increased rates of detection of potentially pathogenic bacteria with Haemophilus influenzae detection associated with higher sputum levels of NE and IL-1ß, while Streptococcus pneumoniae was more common in male ex-smokers with emphysema and a deficit in diffusion capacity. Conclusion Non-pathogenic and pathogenic bacteria were altered in the sputum of patients with COPD. These observations highlight the potential to identify treatment and management strategies that both target specific bacterial pathogens and restore the microbial balance, which may lead to reductions in inflammation and subsequent improvements in lung health.

DOI 10.1111/resp.12734
Citations Scopus - 14Web of Science - 14
Co-authors Peter Gibson, Jodie Simpson, Katherine Baines, Vanessa Mcdonald, Jay Horvat
2016 Haw TJ, Starkey MR, Nair PM, Pavlidis S, Liu G, Nguyen DH, et al., 'A pathogenic role for tumor necrosis factor-related apoptosis-inducing ligand in chronic obstructive pulmonary disease', Mucosal Immunology, 9 859-872 (2016) [C1]

Chronic obstructive pulmonary disease (COPD) is a life-Threatening inflammatory respiratory disorder, often induced by cigarette smoke (CS) exposure. The development of effective ... [more]

Chronic obstructive pulmonary disease (COPD) is a life-Threatening inflammatory respiratory disorder, often induced by cigarette smoke (CS) exposure. The development of effective therapies is impaired by a lack of understanding of the underlining mechanisms. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a cytokine with inflammatory and apoptotic properties. We interrogated a mouse model of CS-induced experimental COPD and human tissues to identify a novel role for TRAIL in COPD pathogenesis. CS exposure of wild-Type mice increased TRAIL and its receptor messenger RNA (mRNA) expression and protein levels, as well as the number of TRAIL + CD11b + monocytes in the lung. TRAIL and its receptor mRNA were also increased in human COPD. CS-exposed TRAIL-deficient mice had decreased pulmonary inflammation, pro-inflammatory mediators, emphysema-like alveolar enlargement, and improved lung function. TRAIL-deficient mice also developed spontaneous small airway changes with increased epithelial cell thickness and collagen deposition, independent of CS exposure. Importantly, therapeutic neutralization of TRAIL, after the establishment of early-stage experimental COPD, reduced pulmonary inflammation, emphysema-like alveolar enlargement, and small airway changes. These data provide further evidence for TRAIL being a pivotal inflammatory factor in respiratory diseases, and the first preclinical evidence to suggest that therapeutic agents that target TRAIL may be effective in COPD therapy.

DOI 10.1038/mi.2015.111
Citations Scopus - 22Web of Science - 20
Co-authors Joerg Mattes, Gang Liu, Paul Foster, Peter Wark, Darryl Knight, Adam Collison, Jay Horvat, Alan Hsu, Malcolm Starkey
2016 Thorburn AN, Tseng H-Y, Donovan C, Hansbro NG, Jarnicki AG, Foster PS, et al., 'TLR2, TLR4 AND MyD88 Mediate Allergic Airway Disease (AAD) and Streptococcus pneumoniae-Induced Suppression of AAD.', PLoS One, 11 e0156402 (2016) [C1]
DOI 10.1371/journal.pone.0156402
Citations Scopus - 6Web of Science - 4
Co-authors Paul Foster, Peter Gibson, Chantal Donovan, Nicole Hansbro
2016 Tang FSM, Hansbro PM, Burgess JK, Ammit AJ, Baines KJ, Oliver BG, 'A novel immunomodulatory function of neutrophils on rhinovirus-Activated monocytes in vitro', Thorax, 71 1039-1049 (2016) [C1]

© 2016 Published by the BMJ Publishing Group Limited. Background Rhinovirus (RV) infections are the major precipitant of asthma exacerbations. While neutrophilic lung inflammation... [more]

© 2016 Published by the BMJ Publishing Group Limited. Background Rhinovirus (RV) infections are the major precipitant of asthma exacerbations. While neutrophilic lung inflammation occurs during such infections, its role remains unclear. Neutrophilic inflammation is associated with increased asthma severity and steroid refractory disease. Neutrophils are vital for controlling infections but also have immunomodulatory functions. Previously, we found that neutrophils respond to viral mimetics but not replication competent RV. We aimed to investigate if neutrophils are activated and/or modulate immune responses of monocytes during RV16 infection. Methods Primary human monocytes and autologous neutrophils were cocultured with or without RV16, in direct contact or separated by transwells. RV16-stimulated monocytes were also exposed to lysed neutrophils, neutrophil membrane components or soluble neutrophil intracellular components. Interleukin 6 (IL-6) and C-X-C motif (CXC)L8 mRNA and proteins were measured by quantitative PCR and ELISA at 24â ¿..hours. Results RV16 induced IL-6 and CXCL8 in monocytes, but not neutrophils. RV16-induced IL-6 and CXCL8 from monocytes was reduced in the presence of live neutrophils. Transwell separation abolished the inhibitory effects. Lysed neutrophils inhibited RV16-induced IL-6 and CXCL8 from monocytes. Neutrophil intracellular components alone effectively inhibited RV16-induced monocyte-derived IL-6 and CXCL8. Neutrophil intracellular components reduced RV16-induced IL-6 and CXCL8 mRNA in monocytes. Conclusions Cell contact between monocytes and neutrophils is required, and preformed neutrophil mediator(s) are likely to be involved in the suppression of cytokine mRNA and protein production. This study demonstrates a novel regulatory function of neutrophils on RV-Activated monocytes in vitro, challenging the paradigm that neutrophils are predominantly proinflammatory.

DOI 10.1136/thoraxjnl-2015-207781
Citations Scopus - 7Web of Science - 6
Co-authors Katherine Baines
2016 Rahman MM, Rumzhum NN, Hansbro PM, Morris JC, Clark AR, Verrills NM, Ammit AJ, 'Activating protein phosphatase 2A (PP2A) enhances tristetraprolin (TTP) anti-inflammatory function in A549 lung epithelial cells', Cellular Signalling, 28 325-334 (2016) [C1]

© 2016. Chronic respiratory diseases are driven by inflammation, but some clinical conditions (severe asthma, COPD) are refractory to conventional anti-inflammatory therapies. Thu... [more]

© 2016. Chronic respiratory diseases are driven by inflammation, but some clinical conditions (severe asthma, COPD) are refractory to conventional anti-inflammatory therapies. Thus, novel anti-inflammatory strategies are necessary. The mRNA destabilizing protein, tristetraprolin (TTP), is an anti-inflammatory molecule that functions to induce mRNA decay of cytokines that drive pathogenesis of respiratory disorders. TTP is regulated by phosphorylation and protein phosphatase 2A (PP2A) is responsible for dephosphorylating (and hence activating) TTP, amongst other targets. PP2A is activated by small molecules, FTY720 and AAL(S), and in this study we examine whether these compounds repress cytokine production in a cellular model of airway inflammation using A549 lung epithelial cells stimulated with tumor necrosis factor a (TNFa) in vitro. PP2A activators significantly increase TNFa-induced PP2A activity and inhibit mRNA expression and protein secretion of interleukin 8 (IL-8) and IL-6; two key pro-inflammatory cytokines implicated in respiratory disease and TTP targets. The effect of PP2A activators is not via an increase in TNFa-induced TTP mRNA expression; instead we demonstrate a link between PP2A activation and TTP anti-inflammatory function by showing that specific knockdown of TTP with siRNA reversed the repression of TNFa-induced IL-8 and IL-6 mRNA expression and protein secretion by FTY720. Therefore we propose that PP2A activators affect the dynamic equilibrium regulating TTP; shifting the equilibrium from phosphorylated (inactive) towards unphosphorylated (active) but unstable TTP. PP2A activators boost the anti-inflammatory function of TTP and have implications for future pharmacotherapeutic strategies to combat inflammation in respiratory disease.

DOI 10.1016/j.cellsig.2016.01.009
Citations Scopus - 12Web of Science - 13
Co-authors Nikki Verrills
2016 Gold MJ, Hiebert PR, Park HY, Stefanowicz D, Le A, Starkey MR, et al., 'Mucosal production of uric acid by airway epithelial cells contributes to particulate matter-induced allergic sensitization', Mucosal Immunology, 9 809-820 (2016) [C1]

Exposure to particulate matter (PM), a major component of air pollution, contributes to increased morbidity and mortality worldwide. PM induces innate immune responses and contrib... [more]

Exposure to particulate matter (PM), a major component of air pollution, contributes to increased morbidity and mortality worldwide. PM induces innate immune responses and contributes to allergic sensitization, although the mechanisms governing this process remain unclear. Lung mucosal uric acid has also been linked to allergic sensitization. The links among PM exposure, uric acid, and allergic sensitization remain unexplored. We therefore investigated the mechanisms behind PM-induced allergic sensitization in the context of lung mucosal uric acid. PM 10 and house dust mite exposure selectively induced lung mucosal uric acid production and secretion in vivo, which did not occur with other challenges (lipopolysaccharide, virus, bacteria, or inflammatory/fibrotic stimuli). PM 10 -induced uric acid mediates allergic sensitization and augments antigen-specific T-cell proliferation, which is inhibited by uricase. We then demonstrate that human airway epithelial cells secrete uric acid basally and after stimulation through a previously unidentified mucosal secretion system. Our work discovers a previously unknown mechanism of air pollution-induced, uric acid-mediated, allergic sensitization that may be important in the pathogenesis of asthma.

DOI 10.1038/mi.2015.104
Citations Scopus - 18Web of Science - 20
Co-authors Gang Liu, Jay Horvat, Malcolm Starkey, Darryl Knight
2016 Jarnicki AG, Schilter H, Liu G, Wheeldon K, Essilfie AT, Foot JS, et al., 'The inhibitor of semicarbazide-sensitive amine oxidase, PXS-4728A, ameliorates key features of chronic obstructive pulmonary disease in a mouse model', British Journal of Pharmacology, 173 3161-3175 (2016) [C1]

© 2016 The British Pharmacological Society Background and Purpose: Chronic obstructive pulmonary disease (COPD) is a major cause of illness and death, often induced by cigarette s... [more]

© 2016 The British Pharmacological Society Background and Purpose: Chronic obstructive pulmonary disease (COPD) is a major cause of illness and death, often induced by cigarette smoking (CS). It is characterized by pulmonary inflammation and fibrosis that impairs lung function. Existing treatments aim to control symptoms but have low efficacy, and there are no broadly effective treatments. A new potential target is the ectoenzyme, semicarbazide-sensitive mono-amine oxidase (SSAO; also known as vascular adhesion protein-1). SSAO is elevated in smokers¿ serum and is a pro-inflammatory enzyme facilitating adhesion and transmigration of leukocytes from the vasculature to sites of inflammation. Experimental Approach: PXS-4728A was developed as a low MW inhibitor of SSAO. A model of COPD induced by CS in mice reproduces key aspects of human COPD, including chronic airway inflammation, fibrosis and impaired lung function. This model was used to assess suppression of SSAO activity and amelioration of inflammation and other characteristic features of COPD. Key Results: Treatment with PXS-4728A completely inhibited lung and systemic SSAO activity induced by acute and chronic CS-exposure. Daily oral treatment inhibited airway inflammation (immune cell influx and inflammatory factors) induced by acute CS-exposure. Therapeutic treatment during chronic CS-exposure, when the key features of experimental COPD develop and progress, substantially suppressed inflammatory cell influx and fibrosis in the airways and improved lung function. Conclusions and Implications: Treatment with a low MW inhibitor of SSAO, PXS-4728A, suppressed airway inflammation and fibrosis and improved lung function in experimental COPD, demonstrating the therapeutic potential of PXS-4728A for this debilitating disease.

DOI 10.1111/bph.13573
Citations Scopus - 9Web of Science - 7
Co-authors Gang Liu
2016 Hsu ACY, Parsons K, Moheimani F, Knight DA, Hansbro PM, Fujita T, Wark PA, 'Impaired antiviral stress granule and IFN-ß enhanceosome formation enhances susceptibility to influenza infection in chronic obstructive pulmonary disease epithelium', American Journal of Respiratory Cell and Molecular Biology, 55 117-127 (2016) [C1]

Chronic obstructive pulmonary disease (COPD) is a serious lung disease that progressively worsens lung function. Those affected are highly susceptible to influenza virus infection... [more]

Chronic obstructive pulmonary disease (COPD) is a serious lung disease that progressively worsens lung function. Those affected are highly susceptible to influenza virus infections that result in exacerbations with exaggerated symptoms with increased mortality. The mechanisms underpinning this increased susceptibility to infection in COPD are unclear. In this study, we show that primary bronchial epithelial cells (pBECs) from subjects with COPD have impaired induction of type I IFN (IFN-ß) and lead to heightened viral replication after influenza viral infection. COPD pBECs have reduced protein levels of protein kinase (PK) R and decreased formation of PKR-mediated antiviral stress granules, which are critical in initiating type I IFNinductions. In addition, reduced protein expression of p300 resulted in decreased activation of IFN regulatory factor 3 and subsequent formation of IFN-ß enhanceosome in COPD pBECs. The decreased p300 induction was the result of enhanced levels of microRNA (miR)-132. Ectopic expression of PKR or miR-132 antagomiR alone failed to restore IFN-ß induction, whereas cotreatment increased antiviral stress granule formation, induction of p300, and IFN-ß in COPD pBECs. This study reveals that decreased induction of both PKR and p300 proteins contribute to impaired induction of IFN-ß in COPD pBECs upon influenza infection.

DOI 10.1165/rcmb.2015-0306OC
Citations Scopus - 7Web of Science - 9
Co-authors Alan Hsu, Peter Wark, Darryl Knight, Fatemeh Moheimani
2016 Wark P, Hsu A, Starkey M, Hansbro P, 'Micro-RNA-125a/b target A20 and MAVS to promote inflammatory and impair antiviral responses in chronic obstructive pulmonary disease', EUROPEAN RESPIRATORY JOURNAL, 48 (2016)
DOI 10.1183/13993003.congress-2016.PA4658
Co-authors Alan Hsu, Peter Wark
2016 Rahman MM, Prunte L, Lebender LF, Patel BS, Gelissen I, Hansbro PM, et al., 'The phosphorylated form of FTY720 activates PP2A, represses inflammation and is devoid of S1P agonism in A549 lung epithelial cells', SCIENTIFIC REPORTS, 6 (2016) [C1]
DOI 10.1038/srep37297
Citations Scopus - 5Web of Science - 5
Co-authors Nikki Verrills
2016 Dhouib R, Othman DSMP, Lin V, Lai XJ, Wijesinghe HGS, Essilfie A-T, et al., 'A Novel, Molybdenum-Containing Methionine Sulfoxide Reductase Supports Survival of Haemophilus influenzae in an In vivo Model of Infection', FRONTIERS IN MICROBIOLOGY, 7 (2016) [C1]
DOI 10.3389/fmicb.2016.01743
Citations Scopus - 2Web of Science - 1
2016 Ge L, Habiel DM, Hansbro PM, Kim RY, Gharib SA, Edelman JD, et al., 'miR-323a-3p regulates lung fibrosis by targeting multiple profibrotic pathways', JCI INSIGHT, 1 (2016) [C1]
DOI 10.1172/jci.insight.90301
Citations Scopus - 5Web of Science - 5
2016 Starkey MR, Nguyen DH, Brown AC, Essilfie AT, Kim RY, Yagita H, et al., 'PD-L1 Promotes Early-life Chlamydia Respiratory Infection-induced Severe Allergic Airway Disease.', American journal of respiratory cell and molecular biology, (2016) [C1]
Citations Scopus - 7Web of Science - 7
Co-authors Malcolm Starkey, Jay Horvat
2016 Rahman MM, Prabhala P, Rumzhum NN, Patel BS, Wickop T, Hansbro PM, et al., 'TLR2 ligation induces corticosteroid insensitivity in A549 lung epithelial cells: Anti-inflammatory impact of PP2A activators', International Journal of Biochemistry and Cell Biology, 78 279-287 (2016) [C1]

© 2016 Elsevier Ltd Corticosteroids are effective anti-inflammatory therapies widely utilized in chronic respiratory diseases. But these medicines can lose their efficacy during r... [more]

© 2016 Elsevier Ltd Corticosteroids are effective anti-inflammatory therapies widely utilized in chronic respiratory diseases. But these medicines can lose their efficacy during respiratory infection resulting in disease exacerbation. Further in vitro research is required to understand how infection worsens lung function control in order to advance therapeutic options to treat infectious exacerbation in the future. In this study, we utilize a cellular model of bacterial exacerbation where we pretreat A549 lung epithelial cells with the synthetic bacterial lipoprotein Pam3CSK4 (a TLR2 ligand) to mimic bacterial infection and tumor necrosis factor a (TNFa) to simulate inflammation. Under these conditions, Pam3CSK4 induces corticosteroid insensitivity; demonstrated by substantially reduced ability of the corticosteroid dexamethasone to repress TNFa-induced interleukin 6 secretion. We then explored the molecular mechanism responsible and found that corticosteroid insensitivity induced by bacterial mimics was not due to altered translocation of the glucocorticoid receptor into the nucleus, nor an impact on the NF-¿B pathway. Moreover, Pam3CSK4 did not affect corticosteroid-induced upregulation of anti-inflammatory MAPK deactivating phosphatase¿MKP-1. However, Pam3CSK4 can induce oxidative stress and we show that a proportion of the MKP-1 produced in response to corticosteroid in the context of TLR2 ligation was rendered inactive by oxidation. Thus to combat inflammation in the context of bacterial exacerbation we sought to discover effective strategies that bypassed this road-block. We show for the first time that known (FTY720) and novel (theophylline) activators of the phosphatase PP2A can serve as non-steroidal anti-inflammatory alternatives and/or corticosteroid-sparing approaches in respiratory inflammation where corticosteroid insensitivity exists.

DOI 10.1016/j.biocel.2016.07.030
Citations Scopus - 3Web of Science - 3
Co-authors Nikki Verrills
2016 Ren S, Hure A, Peel R, D'Este C, Abhayaratna W, Tonkin A, et al., 'Rationale and design of a randomized controlled trial of pneumococcal polysaccharide vaccine for prevention of cardiovascular events: The Australian Study for the Prevention through Immunization of Cardiovascular Events (AUSPICE)', American Heart Journal, 177 58-65 (2016) [C1]
DOI 10.1016/j.ahj.2016.04.003
Citations Scopus - 7Web of Science - 7
Co-authors David Durrheim, Alexis Hure, Roseanne Peel, Christopher Levi, David Newby, Mark Mcevoy, Catherine Deste, John Attia
2016 Gang L, Hsu A, Cooley MA, Jarnicki AG, Nair PM, Haw TJ, et al., 'Fibulin-1 regulates the pathogenesis of tissue remodeling in respiratory diseases', Journal of Clinical Investigation Insight, 1 (2016) [C1]
DOI 10.1172/jci.insight.86380
Citations Web of Science - 24
Co-authors Gang Liu, Michael Fricker, Alan Hsu, Jay Horvat, Darryl Knight, Marjorie Walker, Peter Wark
2016 Camlin NJ, Sobinoff AP, Sutherland JM, Beckett EL, Jarnicki AG, Vanders RL, et al., 'Maternal Smoke Exposure Impairs the Long-Term Fertility of Female Offspring in a Murine Model.', Biol Reprod, 94 39 (2016) [C1]
DOI 10.1095/biolreprod.115.135848
Citations Scopus - 17Web of Science - 15
Co-authors Janet Bristow, Jessie Sutherland, Eileen Mclaughlin, Emma Beckett
2016 J Woods J, L Martin K, 'Cigarette Smoking: A Causal Factor for Alzheimers Disease?', Journal of Gerontology & Geriatric Research, 05 (2016)
DOI 10.4172/2167-7182.1000286
Co-authors Jay Horvat, Liz Milward
2016 Moores N, Rogers DI, Rogers K, Hansbro PM, 'Reclamation of tidal flats and shorebird declines in Saemangeum and elsewhere in the Republic of Korea', Emu, 116 136-146 (2016) [C1]

© BirdLife Australia 2016. Saemangeum, in the Republic of Korea (ROK, commonly called South Korea) was one of the most important shorebird staging sites in the Yellow Sea. It supp... [more]

© BirdLife Australia 2016. Saemangeum, in the Republic of Korea (ROK, commonly called South Korea) was one of the most important shorebird staging sites in the Yellow Sea. It supported at least 330000 shorebirds annually between 1997 and 2001, including ~30% of the world population of Great Knots (Calidris tenuirostris) during both northward and southward migration. Construction of a 33-km long sea-wall was completed in April 2006. We show that shorebird numbers at Saemangeum and two adjacent wetlands decreased by 130000 during northward migration in the next two years and that all species have declined at Saemangeum since completion of the sea-wall. Great Knots were among the most rapidly affected species. Fewer than 5000 shorebirds were recorded at Saemangeum during northward migration in 2014. We found no evidence to suggest that most shorebirds of any species displaced from Saemangeum successfully relocated to other sites in the ROK. Instead, by 2011-13 nearly all species had declined substantially in the ROK since previous national surveys in 1998 and 2008, especially at more heavily reclaimed sites. It is likely that these declines were driven by increased mortality rather than movement to alternate staging sites given that other studies have shown concurrent declines in numbers and survival on the non-breeding grounds. This is the first study in the East Asian-Australasian Flyway to confirm declines of shorebirds at a range of geographical scales following a single reclamation project. The results indicate that if migratory shorebirds are displaced from major staging sites by reclamation they are probably unable to relocate successfully to alternate sites.

DOI 10.1071/MU16006
Citations Scopus - 11Web of Science - 7
2016 Moheimani F, Hsu AC-Y, Reid AT, Williams T, Kicic A, Stick SM, et al., 'The genetic and epigenetic landscapes of the epithelium in asthma', RESPIRATORY RESEARCH, 17 (2016) [C1]
DOI 10.1186/s12931-016-0434-4
Citations Scopus - 17Web of Science - 16
Co-authors Fatemeh Moheimani, Andrew Reid, Alan Hsu, Darryl Knight, Peter Wark
2016 Ormerod KL, Wood DLA, Lachner N, Gellatly SL, Daly JN, Parsons JD, et al., 'Genomic characterization of the uncultured Bacteroidales family S24-7 inhabiting the guts of homeothermic animals.', Microbiome, 4 36 (2016) [C1]
DOI 10.1186/s40168-016-0181-2
Citations Scopus - 72Web of Science - 69
2015 Essilfie A, Horvat JC, Kim RY, Mayall JR, Pinkerton JW, Beckett EL, et al., 'Macrolide therapy suppresses key features of experimental steroid-sensitive and steroid-insensitive asthma', Thorax Journal, 70 458-467 (2015) [C1]
DOI 10.1136/thoraxjnl-2014-206067
Citations Scopus - 44Web of Science - 43
Co-authors Jodie Simpson, Peter Gibson, Malcolm Starkey, Paul Foster, Emma Beckett, Jay Horvat
2015 Vanders RL, Murphy VE, Gibson PG, Hansbro PM, Wark PAB, 'CD8 T cells and dendritic cells: Key players in the attenuated maternal immune response to influenza infection', Journal of Reproductive Immunology, 107 1-9 (2015) [C1]

© 2014 Elsevier Ireland Ltd. Pregnancy provides a unique challenge for maternal immunity, requiring the ability to tolerate the presence of a semi-allogeneic foetus, and yet still... [more]

© 2014 Elsevier Ireland Ltd. Pregnancy provides a unique challenge for maternal immunity, requiring the ability to tolerate the presence of a semi-allogeneic foetus, and yet still being capable of inducing an immune response against invading pathogens. To achieve this, numerous changes must occur in the activity and function of maternal immune cells throughout the course of pregnancy. Respiratory viruses take advantage of these changes, altering the sensitive balance of maternal immunity, leaving the mother with increased susceptibility to viral infections and increased disease severity. Influenza virus is one of the most common respiratory virus infections during pregnancy, leading to an increased risk of ICU hospitalisations, pneumonia, acute respiratory distress syndrome and even death. Whilst much research has been performed to understand the changes that must take place in maternal immunity during pregnancy, considerable work is still needed to fully comprehend this tremendous feat. To date, few studies have focused on the alterations that occur in maternal immunity during respiratory virus infections. This review highlights the role of dendritic cells (DCs) and CD8 T cells during pregnancy, and the changes that occur in these antiviral cells following influenza virus infections.

DOI 10.1016/j.jri.2014.09.051
Citations Scopus - 6Web of Science - 7
Co-authors Vanessa Murphy, Peter Gibson, Peter Wark
2015 Griekspoor P, Hansbro PM, Waldenström J, Olsen B, 'Campylobacter jejuni sequence types show remarkable spatial and temporal stability in Blackbirds.', Infection ecology & epidemiology, 5 1-5 (2015) [C1]
DOI 10.3402/iee.v5.28383
2015 Zouikr I, Ahmed AF, Horvat JC, Beagley KW, Clifton VL, Ray A, et al., 'Programming of formalin-induced nociception by neonatal LPS exposure: Maintenance by peripheral and central neuroimmune activity', Brain, Behavior, and Immunity, 44 235-246 (2015) [C1]

© 2014. The immune and nociceptive systems are shaped during the neonatal period where they undergo fine-tuning and maturation. Painful experiences during this sensitive period of... [more]

© 2014. The immune and nociceptive systems are shaped during the neonatal period where they undergo fine-tuning and maturation. Painful experiences during this sensitive period of development are known to produce long-lasting effects on the immune and nociceptive responses. It is less clear, however, whether inflammatory pain responses are primed by neonatal exposure to mild immunological stimuli, such as with lipopolysaccharide (LPS). Here, we examine the impact of neonatal LPS exposure on inflammatory pain responses, peripheral and hippocampal interleukin-1ß (IL-1ß), as well as mast cell number and degranulation in preadolescent and adult rats. Wistar rats were injected with LPS (0.05 mg/kg IP, Salmonella enteritidis) or saline on postnatal days (PNDs) 3 and 5 and later subjected to the formalin test at PNDs 22 and 80-97. At both time-points, and one-hour after formalin injection, blood and hippocampus were collected for measuring circulating and central IL-1ß levels using ELISA and Western blot, respectively. Paw tissue was also isolated to assess mast cell number and degree of degranulation using Toluidine Blue staining. Behavioural analyses indicate that at PND 22, LPS-challenged rats displayed enhanced flinching (p<.01) and licking (p<.01) in response to formalin injection. At PNDs 80-97, LPS-challenged rats exhibited increased flinching (p<.05), an effect observed in males only. Furthermore, neonatal LPS exposure enhanced circulating IL-1ß and mast cell degranulation in preadolescent but not adult rats following formalin injection. Hippocampal IL-1ß levels were increased in LPS-treated adult but not preadolescent rats in response to formalin injection. These data suggest neonatal LPS exposure produces developmentally regulated changes in formalin-induced behavioural responses, peripheral and central IL-1ß levels, as well as mast cell degranulation following noxious stimulation later in life. These findings highlight the importance of immune activation during the neonatal period in shaping immune response and pain sensitivity later in life. This is of clinical relevance given the high prevalence of bacterial infection during the neonatal period, particularly in the vulnerable population of preterm infants admitted to neonatal intensive care units.

DOI 10.1016/j.bbi.2014.10.014
Citations Scopus - 7Web of Science - 8
Co-authors Rick Thorne, Jay Horvat, Deborah Hodgson
2015 Tay HL, Kaiko GE, Plank M, Li J, Maltby S, Essilfie A-T, et al., 'Correction: Antagonism of miR-328 Increases the Antimicrobial Function of Macrophages and Neutrophils and Rapid Clearance of Non-typeable Haemophilus Influenzae (NTHi) from Infected Lung.', PLoS pathogens, 11 e1004956 (2015) [O1]
DOI 10.1371/journal.ppat.1004956
Citations Scopus - 1
Co-authors Joerg Mattes, Paul Foster, Steven Maltby, Hock Tay, Ming Yang, Gerard Kaiko
2015 King PT, Sharma R, O'Sullivan K, Selemidis S, Lim S, Radhakrishna N, et al., 'Nontypeable Haemophilus influenzae Induces Sustained Lung Oxidative Stress and Protease Expression', PLOS ONE, 10 (2015) [C1]
DOI 10.1371/journal.pone.0120371
Citations Scopus - 12Web of Science - 12
2015 Moheimani F, Roth HM, Cross J, Reid AT, Shaheen F, Warner SM, et al., 'Disruption of ß-catenin/CBP signaling inhibits human airway epithelial-mesenchymal transition and repair', International Journal of Biochemistry and Cell Biology, 68 59-69 (2015) [C1]

© 2015 Elsevier Ltd. The epithelium of asthmatics is characterized by reduced expression of E-cadherin and increased expression of the basal cell markers ck-5 and p63 that is indi... [more]

© 2015 Elsevier Ltd. The epithelium of asthmatics is characterized by reduced expression of E-cadherin and increased expression of the basal cell markers ck-5 and p63 that is indicative of a relatively undifferentiated repairing epithelium. This phenotype correlates with increased proliferation, compromised wound healing and an enhanced capacity to undergo epithelial-mesenchymal transition (EMT). The transcription factor ß-catenin plays a vital role in epithelial cell differentiation and regeneration, depending on the co-factor recruited. Transcriptional programs driven by the ß-catenin/CBP axis are critical for maintaining an undifferentiated and proliferative state, whereas the ß-catenin/p300 axis is associated with cell differentiation. We hypothesized that disrupting the ß-catenin/CBP signaling axis would promote epithelial differentiation and inhibit EMT. We treated monolayer cultures of human airway epithelial cells with TGFß1 in the presence or absence of the selective small molecule ICG-001 to inhibit ß-catenin/CBP signaling. We used western blots to assess expression of an EMT signature, CBP, p300, ß-catenin, fibronectin and ITGß1 and scratch wound assays to assess epithelial cell migration. Snai-1 and -2 expressions were determined using q-PCR. Exposure to TGFß1 induced EMT, characterized by reduced E-cadherin expression with increased expression of a-smooth muscle actin and EDA-fibronectin. Either co-treatment or therapeutic administration of ICG-001 completely inhibited TGFß1-induced EMT. ICG-001 also reduced the expression of ck-5 and -19 independent of TGFß1. Exposure to ICG-001 significantly inhibited epithelial cell proliferation and migration, coincident with a down regulation of ITGß1 and fibronectin expression. These data support our hypothesis that modulating the ß-catenin/CBP signaling axis plays a key role in epithelial plasticity and function.

DOI 10.1016/j.biocel.2015.08.014
Citations Scopus - 20Web of Science - 16
Co-authors Andrew Reid, Fatemeh Moheimani, Darryl Knight
2015 Baillet AC, Rehaume LM, Benham H, O'Meara CP, Armitage CW, Ruscher R, et al., 'High Chlamydia Burden Promotes Tumor Necrosis Factor-Dependent Reactive Arthritis in SKG Mice', ARTHRITIS & RHEUMATOLOGY, 67 1535-1547 (2015) [C1]
DOI 10.1002/art.39041
Citations Scopus - 13Web of Science - 10
2015 Hsu ACY, Starkey MR, Hanish I, Parsons K, Haw TJ, Howland LJ, et al., 'Targeting PI3K-p110a suppresses influenza virus infection in chronic obstructive pulmonary disease', American Journal of Respiratory and Critical Care Medicine, 191 1012-1023 (2015) [C1]

Copyright © 2015 by the American Thoracic Society. Rationale: Chronic obstructive pulmonary disease (COPD) and influenza virus infections are major global health issues. Patients ... [more]

Copyright © 2015 by the American Thoracic Society. Rationale: Chronic obstructive pulmonary disease (COPD) and influenza virus infections are major global health issues. Patients with COPD are more susceptible to infection, which exacerbates their condition and increases morbidity and mortality. The mechanisms of increased susceptibility remain poorly understood, and current preventions and treatments have substantial limitations. Objectives: To characterize the mechanisms of increased susceptibility to influenza virus infection in COPD and the potential for therapeutic targeting. Methods: We used a combination of primary bronchial epithelial cells (pBECs) from COPD and healthy control subjects, a mouse model of cigarette smoke-induced experimental COPD, and influenza infection. The role of the phosphoinositide-3-kinase (PI3K) pathway was characterized using molecular methods, and its potential for targeting assessed using inhibitors. Measurements and Main Results: COPDpBECs were susceptible to increased viral entry and replication. Infected mice with experimental COPD also had more severe infection (increased viral titer and pulmonary inflammation, and compromised lung function). These processes were associated with impaired antiviral immunity, reduced retinoic acid-inducible gene-I, and IFN/cytokine and chemokine responses. Increased PI3K-p110a levels and activity inCOPDpBECs and/or mice were responsible for increased infection and reduced antiviral responses. Global PI3K, specific therapeutic p110a inhibitors, or exogenous IFN-b restored protective antiviral responses, suppressed infection, and improved lung function. Conclusions: The increased susceptibility of individuals with COPD to influenza likely results from impaired antiviral responses, which are mediated by increased PI3K-p110a activity. This pathway may be targeted therapeutically in COPD, or in healthy individuals, during seasonal or pandemic outbreaks to prevent and/or treat influenza.

DOI 10.1164/rccm.201501-0188OC
Citations Scopus - 47Web of Science - 46
Co-authors Paul Foster, Darryl Knight, Peter Wark, Malcolm Starkey, Alan Hsu
2015 Sozo F, Horvat JC, Essilfie A-T, O'Reilly M, Hansbro PM, Harding R, 'Altered lung function at mid-adulthood in mice following neonatal exposure to hyperoxia.', Respir Physiol Neurobiol, 218 21-27 (2015) [C1]
DOI 10.1016/j.resp.2015.07.004
Citations Scopus - 7Web of Science - 6
Co-authors Jay Horvat
2015 Grillo VL, Arzey KE, Hansbro PM, Hurt AC, Warner S, Bergfeld J, et al., 'Avian influenza in Australia: A summary of 5 years of wild bird surveillance', Australian Veterinary Journal, 93 387-393 (2015) [C1]

© 2015 Australian Veterinary Association. Background: Avian influenza viruses (AIVs) are found worldwide in numerous bird species, causing significant disease in gallinaceous poul... [more]

© 2015 Australian Veterinary Association. Background: Avian influenza viruses (AIVs) are found worldwide in numerous bird species, causing significant disease in gallinaceous poultry and occasionally other species. Surveillance of wild bird reservoirs provides an opportunity to add to the understanding of the epidemiology of AIVs. Methods: This study examined key findings from the National Avian Influenza Wild Bird Surveillance Program over a 5-year period (July 2007-June 2012), the main source of information on AIVs circulating in Australia. Results: The overall proportion of birds that tested positive for influenza A via PCR was 1.9±0.1%, with evidence of widespread exposure of Australian wild birds to most low pathogenic avian influenza (LPAI) subtypes (H1-13, H16). LPAI H5 subtypes were found to be dominant and widespread during this 5-year period. Conclusion: Given Australia's isolation, both geographically and ecologically, it is important for Australia not to assume that the epidemiology of AIV from other geographic regions applies here. Despite all previous highly pathogenic avian influenza outbreaks in Australian poultry being attributed to H7 subtypes, widespread detection of H5 subtypes in wild birds may represent an ongoing risk to the Australian poultry industry.

DOI 10.1111/avj.12379
Citations Scopus - 11Web of Science - 9
2015 Singanayagam A, Glanville N, Walton RP, Aniscenko J, Pearson RM, Pinkerton JW, et al., 'A short-term mouse model that reproduces the immunopathological features of rhinovirus-induced exacerbation of COPD.', Clin Sci (Lond), 129 245-258 (2015) [C1]
DOI 10.1042/CS20140654
Citations Scopus - 20Web of Science - 16
Co-authors Nathan Bartlett, Jay Horvat
2015 Plank MW, Maltby S, Tay HL, Stewart J, Eyers F, Hansbro PM, Foster PS, 'MicroRNA Expression Is Altered in an Ovalbumin-Induced Asthma Model and Targeting miR-155 with Antagomirs Reveals Cellular Specificity.', PloS one, 10 1-25 (2015) [C1]
DOI 10.1371/journal.pone.0144810
Citations Scopus - 18Web of Science - 20
Co-authors Paul Foster, Steven Maltby, Hock Tay
2015 Tolosa JM, Parsons KS, Hansbro PM, Smith R, Wark PB, 'The placental protein syncytin-1 impairs antiviral responses and exaggerates inflammatory responses to influenza', PLoS ONE, 10 (2015) [C1]

© 2015 Tolosa et al. Background Pregnancy increases susceptibility to influenza. The placenta releases an immunosuppressive endogenous retroviral protein syncytin-1.We hypothesise... [more]

© 2015 Tolosa et al. Background Pregnancy increases susceptibility to influenza. The placenta releases an immunosuppressive endogenous retroviral protein syncytin-1.We hypothesised that exposure of peripheral monocytes (PBMCs) to syncytin-1 would impair responses to H1N1pdm09 influenza. Methods and Findings Recombinant syncytin-1 was produced. PBMCs from non-pregnant women (n=10) were exposed to H1N1pdm09 in the presence and absence of syncytin-1 and compared to responses of PBMCs from pregnant women (n=12). PBMCs were characterised using flow cytometry, release of interferon (IFN)-a, IFN-¿, IFN-¿, IL-10, IL-2, IL-6 and IL-1ß were measured by cytometric bead array or ELISA. Exposure of PBMCs to H1N1pdm09 resulted in the release of IFN-a, (14,787 pg/mL, 95% CI 7311-22,264 pg/mL) IFN-¿ (1486 pg/mL, 95% CI 756-2216 pg/mL) and IFN-¿ (852 pg/mL, 95% CI 193-1511 pg/mL) after 48 hours. This was significantly impaired in pregnant women (IFN-a; p<0.0001 and IFN-¿; p<0.001). Furthermore, in the presence of syncytin-1, PBMCs demonstrated marked reductions in IFN-a and IFN-¿, while enhanced release of IL-10 as well as IL-6 and IL-1ß. Conclusions Our data indicates that a placental derived protein, syncytin-1 may be responsible for the heightened vulnerability of pregnant women to influenza.

DOI 10.1371/journal.pone.0118629
Citations Scopus - 6Web of Science - 6
Co-authors Roger Smith, Peter Wark
2015 Hirota JA, Gold MJ, Hiebert PR, Parkinson LG, Wee T, Smith D, et al., 'The Nucleotide-Binding Domain, Leucine-Rich Repeat Protein 3 Inflammasome/IL-1 Receptor I Axis Mediates Innate, but Not Adaptive, Immune Responses after Exposure to Particulate Matter under 10 mu m', AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 52 96-105 (2015) [C1]
DOI 10.1165/rcmb.2014-0158OC
Citations Scopus - 28Web of Science - 29
Co-authors Darryl Knight
2015 Ge Q, Chen L, Jaffar J, Argraves WS, Twal WO, Hansbro P, et al., 'Fibulin1C peptide induces cell attachment and extracellular matrix deposition in lung fibroblasts', SCIENTIFIC REPORTS, 5 (2015) [C1]
DOI 10.1038/srep09496
Citations Scopus - 12Web of Science - 12
Co-authors Ling Chen
2015 Kim RY, Pinkerton JW, Gibson PG, Cooper MA, Horvat JC, Hansbro PM, 'Inflammasomes in COPD and neutrophilic asthma', THORAX, 70 1199-1201 (2015) [C1]
DOI 10.1136/thoraxjnl-2014-206736
Citations Scopus - 27Web of Science - 28
Co-authors Peter Gibson, Jay Horvat
2015 Tay HL, Kaiko GE, Plank M, Li JJ, Maltby S, Essilfie AT, et al., 'Antagonism of miR-328 Increases the Antimicrobial Function of Macrophages and Neutrophils and Rapid Clearance of Non-typeable Haemophilus Influenzae (NTHi) from Infected Lung', PLoS Pathogens, 11 (2015) [C1]

© 2015 Tay et al. Pathogenic bacterial infections of the lung are life threatening and underpin chronic lung diseases. Current treatments are often ineffective potentially due to ... [more]

© 2015 Tay et al. Pathogenic bacterial infections of the lung are life threatening and underpin chronic lung diseases. Current treatments are often ineffective potentially due to increasing antibiotic resistance and impairment of innate immunity by disease processes and steroid therapy. Manipulation miRNA directly regulating anti-microbial machinery of the innate immune system may boost host defence responses. Here we demonstrate that miR-328 is a key element of the host response to pulmonary infection with non-typeable haemophilus influenzae and pharmacological inhibition in mouse and human macrophages augments phagocytosis, the production of reactive oxygen species, and microbicidal activity. Moreover, inhibition of miR-328 in respiratory models of infection, steroid-induced immunosuppression, and smoke-induced emphysema enhances bacterial clearance. Thus, miRNA pathways can be targeted in the lung to enhance host defence against a clinically relevant microbial infection and offer a potential new anti-microbial approach for the treatment of respiratory diseases.

DOI 10.1371/journal.ppat.1004549
Citations Scopus - 27Web of Science - 30
Co-authors Ming Yang, Gerard Kaiko, Hock Tay, Steven Maltby, Paul Foster, Joerg Mattes
2015 Dhouib R, Pg Othman DSM, Essilfie AT, Hansbro PM, Hanson JO, McEwan AG, Kappler U, 'Maturation of molybdoenzymes and its influence on the pathogenesis of non-typeable Haemophilus influenzae', Frontiers in Microbiology, 6 (2015) [C1]

© 2015 Dhouib, Pg Othman, Essilfie, Hansbro, Hanson, McEwan and Kappler. Mononuclear molybdenum enzymes of the dimethylsulfoxide (DMSO) reductase family occur exclusively in proka... [more]

© 2015 Dhouib, Pg Othman, Essilfie, Hansbro, Hanson, McEwan and Kappler. Mononuclear molybdenum enzymes of the dimethylsulfoxide (DMSO) reductase family occur exclusively in prokaryotes, and a loss of some these enzymes has been linked to a loss of bacterial virulence in several cases. The MobA protein catalyzes the final step in the synthesis of the molybdenum guanine dinucleotide (MGD) cofactor that is exclusive to enzymes of the DMSO reductase family. MobA has been proposed as a potential target for control of virulence since its inhibition would affect the activities of all molybdoenzymes dependent upon MGD. Here, we have studied the phenotype of a mobA mutant of the host-adapted human pathogen Haemophilus influenzae. H. influenzae causes and contributes to a variety of acute and chronic diseases of the respiratory tract, and several enzymes of the DMSO reductase family are conserved and highly expressed in this bacterium. The mobA mutation caused a significant decrease in the activities of all Mo-enzymes present, and also resulted in a small defect in anaerobic growth. However, we did not detect a defect in in vitro biofilm formation nor in invasion and adherence to human epithelial cells in tissue culture compared to the wild-type. In a murine in vivo model, the mobA mutant showed only a mild attenuation compared to the wild-type. In summary, our data show that MobA is essential for the activities of molybdenum enzymes, but does not appear to affect the fitness of H. influenzae. These results suggest that MobA is unlikely to be a useful target for antimicrobials, at least for the purpose of treating H. influenzae infections.

DOI 10.3389/fmicb.2015.01219
Citations Scopus - 2Web of Science - 2
2014 Starkey MR, Nguyen DH, Essilfie AT, Kim RY, Hatchwell LM, Collison AM, et al., 'Tumor necrosis factor-related apoptosis-inducing ligand translates neonatal respiratory infection into chronic lung disease.', Mucosal Immunol, 7 478-488 (2014) [C1]
DOI 10.1038/mi.2013.65
Citations Scopus - 24Web of Science - 25
Co-authors Malcolm Starkey, Paul Foster, Jay Horvat, Adam Collison, Joerg Mattes
2014 Franklin BS, Bossaller L, De Nardo D, Ratter JM, Stutz A, Engels G, et al., 'The adaptor ASC has extracellular and 'prionoid' activities that propagate inflammation.', Nat Immunol, 15 727-737 (2014) [C1]
DOI 10.1038/ni.2913
Citations Scopus - 229Web of Science - 223
2014 Olson SH, Parmley J, Soos C, Gilbert M, Latorre-Margalef N, Hall JS, et al., 'Sampling strategies and biodiversity of influenza A subtypes in wild birds', PLoS ONE, 9 (2014) [C1]

Wild aquatic birds are recognized as the natural reservoir of avian influenza A viruses (AIV), but across high and low pathogenic AIV strains, scientists have yet to rigorously id... [more]

Wild aquatic birds are recognized as the natural reservoir of avian influenza A viruses (AIV), but across high and low pathogenic AIV strains, scientists have yet to rigorously identify most competent hosts for the various subtypes. We examined 11,870 GenBank records to provide a baseline inventory and insight into patterns of global AIV subtype diversity and richness. Further, we conducted an extensive literature review and communicated directly with scientists to accumulate data from 50 non-overlapping studies and over 250,000 birds to assess the status of historic sampling effort. We then built virus subtype sample-based accumulation curves to better estimate sample size targets that capture a specific percentage of virus subtype richness at seven sampling locations. Our study identifies a sampling methodology that will detect an estimated 75% of circulating virus subtypes from a targeted bird population and outlines future surveillance and research priorities that are needed to explore the influence of host and virus biodiversity on emergence and transmission.

DOI 10.1371/journal.pone.0090826
Citations Scopus - 26Web of Science - 22
2014 Grafton KT, Moir LM, Black JL, Hansbro NG, Hansbro PM, Burgess JK, Oliver BG, 'LF-15 & T7, synthetic peptides derived from tumstatin, attenuate aspects of airway remodelling in a murine model of chronic OVA-induced allergic airway disease', PLoS ONE, 9 (2014) [C1]

Background: Tumstatin is a segment of the collagen-IV protein that is markedly reduced in the airways of asthmatics. Tumstatin can play an important role in the development of air... [more]

Background: Tumstatin is a segment of the collagen-IV protein that is markedly reduced in the airways of asthmatics. Tumstatin can play an important role in the development of airway remodelling associated with asthma due to its antiangiogenic properties. This study assessed the anti-angiogenic properties of smaller peptides derived from tumstatin, which contain the interface tumstatin uses to interact with the aVb3 integrin. Methods: Primary human lung endothelial cells were exposed to the LF-15, T3 and T7 tumstatin-derived peptides and assessed for cell viability and tube formation in vitro. The impact of the anti-angiogenic properties on airways hyperresponsiveness (AHR) was then examined using a murine model of chronic OVA-induced allergic airways disease. Results: The LF-15 and T7 peptides significantly reduced endothelial cell viability and attenuated tube formation in vitro. Mice exposed to OVA+ LF-15 or OVA+T7 also had reduced total lung vascularity and AHR was attenuated compared to mice exposed to OVA alone. T3 peptides reduced cell viability but had no effect on any other parameters. Conclusion: The LF-15 and T7 peptides may be appropriate candidates for use as novel pharmacotherapies due to their small size and anti-angiogenic properties observed in vitro and in vivo. © 2014 Grafton et al.

DOI 10.1371/journal.pone.0085655
Citations Scopus - 4Web of Science - 4
Co-authors Nicole Hansbro
2014 Simpson JL, Powell H, Baines KJ, Milne D, Coxson HO, Hansbro PM, Gibson PG, 'The Effect of Azithromycin in Adults with Stable Neutrophilic COPD: A Double Blind Randomised, Placebo Controlled Trial', PLOS ONE, 9 (2014) [C1]
DOI 10.1371/journal.pone.0105609
Citations Scopus - 23Web of Science - 27
Co-authors Peter Gibson, Jodie Simpson, Katherine Baines
2014 Rehaume LM, Mondot S, Aguirre De Cárcer D, Velasco J, Benham H, Hasnain SZ, et al., 'ZAP-70 genotype disrupts the relationship between microbiota and host, leading to spondyloarthritis and ileitis in SKG mice', Arthritis and Rheumatology, 66 2780-2792 (2014) [C1]

Copyright © 2014 by the American College of Rheumatology. Objective The spondyloarthritides share genetic susceptibility, interleukin-23 (IL-23) dependence, and the involvement of... [more]

Copyright © 2014 by the American College of Rheumatology. Objective The spondyloarthritides share genetic susceptibility, interleukin-23 (IL-23) dependence, and the involvement of microbiota. The aim of the current study was to elucidate how host genetics influence gut microbiota and the relationship between microbiota and organ inflammation in spondyloarthritides.Methods BALB/c ZAP-70W163C-mutant (SKG) mice, Toll-like receptor 4 (TLR-4)-deficient SKG mice, and wild-type BALB/c mice were housed under specific pathogen-free conditions. SKG and wild-type BALB/c mice were maintained under germ-free conditions, and some of these mice were recolonized with altered Schaedler flora. All of the mice were injected intraperitoneally with microbial ß-1,3-glucan (curdlan). Arthritis, spondylitis, and ileitis were assessed histologically. Microbiome composition was analyzed in serial fecal samples obtained from mice that were co-housed beginning at the time of weaning, using 454 pyrosequencing. Infiltrating cells and cytokines in the peritoneal cavity were measured by flow cytometry and enzyme-linked immunosorbent assay. Cytokine, endoplasmic reticulum (ER) stress marker, and tight junction protein transcription was measured by quantitative real-time polymerase chain reaction.Results Microbiota content and response to curdlan varied according to whether T cell receptor signal strength was normal or was impaired due to the ZAP-70W163C mutation. Curdlan triggered acute inflammation regardless of the presence of the SKG allele or microbiota. However, no or limited microbiota content attenuated the severity of arthritis. In contrast, ileal IL-23 expression, ER stress, lymph node IL-17A production, goblet cell loss, and ileitis development were microbiota-dependent. Ileitis but not arthritis was suppressed by microbiota transfer upon co-housing SKG mice with wild-type BALB/c mice, as well as by TLR-4 deficiency.Conclusion The interaction between immunogenetic background and host microbiota leads to an IL-23-dependent loss of mucosal function, triggering ileitis in response to curdlan.

DOI 10.1002/art.38773
Citations Scopus - 51Web of Science - 53
2014 Keely S, Hansbro PM, 'Lung-Gut Cross Talk A Potential Mechanism for Intestinal Dysfunction in Patients With COPD', CHEST, 145 199-200 (2014) [C3]
DOI 10.1378/chest.13-2077
Citations Scopus - 12Web of Science - 11
Co-authors Simon Keely
2014 Jaffer J, Unger S, Corte TJ, Keller M, Wolters PJ, Richeldi L, et al., 'Fibulin-1 Predicts Disease Progression in Patients With Idiopathic Pulmonary Fibrosis', CHEST, 146 1055-1063 (2014) [C1]
DOI 10.1378/chest.13-2688
Citations Scopus - 13Web of Science - 13
2014 Hansbro PM, Hamilton MJ, Fricker M, Gellatly SL, Jarnicki AG, Zheng D, et al., 'Importance of mast cell Prss31/transmembrane tryptase/tryptase-¿ in lung function and experimental chronic obstructive pulmonary disease and colitis', Journal of Biological Chemistry, 289 18214-18227 (2014) [C1]

Protease serine member S31 (Prss31)/transmembrane tryptase/tryptase-¿ is a mast cell (MC)-restricted protease of unknown function that is retained on the outer leaflet of the plas... [more]

Protease serine member S31 (Prss31)/transmembrane tryptase/tryptase-¿ is a mast cell (MC)-restricted protease of unknown function that is retained on the outer leaflet of the plasma membrane when MCs are activated. We determined the nucleotide sequences of the Prss31 gene in different mouse strains and then used a Cre/loxP homologous recombination approach to create a novel Prss31 -/- C57BL/6 mouse line. The resulting animals exhibited no obvious developmental abnormality, contained normal numbers of granulated MCs in their tissues, and did not compensate for their loss of the membrane tryptase by increasing their expression of other granule proteases. When Prss31-null MCs were activated with a calcium ionophore or by their high affinity IgE receptors, they degranulated in a pattern similar to that of WT MCs. Prss31-null mice had increased baseline airway reactivity to methacholine but markedly reduced experimental chronic obstructive pulmonary disease and colitis, thereby indicating both beneficial and adverse functional roles for the tryptase. In a cigarette smokeinduced model of chronic obstructive pulmonary disease, WT mice had more pulmonary macrophages, higher histopathology scores, and more fibrosis in their small airways than similarly treated Prss31-null mice. In a dextran sodium sulfate-induced acute colitis model, WT mice lost more weight, had higher histopathology scores, and contained more Cxcl-2 and IL-6 mRNA in their colons than similarly treated Prss31-null mice. The accumulated data raise the possibility that inhibitors of this membrane tryptase may provide additional therapeutic benefit in the treatment of humans with these MC-dependent inflammatory diseases. © 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

DOI 10.1074/jbc.M114.548594
Citations Scopus - 34Web of Science - 35
Co-authors Paul Foster, Michael Fricker
2014 Chevalier N, Thorburn AN, Macia L, Tan J, Juglair L, Yagita H, et al., 'Inflammation and lymphopenia trigger autoimmunity by suppression of il-2-controlled regulatory t cell and increase of il-21-mediated effector t cell expansion', Journal of Immunology, 193 4845-4858 (2014) [C1]

© 2014 by The American Association of Immunologists, Inc. The dynamic interplay between regulatory T cells (Tregs) and effector T cells (Teffs) governs the balance between toleran... [more]

© 2014 by The American Association of Immunologists, Inc. The dynamic interplay between regulatory T cells (Tregs) and effector T cells (Teffs) governs the balance between tolerance and effector immune responses. Perturbations of Treg frequency and function or imbalances in Treg/Teff levels are associated with the development of autoimmunity. The factors that mediate these changes remain poorly understood and were investigated in this study in murine autoimmune arthritis. Tregs displayed a stable phenotype in arthritic mice and were fully functional in in vitro suppression assays. However, their expansion was delayed relative to Teffs (T follicular helper cells and Th17 cells) during the early stages of autoimmune reactivity. This imbalance is likely to have led to insufficient Treg control of Teffs and induced autoimmunity. Moreover, a counterregulatory and probably IL-7-driven increase in thymic Treg production and recruitment to inflamed tissues was too slow for disease prevention. Increased Teff over Treg expansion was further aggravated by inflammation and lymphopenia. Both these conditions contribute to autoimmune pathogenesis and were accompanied by decreases in the availability of IL-2 and increases in levels of IL-21. IL-2 neutralization or supplementation was used to show that Treg expansion mainly depended on this cytokine. IL-21R2/2 cells were used to demonstrate that IL-21 promoted the maintenance of Teffs. Thus, at inflammatory sites in experimental arthritis, a deficit in IL-2 hampers Treg proliferation, whereas exaggerated IL-21 levels overwhelm Treg control by supporting Teff expansion. This identifies IL-2 and IL-21 as targets for manipulation in therapies for autoimmunity.

DOI 10.4049/jimmunol.1302966
Citations Scopus - 6Web of Science - 7
2014 McIlroy DJ, Jarnicki AG, Au GG, Lott N, Smith DW, Hansbro PM, Balogh ZJ, 'Mitochondrial DNA neutrophil extracellular traps are formed after trauma and subsequent surgery', Journal of Critical Care, 29 1133.e1-1133.e5 (2014) [C1]

© 2014 The Authors. Introduction: Neutrophil extracellular traps (NETs) have not been demonstrated after trauma and subsequent surgery. Neutrophil extracellular traps are formed f... [more]

© 2014 The Authors. Introduction: Neutrophil extracellular traps (NETs) have not been demonstrated after trauma and subsequent surgery. Neutrophil extracellular traps are formed from pure mitochondrial DNA (mtDNA) under certain conditions, which is potently proinflammatory. We hypothesized that injury and orthopedic trauma surgery would induce NET production with mtDNA as a structural component. Methods: Neutrophils were isolated 8 trauma patients requiring orthopedic surgery postinjury and up to 5 days postoperatively. Four healthy volunteers provided positive and negative controls. Total hip replacement patients acted as an uninjured surgical control group. Neutrophil extracellular traps were visualized with DNA (Hoechst 33342TM/Sytox Green/MitoSox/MitoTracker) stains using live cell fluorescence microscopy with downstream quantitative polymerase chain reaction analysis of DNA composition. Results: Neutrophil extracellular traps were present after injury in all 8 trauma patients. They persisted for 5 days postoperatively. Delayed surgery resulted in NET resolution, but they reformed postoperatively. Total hip replacement patients developed NETs postoperatively, which resolved by day 5. Quantitative polymerase chain reaction analysis of NET-DNA composition revealed that NETs formed after injury and surgery were made of mtDNA with no detectable nuclear DNA component. Conclusions: Neutrophil extracellular traps formed after major trauma and subsequent surgery contain mtDNA and represent a novel marker of heightened innate immune activation. They could be considered when timing surgery after trauma to prevent systemic NET-induced inflammatory complications.

DOI 10.1016/j.jcrc.2014.07.013
Citations Scopus - 33Web of Science - 25
Co-authors Douglas Smith, Gough Au, Zsolt Balogh
2014 Prieto-García A, Castells MC, Hansbro PM, Stevens RL, 'Mast cell-restricted tetramer-forming tryptases and their beneficial roles in hemostasis and blood coagulation', Immunology and Allergy Clinics of North America, 34 263-281 (2014) [C1]

Tetramer-forming tryptase (hTryptase-ß) was recently discovered to have a prominent role in preventing the internal accumulation of life-threatening fibrin deposits and fibrin-pla... [more]

Tetramer-forming tryptase (hTryptase-ß) was recently discovered to have a prominent role in preventing the internal accumulation of life-threatening fibrin deposits and fibrin-platelet clots. The anticoagulant activity of hTryptase-ß is an explanation for the presence of hemorrhagic disorders in some patients with anaphylaxis or mastocytosis. The fragments of hFibrinogen formed by the proteolysis of this prominent protein by hTryptase-ß could be used as biomarkers in the blood and/or urine for the identification and monitoring of patients with mast cell-dependent disorders. Recombinant hTryptase-ß has potential to be used in clinical settings where it is desirable to inhibit blood coagulation. © 2014 Elsevier Inc.

DOI 10.1016/j.iac.2014.01.001
Citations Scopus - 5Web of Science - 4
2014 Hallstrand TS, Hackett TL, Altemeier WA, Matute-Bello G, Hansbro PM, Knight DA, 'Airway epithelial regulation of pulmonary immune homeostasis and inflammation', Clinical Immunology, 151 1-15 (2014) [C1]

Recent genetic, structural and functional studies have identified the airway and lung epithelium as a key orchestrator of the immune response. Further, there is now strong evidenc... [more]

Recent genetic, structural and functional studies have identified the airway and lung epithelium as a key orchestrator of the immune response. Further, there is now strong evidence that epithelium dysfunction is involved in the development of inflammatory disorders of the lung. Here we review the characteristic immune responses that are orchestrated by the epithelium in response to diverse triggers such as pollutants, cigarette smoke, bacterial peptides, and viruses. We focus in part on the role of epithelium-derived interleukin (IL)-25, IL-33 and thymic stromal lymphopoietin (TSLP), as well as CC family chemokines as critical regulators of the immune response. We cite examples of the function of the epithelium in host defense and the role of epithelium dysfunction in the development of inflammatory diseases. © 2013 Elsevier Inc.

DOI 10.1016/j.clim.2013.12.003
Citations Scopus - 92Web of Science - 88
Co-authors Darryl Knight
2014 Hirota JA, Alexis NE, Pui M, Wong S, Fung E, Hansbro P, et al., 'PM10-stimulated airway epithelial cells activate primary human dendritic cells independent of uric acid: Application of an in vitro model system exposing dendritic cells to airway epithelial cell-conditioned media', Respirology, 19 881-890 (2014) [C1]

Background and objective Airway epithelial cells represent the first line of defence against inhaled insults, including air pollution. Air pollution can activate innate immune sig... [more]

Background and objective Airway epithelial cells represent the first line of defence against inhaled insults, including air pollution. Air pollution can activate innate immune signalling in airway epithelial cells leading to the production of soluble mediators that can influence downstream inflammatory cells. Our objective was to develop and validate a model of dendritic cell exposure to airway epithelial cell-conditioned media. After establishing the model, we explored how soluble mediators released from airway epithelial cells in response to air pollution influenced the phenotype of dendritic cells. Methods Human airway epithelial cells were cultured under control and urban particulate matter (PM10) exposure conditions with or without pharmacological inhibitors of the uric acid pathway. Culture supernatants were collected for conditioned media experiments with peripheral blood mononuclear cell-derived dendritic cells analysed by flow cytometry. Results Monocytes derived from peripheral blood mononuclear cells cultured in interleukin-4 and granulocyte macrophage colony stimulating factor differentiated into immature dendritic cells that phenotypically differentiated into mature dendritic cells in response to conditioned media from phorbol myristate acetate-activated THP-1 monocytes. Exposure of immature dendritic cells to conditioned media from airway epithelial cells exposed to PM10 resulted in dendritic cell maturation that was independent of uric acid. Conclusions We present a conditioned media model useful for interrogating the contribution of soluble mediators produced by airway epithelial cells to dendritic cell phenotype and function. Furthermore, we demonstrate that PM10 exposure induces airway epithelial cell production of soluble mediators that induce maturation of dendritic cells independent of uric acid. We developed and validated a model of airway epithelial cell conditioned media exposure to primary human dendritic cells. Using this model, we then tested the hypothesis that urban particulate matter exposure to airway epithelial cells resulted in production of soluble mediators capable of inducing dendritic cell maturation. © 2014 Asian Pacific Society of Respirology.

DOI 10.1111/resp.12316
Citations Scopus - 5Web of Science - 5
Co-authors Darryl Knight
2014 Fricker M, Deane A, Hansbro PM, 'Animal models of chronic obstructive pulmonary disease', Expert Opinion on Drug Discovery, 9 629-645 (2014) [C1]

Introduction: Chronic obstructive pulmonary disease (COPD) is a leading global cause of mortality and chronic morbidity. Inhalation of cigarette smoke is the principal risk factor... [more]

Introduction: Chronic obstructive pulmonary disease (COPD) is a leading global cause of mortality and chronic morbidity. Inhalation of cigarette smoke is the principal risk factor for development of this disease. COPD is a progressive disease that is typically characterised by chronic pulmonary inflammation, mucus hypersecretion, airway remodelling and emphysema that collectively reduce lung function. There are currently no therapies that effectively halt or reverse disease progression. It is hoped that the development of animal models that develop the hallmark features of COPD, in a short time frame, will aid in the identifying and testing of new therapeutic approaches. Areas covered: The authors review the recent developments in mouse models of chronic cigarette smoke-induced COPD as well as the principal findings. Furthermore, the authors discuss the use of mouse models to understand the pathogenesis and the contribution of infectious exacerbations. They also discuss the investigations of the systemic co-morbidities of COPD (pulmonary hypertension, cachexia and osteoporosis). Expert opinion: Recent advances in the field mark a point where animal models recapitulate the pathologies of COPD patients in a short time frame. They also reveal novel insights into the pathogenesis and potential treatment of this debilitating disease. © 2014 Informa UK, Ltd.

DOI 10.1517/17460441.2014.909805
Citations Scopus - 53Web of Science - 57
Co-authors Michael Fricker
2014 O'Reilly M, Hansbro PM, Horvat JC, Beckett EL, Harding R, Sozo F, 'Bronchiolar Remodeling in Adult Mice Following Neonatal Exposure to Hyperoxia: Relation to Growth', Anatomical Record, 297 758-769 (2014) [C1]

Preterm infants who receive supplemental oxygen for prolonged periods are at increased risk of impaired lung function later in life. This suggests that neonatal hyperoxia induces ... [more]

Preterm infants who receive supplemental oxygen for prolonged periods are at increased risk of impaired lung function later in life. This suggests that neonatal hyperoxia induces persistent changes in small conducting airways (bronchioles). Although the effects of neonatal hyperoxia on alveolarization are well documented, little is known about its effects on developing bronchioles. We hypothesized that neonatal hyperoxia would remodel the bronchiolar walls, contributing to altered lung function in adulthood. We studied three groups of mice (C57BL/6J) to postnatal day 56 (P56; adulthood) when they either underwent lung function testing or necropsy for histological analysis of the bronchiolar wall. One group inhaled 65% O2 from birth until P7, after which they breathed room air; this group experienced growth restriction (HE+GR group). We also used a group in which hyperoxia-induced GR was prevented by dam rotation (HE group). A control group inhaled room air from birth. At P56, the bronchiolar epithelium of HE mice contained fewer Clara cells and more ciliated cells, and the bronchiolar wall contained ~25% less collagen than controls; in HE+GR mice the bronchiolar walls had ~13% more collagen than controls. Male HE and HE+GR mice had significantly thicker bronchiolar epithelium than control males and altered lung function (HE males: greater dynamic compliance; HE+GR males: lower dynamic compliance). We conclude that neonatal hyperoxia remodels the bronchiolar wall and, in adult males, affects lung function, but effects are altered by concomitant growth restriction. Our findings may partly explain the reports of poor lung function in ex-preterm children and adults. Anat Rec, 297:758-769, 2014. © 2014 Wiley Periodicals, Inc.

DOI 10.1002/ar.22867
Citations Scopus - 14Web of Science - 14
Co-authors Emma Beckett, Jay Horvat
2014 Keely S, Campbell EL, Baird AW, Hansbro PM, Shalwitz RA, Kotsakis A, et al., 'Contribution of epithelial innate immunity to systemic protection afforded by prolyl hydroxylase inhibition in murine colitis', Mucosal Immunology, 7 114-123 (2014) [C1]

Pharmacological stabilization of hypoxia-inducible factor (HIF) through prolyl hydroxylase (PHD) inhibition limits mucosal damage associated with models of murine colitis. However... [more]

Pharmacological stabilization of hypoxia-inducible factor (HIF) through prolyl hydroxylase (PHD) inhibition limits mucosal damage associated with models of murine colitis. However, little is known about how PHD inhibitors (PHDi) influence systemic immune function during mucosal inflammation or the relative importance of immunological changes to mucosal protection. We hypothesized that PHDi enhances systemic innate immune responses to colitis-associated bacteremia. Mice with colitis induced by trinitrobenzene sulfonic acid were treated with AKB-4924, a new HIF-1 isoform-predominant PHDi, and clinical, immunological, and biochemical endpoints were assessed. Administration of AKB-4924 led to significantly reduced weight loss and disease activity compared with vehicle controls. Treated groups were pyrexic but did not become subsequently hypothermic. PHDi treatment augmented epithelial barrier function and led to an approximately 50-fold reduction in serum endotoxin during colitis. AKB-4924 also decreased cytokines involved in pyrogenesis and hypothermia, significantly reducing serum levels of interleukin (IL)-1ß, IL-6, and tumor necrosis factor (TNF)-a while increasing IL-10. Treatment offered no protection against colitis in epithelial-specific HIF-1a-deficient mice, strongly implicating epithelial HIF-1a as the tissue target for AKB-4924-mediated protection. Taken together, these results indicate that inhibition of prolyl hydroxylase with AKB-4924 enhances innate immunity and identifies that the epithelium is a central site of inflammatory protection afforded by PHDi in murine colitis. © 2014 Society for Mucosal Immunology.

DOI 10.1038/mi.2013.29
Citations Scopus - 52Web of Science - 50
Co-authors Simon Keely
2014 Chambers DC, Gellatly SL, Hugenholtz P, Hansbro PM, 'JTD special edition 'Hot Topics in COPD'-The microbiome in COPD', Journal of Thoracic Disease, 6 1525-1531 (2014) [C1]

© 2014 American Thoracic Society. The pathogenesis of chronic obstructive pulmonary disease (COPD) and its exacerbations, are intricately linked to colonisation and infection with... [more]

© 2014 American Thoracic Society. The pathogenesis of chronic obstructive pulmonary disease (COPD) and its exacerbations, are intricately linked to colonisation and infection with bacteria and other microbes. Despite their undeniable importance, we have a poor understanding of the complex relationships between COPD phenotypes, physiology, cellular and molecular biology and the roles of colonising microbe or infecting pathogens. The management algorithms for the care of patients with COPD that include microbial influences, have almost exclusively been developed using microbial methods that were entirely dependent on the ability to grow bacteria on suitable media. The shortcomings of this approach are becoming clear now that it is possible to completely and accurately define the microbial ecology of ecosystems using genomic methods, which do not rely on the ability to cultivate the organisms present. Whilst our appreciation of the relationships between some bacterial ecosystems and the organ in which they reside in humans is now relatively advanced, this is not true for lung. This perspective serves to highlight the growing importance of including an accurate description of bacterial ecology in any attempt to decipher the pathobiology of COPD. While this field is in its infancy, there is significant potential to gain new insights which will translate into more rational and effective treatment algorithms for patients with COPD.

DOI 10.3978/j.issn.2072-1439.2014.11.08
Citations Scopus - 15Web of Science - 17
2014 Hansbro PM, Starkey MR, Mattes J, Horvat JC, 'Pulmonary immunity during respiratory infections in early life and the development of severe asthma', Annals of the American Thoracic Society, 11 S297-S302 (2014) [C1]

Copyright © 2014 by the American Thoracic Society Asthma affects 10% of the population in Westernized countries, being most common in children. It is a heterogeneous condition cha... [more]

Copyright © 2014 by the American Thoracic Society Asthma affects 10% of the population in Westernized countries, being most common in children. It is a heterogeneous condition characterized by chronic allergic airway inflammation, mucus hypersecretion, and airway hyperresponsiveness (AHR) to normally innocuous antigens. Combination therapies with inhaled corticosteroids and bronchodilators effectively manage mild to moderate asthma, but there are no cures, and patients with severe asthma do not respond to these treatments. The inception of asthma is linked to respiratory viral (respiratory syncytial virus, rhinovirus) and bacterial (Chlamydia, Mycoplasma) infections. The examination of mouse models of early-life infections and allergic airway disease (AAD) provides valuable insights into the mechanisms of disease inception that may lead to the development of more effective therapeutics. For example, early-life, but not adult, Chlamydia respiratory infections in mice permanently modify immunity and lung physiology. This increases the severity of AAD by promoting IL-13 expression, mucus hypersecretion, and AHR. We have identified novel roles for tumor necrosis factor-related apoptosisinducing ligand (TRAIL) and IL-13 in promoting infection-induced pathology in early life and subsequent chronic lung disease. Genetic deletion of TRAIL or IL-13 variously protected against neonatal infection-induced inflammation, mucus hypersecretion, altered lung structure, AHR, and impaired lung function. Therapeutic neutralization of these factors prevented infection-induced severe AAD. Other novel mechanisms and avenues for intervention are also being explored. Such studies indicate the immunological mechanisms that may underpin the association between early-life respiratory infections and the development of more severe asthma and may facilitate the development of tailored preventions and treatments.

DOI 10.1513/AnnalsATS.201402-086AW
Citations Scopus - 17
Co-authors Jay Horvat, Malcolm Starkey, Joerg Mattes
2014 Sobinoff AP, Sutherland JM, Beckett EL, Stanger SJ, Johnson R, Jarnicki AG, et al., 'Damaging legacy: maternal cigarette smoking has long-term consequences for male offspring fertility.', Hum Reprod, 29 2719-2735 (2014) [C1]
DOI 10.1093/humrep/deu235
Citations Scopus - 22Web of Science - 22
Co-authors Adam Mccluskey, Eileen Mclaughlin, Jessie Sutherland, Emma Beckett
2013 Starkey MR, Nguyen DH, Kim RY, Nair PM, Brown AC, Essifie A-T, et al., 'Programming of the Lung in Early Life by Bacterial Infections Predisposes to Chronic Respiratory Disease', CLINICAL OBSTETRICS AND GYNECOLOGY, 56 566-576 (2013) [C1]
DOI 10.1097/GRF.0b013e3182993a0c
Citations Scopus - 7Web of Science - 6
Co-authors Malcolm Starkey, Jay Horvat
2013 Hansbro P, Beckett E, Stevens R, Jarnicki A, Wark P, Foster P, 'A short-term model of COPD identifies a role for mast cell tryptase', EUROPEAN RESPIRATORY JOURNAL, 42 (2013) [C3]
Co-authors Jay Horvat, Peter Wark, Paul Foster, Simon Keely
2013 Thorburn AN, Brown AC, Nair PM, Chevalier N, Foster PS, Gibson PG, Hansbro PM, 'Pneumococcal Components Induce Regulatory T Cells That Attenuate the Development of Allergic Airways Disease by Deviating and Suppressing the Immune Response to Allergen', JOURNAL OF IMMUNOLOGY, 191 4112-4120 (2013) [C1]
DOI 10.4049/jimmunol.1201232
Citations Scopus - 11Web of Science - 9
Co-authors Peter Gibson, Paul Foster
2013 Vijaykrishna D, Deng Y-M, Su YCF, Fourment M, Iannello P, Arzey GG, et al., 'The Recent Establishment of North American H10 Lineage Influenza Viruses in Australian Wild Waterfowl and the Evolution of Australian Avian Influenza Viruses', JOURNAL OF VIROLOGY, 87 10182-10189 (2013) [C1]
DOI 10.1128/JVI.03437-12
Citations Scopus - 20Web of Science - 19
2013 Fung KY, Mangan NE, Cumming H, Horvat JC, Mayall JR, Stifter SA, et al., 'Interferon-epsilon Protects the Female Reproductive Tract from Viral and Bacterial Infection', SCIENCE, 339 1088-1092 (2013) [C1]
DOI 10.1126/science.1233321
Citations Scopus - 82Web of Science - 80
Co-authors Jay Horvat
2013 Sobinoff AP, Beckett EL, Jarnicki AG, Sutherland JM, McCluskey A, Hansbro PM, McLaughlin EA, 'Scrambled and fried: Cigarette smoke exposure causes antral follicle destruction and oocyte dysfunction through oxidative stress', TOXICOLOGY AND APPLIED PHARMACOLOGY, 271 156-167 (2013) [C1]
DOI 10.1016/j.taap.2013.05.009
Citations Scopus - 28Web of Science - 26
Co-authors Jessie Sutherland, Adam Mccluskey, Emma Beckett, Eileen Mclaughlin
2013 Beckett EL, Stevens RL, Jarnicki AG, Kim RY, Hanish I, Hansbro NG, et al., 'A new short-term mouse model of chronic obstructive pulmonary disease identifies a role for mast cell tryptase in pathogenesis', The Journal of Allergy and Clinical Immunology, 131 752-762 (2013) [C1]
Citations Scopus - 98Web of Science - 98
Co-authors Jay Horvat, Emma Beckett, Ming Yang, Simon Keely, Peter Wark, Paul Foster, Nicole Hansbro
2013 Foster PS, Plank MW, Collison AM, Tay HL, Kaiko GE, Li J, et al., 'The emerging role of microRNAs in regulating immune and inflammatory responses in the lung', Immunological Reviews, 253 198-215 (2013) [C1]
Citations Scopus - 57Web of Science - 59
Co-authors Adam Collison, Gerard Kaiko, Ming Yang, Hock Tay, Paul Foster, Joerg Mattes
2013 Balogh ZJ, McIlroy DJ, Smith DW, Hansbro PM, 'The origin and the role of mitochondrial DNA in postinjury inflammation', Journal of Critical Care, 28 1099-1100 (2013) [C3]
DOI 10.1016/j.jcrc.2013.08.027
Citations Scopus - 4Web of Science - 3
Co-authors Douglas Smith, Zsolt Balogh
2013 Griekspoor P, Colles FM, Mccarthy ND, Hansbro PM, Ashhurst-Smith C, Olsen B, et al., 'Marked host specificity and lack of phylogeographic population structure of Campylobacter jejuni in wild birds', MOLECULAR ECOLOGY, 22 1463-1472 (2013) [C1]
DOI 10.1111/mec.12144
Citations Scopus - 41Web of Science - 41
2013 Simpson JL, McDonald VM, Baines KJ, Oreo KM, Wang F, Hansbro PM, Gibson PG, 'Influence of Age, Past Smoking, and Disease Severity on TLR2, Neutrophilic Inflammation, and MMP-9 Levels in COPD', MEDIATORS OF INFLAMMATION, (2013) [C1]
DOI 10.1155/2013/462934
Citations Scopus - 23Web of Science - 18
Co-authors Peter Gibson, Jodie Simpson, Vanessa Mcdonald, Nicole Hansbro, Katherine Baines
2013 Hansbro PM, Knight DA, 'Are Lymphoid Follicles Important in the Pathogenesis of Chronic Obstructive Pulmonary Disease?', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 188 267-269 (2013) [C3]
DOI 10.1164/rccm.201306-1073ED
Citations Scopus - 1Web of Science - 1
Co-authors Darryl Knight
2013 Hansbro PM, Scott GV, Essilfie A-T, Kim RY, Starkey MR, Nguyen D, et al., 'Th2 cytokine antagonists: Potential treatments for severe asthma', Expert Opinion on Investigational Drugs, 22 49-69 (2013) [C1]
Citations Scopus - 40Web of Science - 38
Co-authors Gerard Kaiko, Malcolm Starkey, Ming Yang, Paul Foster, Jay Horvat
2013 Starkey MR, Jarnicki AG, Essilfie A-T, Gellatly SL, Kim RY, Brown AC, et al., 'Murine models of infectious exacerbations of airway inflammation', CURRENT OPINION IN PHARMACOLOGY, 13 337-344 (2013) [C1]
DOI 10.1016/j.coph.2013.03.005
Citations Scopus - 34Web of Science - 32
Co-authors Malcolm Starkey, Paul Foster, Jay Horvat
2013 Li JJ, Tay HL, Plank M, Essilfie A-T, Hansbro PM, Foster PS, Yang M, 'Activation of Olfactory Receptors on Mouse Pulmonary Macrophages Promotes Monocyte Chemotactic Protein-1 Production', PLOS ONE, 8 (2013) [C1]
DOI 10.1371/journal.pone.0080148
Citations Scopus - 13Web of Science - 5
Co-authors Ming Yang, Paul Foster, Hock Tay
2013 Starkey MR, Essilfie A-T, Horvat JC, Kim RY, Nguyen DH, Beagley KW, et al., 'Constitutive production of IL-13 promotes early-life Chlamydia respiratory infection and allergic airway disease', Mucosal Immunology, 6 569-579 (2013) [C1]
Citations Scopus - 30Web of Science - 27
Co-authors Jay Horvat, Malcolm Starkey, Joerg Mattes, Paul Foster
2012 Wynne OL, Horvat JC, Smith R, Hansbro PM, Clifton VL, Hodgson DM, 'Effect of neonatal respiratory infection on adult BALB/c hippocampal glucocorticoid and mineralocorticoid receptors', Developmental Psychobiology, 54 568-575 (2012) [C1]
Citations Scopus - 2Web of Science - 2
Co-authors Jay Horvat, Roger Smith, Olivia Wynne, Deborah Hodgson
2012 Prieto-Garcia A, Zheng D, Adachi R, Xing W, Xing W, Chung K, et al., 'Mast cell restricted mouse and human tryptase-heparin complexes hinder thrombin-induced coagulation of plasma and the generation of fibrin by proteolytically destroying fibrinogen', Journal of Biological Chemistry, 287 7834-7844 (2012) [C1]
Citations Scopus - 32Web of Science - 33
2012 Thorburn AN, Foster PS, Gibson PG, Hansbro PM, 'Components of streptococcus pneumoniae suppress allergic airways disease and NKT cells by inducing regulatory T cells', The Journal of Immunology, 188 4611-4620 (2012) [C1]
Citations Scopus - 45Web of Science - 40
Co-authors Paul Foster, Peter Gibson
2012 Essilfie A-T, Simpson JL, Dunkley ML, Morgan LC, Oliver BG, Gibson PG, et al., 'Combined haemophilus influenzae respiratory infection and allergic airways disease drives chronic infection and features of neutrophilic asthma', Thorax, 67 588-599 (2012) [C1]
DOI 10.1136/thoraxjnl-2011-200160
Citations Scopus - 73Web of Science - 64
Co-authors Peter Gibson, Margaret Dunkley, Jodie Simpson, Paul Foster
2012 Suthers B, Hansbro PM, Thambar S, McEvoy MA, Peel R, Attia JR, 'Pneumococcal vaccination may induce anti-oxidized low-density lipoprotein antibodies that have potentially protective effects against cardiovascular disease', Vaccine, 30 3983-3985 (2012) [C1]
Citations Scopus - 9Web of Science - 10
Co-authors John Attia, Mark Mcevoy, Roseanne Peel
2012 Yang M, Kumar RK, Hansbro PM, Foster PS, 'Emerging roles of pulmonary macrophages in driving the development of severe asthma', Journal of Leukocyte Biology, 91 557-569 (2012) [C1]
Citations Scopus - 57Web of Science - 56
Co-authors Ming Yang, Paul Foster
2012 Hansbro PM, Jarnicki AG, 'Macrolides for macrophages in chronic obstructive pulmonary disease', Respirology, 17 739-740 (2012) [C3]
Citations Scopus - 5Web of Science - 5
2012 Hsu A, See HV, Hansbro PM, Wark PA, 'Innate immunity to influenza in chronic airways diseases', Respirology, 17 1166-1175 (2012) [C1]
DOI 10.1111/j.1440-1843.2012.02200.x
Citations Scopus - 21Web of Science - 19
Co-authors Peter Wark, Alan Hsu
2012 Beckett EL, Phipps S, Starkey MR, Horvat JC, Beagley KW, Foster PS, Hansbro PM, 'TLR2, but not TLR4, is required for effective host defence against chlamydia respiratory tract infection in early life', PLOS One, 7 (2012) [C1]
DOI 10.1371/journal.pone.0039460
Citations Scopus - 36Web of Science - 30
Co-authors Paul Foster, Malcolm Starkey, Jay Horvat, Emma Beckett
2012 Hsu A, Parsons KS, Barr I, Lowther S, Middleton D, Hansbro PM, Wark PA, 'Critical role of constitutive type I interferon response in bronchial epithelial cell to influenza infection', PLoS One, 7 (2012) [C1]
DOI 10.1371/journal.pone.0032947
Citations Scopus - 38Web of Science - 42
Co-authors Alan Hsu, Peter Wark
2012 Starkey MR, Kim RY, Beckett EL, Schilter HC, Shim D, Essilfie A-T, et al., 'Chlamydia muridarum lung infection in infants alters hematopoietic cells to promote allergic airway disease in mice', PLoS One, 7 (2012) [C1]
DOI 10.1371/journal.pone.0042588
Citations Scopus - 18Web of Science - 19
Co-authors Joerg Mattes, Jay Horvat, Malcolm Starkey, Emma Beckett
2012 Keely S, Talley NJ, Hansbro PM, 'Pulmonary-intestinal cross-talk in mucosal inflammatory disease', Mucosal Immunology, 5 7-18 (2012) [C1]
DOI 10.1038/mi.2011.55
Citations Scopus - 83Web of Science - 78
Co-authors Nicholas Talley, Simon Keely
2012 Hansbro PM, Starkey MR, Kim RY, Stevens RL, Foster PS, Horvat JC, 'Programming of the lung by early-life infection', Journal of Developmental Origins of Health and Disease, 3 153-158 (2012) [C1]
Citations Scopus - 7Web of Science - 5
Co-authors Malcolm Starkey, Jay Horvat, Paul Foster
2011 Essilfie A-T, Simpson JL, Horvat JC, Preston JA, Dunkley ML, Foster PS, et al., 'Haemophilus influenzae infection drives IL-17-mediated neutrophilic allergic airways disease', PLoS Pathogens, 7 e1002244 (2011) [C1]
Co-authors Margaret Dunkley, Jay Horvat, Peter Gibson, Jodie Simpson, Paul Foster
2011 Asquith KL, Horvat JC, Kaiko GE, Carey AJ, Beagley KW, Hansbro PM, Foster PS, 'Interleukin-13 promotes susceptibility to chlamydial infection of the respiratory and genital tracts', PLoS Pathogens, 7 (2011) [C1]
DOI 10.1371/journal.ppat.1001339
Citations Scopus - 41Web of Science - 41
Co-authors Gerard Kaiko, Paul Foster, Kelly Asquith, Jay Horvat
2011 Temple SEL, Hansbro PM, 'New insights into the immune response to pneumococci', Current Respiratory Medicine Reviews, 7 257-261 (2011) [C1]
DOI 10.2174/157339811798281188
2011 Wang W, Hansbro PM, Foster PS, Yang M, 'An alternate STAT6-independent pathway promotes eosinophil influx into blood during allergic airway inflammation', PLoS ONE, 6 (2011) [C1]
DOI 10.1371/journal.pone.0017766
Citations Scopus - 9Web of Science - 7
Co-authors Ming Yang, Paul Foster
2011 Hansbro PM, Kaiko GE, Foster PS, 'Cytokine/anti-cytokine therapy - Novel treatments for asthma?', British Journal of Pharmacology, 163 81-95 (2011) [C2]
DOI 10.1111/j.1476-5381.2011.01219.x
Citations Scopus - 91Web of Science - 84
Co-authors Gerard Kaiko, Paul Foster
2011 Jennings PC, Merriman-Jones JA, Beckett EL, Hansbro PM, Jones KT, 'Increased zona pellucida thickness and meiotic spindle disruption in oocytes from cigarette smoking mice', Human Reproduction, 26 878-884 (2011) [C1]
DOI 10.1093/humrep/deq393
Citations Scopus - 27Web of Science - 23
Co-authors Emma Beckett
2011 Wynne OL, Horvat JC, Kim RY, Ong LK, Smith R, Hansbro PM, et al., 'Neonatal respiratory infection and adult re-infection: Effect on glucocorticoid and mineralocorticoid receptors in the hippocampus in BALB/c mice', Brain Behavior and Immunity, 25 1214-1222 (2011) [C1]
DOI 10.1016/j.bbi.2011.03.014
Citations Scopus - 4Web of Science - 4
Co-authors Olivia Wynne, Jay Horvat, Roger Smith, Linkooi Ong, Deborah Hodgson
2011 Hazlewood LC, Wood LG, Hansbro PM, Foster PS, 'Dietary lycopene supplementation suppresses Th2 responses and lung eosinophilia in a mouse model of allergic asthma', Journal of Nutritional Biochemistry, 22 95-100 (2011) [C1]
DOI 10.1016/j.jnutbio.2009.12.003
Citations Scopus - 26Web of Science - 23
Co-authors Lisa Wood, Paul Foster
2011 Wynne OL, Horvat JC, Osei-Kumah A, Smith R, Hansbro PM, Clifton VL, Hodgson DM, 'Early life infection alters adult BALB/c hippocampal gene expression in a sex specific manner', Stress-the International Journal on the Biology of Stress, 14 247-261 (2011) [C1]
DOI 10.3109/10253890.2010.532576
Citations Scopus - 11Web of Science - 11
Co-authors Deborah Hodgson, Jay Horvat, Roger Smith, Olivia Wynne
2011 Preston JA, Thorburn AN, Starkey MR, Beckett EL, Horvat JC, Wade MA, et al., 'Streptococcus pneumoniae infection suppresses allergic airways disease by inducing regulatory T-cells', European Respiratory Journal, 37 53-64 (2011) [C1]
DOI 10.1183/09031936.00049510
Citations Scopus - 51Web of Science - 46
Co-authors Emma Beckett, Paul Foster, Malcolm Starkey, Jay Horvat, Peter Gibson
2011 Hsu A, Barr I, Hansbro PM, Wark PA, 'Human influenza is more effective than Avian influenza at antiviral suppression in airway cells', American Journal of Respiratory Cell and Molecular Biology, 44 906-913 (2011) [C1]
DOI 10.1165/rcmb.2010-0157OC
Citations Scopus - 21Web of Science - 22
Co-authors Alan Hsu, Peter Wark
2011 Hansbro PM, Hurt AC, 'Influenza surveillance in wild birds in Australia', Microbiology Australia, 32 48-51 (2011) [C1]
2010 Lau JY, Oliver BG, Baraket M, Beckett EL, Hansbro NG, Moir LM, et al., 'Fibulin-1 Is increased in asthma - A novel mediator of airway remodeling?', Plos One, 5 1-13 (2010) [C1]
DOI 10.1371/journal.pone.0013360
Citations Scopus - 29Web of Science - 28
Co-authors Emma Beckett, Paul Foster, Nicole Hansbro
2010 Horvat JC, Starkey MR, Kim RY, Beagley KW, Preston JA, Gibson PG, et al., 'Chlamydial respiratory infection during allergen sensitization drives neutrophilic allergic airways disease', Journal of Immunology, 184 4159-4169 (2010) [C1]
DOI 10.4049/jimmunol.0902287
Citations Scopus - 58Web of Science - 54
Co-authors Paul Foster, Jay Horvat, Malcolm Starkey, Peter Gibson
2010 Li J, Wang W, Baines KJ, Bowden NA, Hansbro PM, Gibson PG, et al., 'IL-27/IFN-y induce MyD88-dependent steroid-resistant airway hyperresponsiveness by inhibiting glucocorticoid signaling in macrophages', Journal of Immunology, 185 4401-4409 (2010) [C1]
DOI 10.4049/jimmunol.1001039
Citations Scopus - 68Web of Science - 62
Co-authors Nikola Bowden, Katherine Baines, Ming Yang, Peter Gibson, Paul Foster
2010 Thorburn AN, O'Sullivan BJ, Thomas R, Kumar RK, Foster PS, Gibson PG, Hansbro PM, 'Pneumococcal conjugate vaccine-induced regulatory T cells suppress the development of allergic airways disease', Thorax, 65 1053-1060 (2010) [C1]
DOI 10.1136/thx.2009.131508
Citations Scopus - 43Web of Science - 43
Co-authors Peter Gibson, Paul Foster
2010 Horvat JC, Starkey MR, Kim RY, Phipps S, Gibson PG, Beagley KW, et al., 'Early-life chlamydial lung infection enhances allergic airways disease through age-dependent differences in immunopathology', Journal of Allergy and Clinical Immunology, 125 617-625 (2010) [C1]
DOI 10.1016/j.jaci.2009.10.018
Co-authors Malcolm Starkey, Paul Foster, Peter Gibson, Jay Horvat
2010 Starkey MR, Horvat JC, Kim RY, Hansbro PM, 'Reply', Journal of Allergy and Clinical Immunology, 125 1415 (2010) [C3]
DOI 10.1016/j.jaci.2010.03.033
Co-authors Malcolm Starkey, Jay Horvat
2010 Thorburn A, Foster P, Gibson P, Hansbro P, 'Induction of regulatory T cells by a novel immunoregulatory therapy suppresses the development of allergic airways disease', JOURNAL OF IMMUNOLOGY, 184 (2010)
Co-authors Paul Foster, Peter Gibson
2010 Wood LG, Hazlewood LC, Foster PS, Hansbro PM, 'Lyprinol reduces inflammation and improves lung function in a mouse model of allergic airways disease', Clinical and Experimental Allergy, 40 1785-1793 (2010) [C1]
DOI 10.1111/j.1365-2222.2010.03503.x
Citations Scopus - 16Web of Science - 15
Co-authors Paul Foster, Lisa Wood
2010 Thorburn AN, Hansbro PM, 'Harnessing regulatory T cells to suppress asthma: From Potential to therapy', American Journal of Respiratory Cell and Molecular Biology, 43 511-519 (2010) [C1]
DOI 10.1165/rcmb.2009-0342TR
Citations Scopus - 55Web of Science - 50
2010 Wood LG, Simpson JL, Hansbro PM, Gibson PG, 'Potentially pathogenic bacteria cultured from the sputum of stable asthmatics are associated with increased 8-isoprostane and airway neutrophilia', Free Radical Research, 44 146-154 (2010) [C1]
DOI 10.3109/10715760903362576
Citations Scopus - 57Web of Science - 50
Co-authors Lisa Wood, Peter Gibson, Jodie Simpson
2010 Burgess JK, Boustany S, Moir LM, Weckmann M, Lau JY, Grafton K, et al., 'Reduction of tumstatin in asthmatic airways contributes to angiogenesis, inflammation, and hyperresponsiveness', American Journal of Respiratory and Critical Care Medicine, 181 106-115 (2010) [C1]
DOI 10.1164/rccm.200904-0631oc
Citations Scopus - 40Web of Science - 37
Co-authors Paul Foster, Nicole Hansbro
2010 Hansbro PM, Warner S, Tracey JP, Arzey KE, Selleck P, O'Riley K, et al., 'Surveillance and analysis of avian influenza viruses, Australia', Emerging Infectious Diseases, 16 1896-1904 (2010) [C1]
DOI 10.3201/eid1612.100776
Citations Scopus - 43Web of Science - 42
Co-authors Emma Beckett
2010 Wang W, Li J, Foster PS, Hansbro PM, Yang M, 'Potential therapeutic targets for steroid-resistant asthma', Current Drug Targets, 11 957-970 (2010) [C1]
DOI 10.2174/138945010791591412
Citations Scopus - 40Web of Science - 44
Co-authors Ming Yang, Paul Foster
2009 Thorburn AN, Hansbro PM, Gibson PG, 'Pneumococcal vaccines for allergic airways diseases', Expert Opinion on Biological Therapy, 9 621-629 (2009) [C1]
DOI 10.1517/14712590902916999
Citations Scopus - 16Web of Science - 14
Co-authors Peter Gibson
2009 Haynes L, Arzey E, Bell C, Buchanan N, Burgess G, Cronan V, et al., 'Australian surveillance for avian influenza viruses in wild birds between July 2005 and June 2007', Australian Veterinary Journal, 87 266-272 (2009) [C1]
DOI 10.1111/j.1751-0813.2009.00446.x
Citations Scopus - 36Web of Science - 31
2009 Beagley K, Huston WM, Hansbro PM, Timms P, 'Chlamydial infection of immune cells: Altered function and implications for disease', Critical Reviews in Immunology, 29 275-305 (2009) [C1]
DOI 10.1615/CritRevImmunol.v29.i4.10
Citations Scopus - 45Web of Science - 44
2008 Kaiko GE, Horvat JC, Beagley KW, Hansbro PM, 'Immunological decision-making: How does the immune system decide to mount a helper T-cell response?', Immunology, 123 326-338 (2008) [C1]
DOI 10.1111/j.1365-2567.2007.02719.x
Citations Scopus - 234Web of Science - 217
Co-authors Jay Horvat, Gerard Kaiko
2008 Kaiko GE, Phipps S, Hickey DK, Lam CE, Hansbro PM, Foster PS, Beagley KW, 'Chlamydia muridarum infection subverts dendritic cell function to promote Th2 immunity and airways hyperreactivity', Journal of Immunology, 180 2225-2232 (2008) [C1]
Citations Scopus - 36Web of Science - 37
Co-authors Gerard Kaiko, Paul Foster
2008 Asquith KL, Ramshaw HS, Hansbro PM, Beagley KW, Lopez AF, Foster PS, 'The IL-3/IL-5/GM-CSF common beta receptor plays a pivotal role in the regulation of Th2 immunity and allergic airway inflammation', Journal of Immunology, 180 1199-1206 (2008) [C1]
Citations Scopus - 77Web of Science - 74
Co-authors Kelly Asquith, Paul Foster
2008 Hansbro NG, Horvat JC, Wark PA, Hansbro PM, 'Understanding the mechanisms of viral induced asthma: New therapeutic directions', Pharmacology & Therapeutics, 117 313-353 (2008) [C1]
DOI 10.1016/j.pharmthera.2007.11.002
Citations Scopus - 76Web of Science - 71
Co-authors Nicole Hansbro, Peter Wark, Jay Horvat
2007 Ashhurst-Smith CIJ, Hall ST, Walker PJ, Stuart JE, Hansbro PM, Blackwell CC, 'Isolation of Alloiococcus otitidis from Indigenous and non-Indigenous Australian children with chronic otitis media with effusion', FEMS Immunology and Medical Microbiology, 51 163-170 (2007) [C1]
DOI 10.1111/j.1574-695X.2007.00297.x
Citations Scopus - 28Web of Science - 25
Co-authors John Stuart, Caroline Blackwell, Sharron Hall, Paul Walker
2007 Horvat JC, Beagley KW, Wade MA, Preston JA, Hansbro NG, Hickey DK, et al., 'Neonatal chlamydial infection induces mixed T-cell responses that drive allergic airway disease', American Journal of Respiratory and Critical Care Medicine, 176 556-564 (2007) [C1]
DOI 10.1164/rccm.200607-1005OC
Citations Scopus - 66Web of Science - 65
Co-authors Peter Gibson, Paul Foster, Nicole Hansbro, Gerard Kaiko, Jay Horvat
2007 Preston JA, Essilfie AT, Horvat JC, Wade MA, Beagley KW, Gibson PG, et al., 'Inhibition of allergic airways disease by immunomodulatory therapy with whole killed Streptococcus pneumoniae', Vaccine, 25 8154-8162 (2007) [C1]
DOI 10.1016/j.vaccine.2007.09.034
Citations Scopus - 42Web of Science - 42
Co-authors Jay Horvat, Peter Gibson, Paul Foster
2006 Skelding KA, Hickey DK, Horvat JC, Bao SS, Roberts KG, Read JM, et al., 'Comparison of intranasal and transcutaneous immunization for induction of protective immunity against Chlamydia muridarum respiratory tract infection', Vaccine, 24 355-366 (2006) [C1]
DOI 10.1016/j.vaccine.2005.07.104
Citations Scopus - 30Web of Science - 28
Co-authors Jay Horvat, Kathryn Skelding
2006 Hurt AC, Hansbro PM, Selleck P, Olsen B, Minton C, Hampson AW, Barr IG, 'Isolation of avian influenza viruses from two different transhemispheric migratory shorebird species in Australia', Archives of Virology, 151 2301-2309 (2006) [C1]
DOI 10.1007/s00705-006-0784-1
Citations Scopus - 42Web of Science - 37
2006 Gasanov U, Koina CA, Beagley KW, Aitken RJ, Hansbro PM, 'Identification of the insulin-like growth factor II receptor as a novel receptor for binding and invasion by Listeria monocytogenes', Infection and Immunity, 74 566-577 (2006) [C1]
DOI 10.1128/IAI.74.1.566-577.2006
Citations Scopus - 9Web of Science - 6
Co-authors John Aitken
2006 Sharkhuu T, Matthaei KI, Forbes E, Mahalingam S, Hogan SP, Hansbro PM, Foster PS, 'Mechanism of interleukin-25 (IL-17E)-induced pulmonary inflammation and airways hyper-reactivity', Clinical and Experimental Allergy, 36 1575-1583 (2006) [C1]
DOI 10.1111/j.1365-2222.2006.02595.x
Citations Scopus - 83Web of Science - 75
Co-authors Paul Foster
2006 Yang M, Mattes J, Hansbro PM, Foster PS, 'Employment of microRNA profiles and RNA interference and antagomirs for the characterization and treatment of respiratory disease', Drug Discovery Today: Therapeutic Strategies, 3 325-332 (2006) [C1]
DOI 10.1016/j.ddstr.2006.10.001
Citations Scopus - 5
Co-authors Paul Foster, Joerg Mattes, Ming Yang
2005 Gasanov U, Hughes D, Hansbro PM, 'Methods for the isolation and identification of Listeria spp. and Listeria monocytogenes: a review', FEMS Microbiology Reviews, 29 851-875 (2005) [C1]
DOI 10.1016/j.femsre.2004.12.002
Citations Scopus - 202Web of Science - 179
2005 Stephenson J, Budd GM, Manning J, Hansbro PM, 'Major eruption-induced changes to the McDonald Islands, southern Indian Ocean', Antarctic Science, 17 259-266 (2005) [C1]
DOI 10.1017/S095410200500266X
Citations Scopus - 2Web of Science - 2
2004 Howland LJ, Hickey DK, Skelding KA, Bao S, Rendina AM, Hansbro PM, et al., 'Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection', Infection and Immunity, 72 1019-1028 (2004) [C1]
DOI 10.1128/IAI.72.2.1019-1028.2004
Citations Scopus - 114Web of Science - 104
Co-authors Kathryn Skelding
2004 Hansbro PM, Beagley KW, Horvat JC, Gibson PG, 'Role of atypical bacterial infection of the lung in predisposition/protection of asthma', Pharmacology and Therapeutics, 101 193-210 (2004) [C1]
DOI 10.1016/j.pharmthera.2003.10.007
Citations Scopus - 74Web of Science - 67
Co-authors Jay Horvat, Peter Gibson
2004 Preston JA, Beagley KW, Gibson PG, Hansbro PM, 'Genetic background affects susceptibility in nonfatal pneumococcal bronchopneumonia', Eur Respir J, 23 224-231 (2004) [C1]
DOI 10.1183/09031936.03.00081403
Citations Scopus - 22Web of Science - 20
Co-authors Peter Gibson
2002 Badcock D, Hansbro PM, Hanniffy S, Clarke V, Schofield K, Robinson K, et al., 'Identification of Pneumoccal Vaccine Antigens Using a Gram-positive Secretion Reporter Screen in Lactococcus lactis', 3rd International Symposium on Pneumococci and Pneumococcal Diseases, n/a 103 (2002) [C3]
2002 Preston JA, Beagley KW, Gibson PG, Hansbro PM, 'Development of a Pneumococcal Pneumonia Recovery Model in Mice', 3rd International Symposium on Pneumococci and Pneumococcal Diseases, n/a 91 (2002) [C3]
Co-authors Peter Gibson
2001 Preston JA, Beagley KW, Gibson PG, Hansbro PM, 'Effects of Infections by Streptococcus pneumoniae on Eosinophilic Immune Responses', Official Journal of the Australian Society for Microbiology, 22 A82 (2001) [C3]
Co-authors Peter Gibson
2001 Hansbro PM, Wells JM, Le Page RWF, Kyd J, 'Characterisation of a 37 kDa surface protein of Streptococcus pneumoniae that is protective against pneumococcal challenge', Final Program American Society for Microbiology, 101 General Meeting, 101 74 (2001) [C3]
2000 Clark-Walker GD, Hansbro PM, Gibson F, Chen XJ, 'Mutant residues suppressing rho(0)-lethality in Kluyveromyces lactis occur at contact sites between subunits of F-1-ATPase', BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 1478 125-137 (2000)
DOI 10.1016/S0167-4838(00)00003-0
Citations Scopus - 22Web of Science - 24
1998 Chen XJ, Hansbro PM, Clark-Walker GD, 'Suppression of rho(0) lethality by mitochondrial ATP synthase F-1 mutations in Kluyveromyces lactis occurs in the absence of F-0', MOLECULAR AND GENERAL GENETICS, 259 457-467 (1998)
DOI 10.1007/s004380050836
Citations Scopus - 14Web of Science - 16
1998 Hansbro PM, Chen XJ, Clark-Walker GD, 'Allele specific expression of the Mgi(-) phenotype on disruption of the F-1-ATPase delta-subunit gene in Kluyveromyces lactis', CURRENT GENETICS, 33 46-51 (1998)
DOI 10.1007/s002940050307
Citations Scopus - 4Web of Science - 7
1995 O'Brien R, Taske N, Hansbro P, Matthaei K, Hogan S, Denborough M, Foster PS, 'Exclusion of defects in the skeletal muscle specific regions of the DHPR alpha 1 subunit as frequent causes of malignant hyperthermia', Journal of Medical Genetics, 32 913-914 (1995) [C1]
Citations Scopus - 6Web of Science - 8
Co-authors Paul Foster
1994 Hansbro P, Foster PS, Hogan S, Ozaki S, Denborough M, 'Purification and characterization of D-myo-Inositol (1,4,5)/(1,3,4,5)-polyphosphate 5-phosphatase from skeletal muscle', Archives of Biochemistry and Biophysics, 311 47-54 (1994) [C1]
Citations Scopus - 4Web of Science - 5
Co-authors Paul Foster
1994 Foster PS, Hansbro P, Liu C, Potter B, Denborough M, 'Kinetic analysis of novel inhibitors of inositol polyphosphate metabolism', Biochemical and Biophysical Research Communications, 200 8-15 (1994) [C1]
Citations Scopus - 3Web of Science - 3
Co-authors Paul Foster
1994 Foster PS, Hogan S, Hansbro P, O'Brien R, Potter B, Ozaki S, Denborough M, 'The metabolism of D-myo-inositol 1,4,5-trisphosphate and D-myo-inositol 1,3,4,5-tetrakisphosphate by porcine skeletal muscle', European Journal of Biochemistry, 222 955-964 (1994) [C1]
Citations Scopus - 12Web of Science - 12
Co-authors Paul Foster
1994 Hogan S, Foster PS, Hansbro P, Ozaki S, Denborough M, 'Detection and partial purification of inositol 1,4,5-trisphosphate 3-kinase from porcine skeletal muscle', Cellular Signalling, 6 233-243 (1994) [C1]
Citations Scopus - 5Web of Science - 4
Co-authors Paul Foster
1992 HANSBRO PM, BYARD SJ, BUSHBY RJ, TURNBULL PJH, BODEN N, SAUNDERS MR, et al., 'THE CONFORMATIONAL BEHAVIOR OF PHOSPHATIDYLINOSITOL IN MODEL MEMBRANES - H-2-NMR STUDIES', BIOCHIMICA ET BIOPHYSICA ACTA, 1112 187-196 (1992)
DOI 10.1016/0005-2736(92)90391-X
Citations Scopus - 29Web of Science - 27
1990 BUSHBY RJ, BYARD SJ, HANSBRO PM, REID DG, 'THE CONFORMATIONAL BEHAVIOR OF PHOSPHATIDYLINOSITOL', BIOCHIMICA ET BIOPHYSICA ACTA, 1044 231-236 (1990)
DOI 10.1016/0005-2760(90)90307-J
Citations Scopus - 15Web of Science - 16
1988 SCHORAH CJ, BISHOP N, WALES JK, HANSBRO PM, HABIBZADEH N, 'BLOOD VITAMIN-C CONCENTRATIONS IN PATIENTS WITH DIABETES-MELLITUS', INTERNATIONAL JOURNAL FOR VITAMIN AND NUTRITION RESEARCH, 58 312-318 (1988)
Citations Scopus - 16Web of Science - 17
Show 226 more journal articles

Review (1 outputs)

Year Citation Altmetrics Link
2015 Mateer SW, Maltby S, Marks E, Foster PS, Horvat JC, Hansbro PM, Keely S, 'Potential mechanisms regulating pulmonary pathology in inflammatory bowel disease.', J Leukoc Biol (2015) [C1]
DOI 10.1189/jlb.3RU1114-563R
Citations Scopus - 7Web of Science - 5
Co-authors Simon Keely, Paul Foster, Jay Horvat, Steven Maltby

Conference (192 outputs)

Year Citation Altmetrics Link
2018 Hsu A, Hansbro P, Wark P, 'HDAC6 PROMOTES DDX1-MEDIATED ANTIVIRAL IMMUNITY AND IS IMPAIRED IN COPD', RESPIROLOGY (2018)
Co-authors Alan Hsu, Peter Wark
2018 Rutting S, Papanicolaou M, Xenaki D, Wood L, Horvat J, Hansbro P, Oliver B, 'THE EFFECT OF THE DIETARY omega-6 POLYUNSATURATED FATTY ACID, ARACHIDONIC ACID, ON AIRWAY INFLAMMATION AND REMODELING IN COPD', RESPIROLOGY (2018)
Co-authors Jay Horvat
2018 Reid A, Nichol K, Wei L, Moheimani F, Bartlett N, Hansbro P, et al., 'NOTCH3 INHIBITION SIGNIFICANTLY REDUCES MUC5AC IN HUMAN AIRWAY EPITHELIAL CELLS', RESPIROLOGY (2018)
Co-authors Darryl Knight, Fatemeh Moheimani, Christopher Grainge, Peter Wark, Nathan Bartlett
2018 Rutting S, Xenaki D, Wood L, Horvat J, Hansbro P, Oliver B, 'THE EFFECT OF DIETARY FATTY ACIDS ON INFLAMMATION IN PRIMARY LUNG MESENCHYMAL AND EPITHELIAL CELLS', RESPIROLOGY (2018)
Co-authors Jay Horvat
2018 Moheimani F, Williams T, Reid A, Hansbro P, Wark P, Knight D, 'ABNORMAL MIRNA-22 EXPRESSION AFTER INFLUENZA INFECTION FACILITATES EPITHELIUM REMODELING IN ASTHMA', RESPIROLOGY (2018)
Co-authors Darryl Knight, Fatemeh Moheimani, Peter Wark
2018 Periyalil HA, Wood LG, Wright TA, Karihaloo C, Starkey MR, Miu AS, Baines KJ, 'Obese asthmatics are characterized by altered adipose tissue macrophage activation', CLINICAL AND EXPERIMENTAL ALLERGY (2018)
DOI 10.1111/cea.13109
Citations Scopus - 1Web of Science - 1
Co-authors Malcolm Starkey, Katherine Baines, Lisa Wood, Peter Gibson
2018 Sultana Z, Maiti K, Smith R, Hansbro P, Mononair P, 'Growth Factor Depletion in Placental Cells Increases Lipid Peroxidation and Reduces Mitochondrial Function and mTOR Activity via Aldehyde Oxidase Mediated Pathways', San Diego, CA (2018)
DOI 10.1177/1933719118759999
Co-authors Roger Smith, Zakia Sultana
2018 Chimankar V, Harrison C, Rahman A, Pickles S, Sahu P, Watkins N, Hansbro P, 'Mouse Models to Investigate the Genetic Mechanism Underlying the Development of Non-Small Cell Lung Cancer', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2018)
2018 Gomes G, Starkey M, Belinelo DGP, Jesson K, Hansbro P, Murphy V, et al., 'PROFILING INNATE LYMPHOID CELLS IN THE CORD BLOOD OF INFANTS BORN TO MOTHERS WITH ASTHMA IN PREGNANCY', RESPIROLOGY (2018)
Co-authors Adam Collison, Vanessa Murphy, Joerg Mattes, Peter Gibson
2017 Mang NE, De Geus E, Mielke L, Gould J, Cumming H, Woodhouse I, et al., 'Interferon epsilon in the regulation of mucosal innate immune responses in the female reproductive tract', CYTOKINE, Int Cytokine & Interferon Soc, Kanazawa, JAPAN (2017)
2017 Eapen M, Hansbro P, Tan E, Ward C, Walters H, Sohal SS, 'INCREASED UPREGULATION OF LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1 (LAMP-1) IN THE AIRWAY WALL OF COPD IS ASSOCIATED WITH DECREASED PHYSIOLOGICAL OUTCOMES AND POTENTIAL ROLE IN AUTOPHAGY', RESPIROLOGY (2017)
2017 Horvat JC, Ali MK, Johnstone D, Kim RY, Mayall JR, Karim R, et al., 'Role for dysregulated iron in the pathogenesis of murine models of lung disease', Washington, DC (2017)
Co-authors Liz Milward, Jay Horvat
2017 Chimankar V, Harrison C, Rahman A, Sahu P, Scott R, Watkins N, Hansbro P, 'Investigating the Genetics of the Development of Lung Cancer', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2017)
Co-authors Rodney Scott
2017 Horvat JC, Alit M, Johnstone D, Essilfie A-T, Mayall J, Pinkerton JW, et al., 'Role Of Increased Iron Levels In The Pathogenesis Of Lung Disease', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Washington, DC (2017)
Co-authors Gang Liu, Liz Milward, Chantal Donovan, Jay Horvat
2017 Kim RY, Pinkerton JW, Rae B, Mayall JR, Brown AC, Ali M, et al., 'Impaired Induction Of Slc26a4 Promotes Respiratory Acidosis And Severe, Steroid-Insensitive Asthma', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Washington, DC (2017)
Co-authors Jay Horvat, Malcolm Starkey
2017 Starkey MR, Dua K, Hsu AC, Nair PM, Haw TJ, Nguyen DH, et al., 'Interleukin-13 Predisposes To More Severe Influenza Infection In Mice And Human Epithelial Cells By Suppressing Interferon Responses And Activating The Microrna-21/pi3k Signaling Pathway', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Washington, DC (2017)
Co-authors Peter Wark, Alan Hsu, Malcolm Starkey, Jay Horvat
2017 Moheimani F, Williams T, Koops J, Reid AT, Hansbro PM, Wark PAB, Knight D, 'Micrornas As Potential Epigenetic Targets To Restore The Airway Epithelium Integrity In Asthmatics', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Washington, DC (2017)
Co-authors Fatemeh Moheimani, Andrew Reid, Peter Wark, Darryl Knight
2017 Starkey MR, Nguyen DH, Kim RY, Nair PM, Haw TJ, Horvat JC, et al., 'Early Life Respiratory Bacterial Infection-Induced Chronic Lung Disease Is Driven By A Novel Tlr2/il-13/mir-21/pi3k Signaling Pathway', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Washington, DC (2017)
Co-authors Malcolm Starkey, Jay Horvat
2017 Reid AT, Moheimani F, Nichol K, Bartlett N, Wark PAB, Grainge C, et al., 'Short-Term Inhibition Of Notch Signalling Ablates Muc5ac Production In Human Airway Epithelial Cells From Asthmatic, Non-Asthmatic And COPD Donors', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Washington, DC (2017)
Co-authors Darryl Knight, Peter Wark, Christopher Grainge, Andrew Reid, Nathan Bartlett, Fatemeh Moheimani
2017 Tay HL, Hsu A, Nguyen T, Donovan C, Collison A, Mattes J, et al., 'Interleukin-36 gamma: Roles in lungs innate immunity, inflammation and allergy', CYTOKINE, Int Cytokine & Interferon Soc, Kanazawa, JAPAN (2017)
Co-authors Alan Hsu, Adam Collison, Chantal Donovan, Paul Foster, Joerg Mattes, Hock Tay, Gerard Kaiko, Ming Yang
2017 Rutting S, Wood L, Hansbro P, Oliver B, 'INTERACTION OF DIETARY FATTY ACIDS WITH OBESITY-INDUCED CYTOKINES IN PRIMARY PULMONARY FIBROBLASTS', RESPIROLOGY (2017)
Co-authors Lisa Wood
2017 Ali MK, Kim R, Johnstone D, Essilfie A-T, Mayall J, Karim R, et al., 'ROLE OF INCREASED IRON LEVELS IN THE PATHOGENESIS OF LUNG DISEASE', RESPIROLOGY (2017)
Co-authors Jay Horvat, Chantal Donovan, Gang Liu, Liz Milward
2017 Liu G, Cooley MA, Jarnicki AG, Hsu AC-Y, Nair PM, Haw TJ, et al., 'FIUBLIN-1C PLAYS CRITICAL ROLES IN LUNG REMODELLING IN IDIOPATHIC PULMONARY FIBROSIS', RESPIROLOGY (2017)
Co-authors Marjorie Walker, Darryl Knight, Jay Horvat, Alan Hsu, Michael Fricker, Gang Liu
2017 Kim R, Sunkara K, Jarnicki A, Bracke K, Haw TJ, Wark P, et al., 'MicroRNA-21 DRIVES EXPERIMENTAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE THROUGH A SATB1/S100A9/NF-kappa B AXIS', RESPIROLOGY (2017)
Co-authors Peter Wark, Jay Horvat, Paul Foster
2017 Collison A, Li J, De Siqueira AP, Lv X, Toop HD, Morris JC, et al., 'THE E3 UBIQUITIN LIGASE MID1 PROMOTES IDIOPATHIC PULMONARY FIBROSIS', RESPIROLOGY (2017)
Co-authors Joerg Mattes, Malcolm Starkey, Adam Collison
2017 Budden K, Gellatly S, Wood D, Morrison M, Cooper M, Dennis PG, et al., 'DIETARY FIBRE AND MICROBIAL METABOLITES PROTECT AGAINST CIGARETTE SMOKE-INDUCED LUNG PATHOLOGY IN MICE', RESPIROLOGY (2017)
2017 Eapen M, Hansbro P, Mcalinden K, Ward C, Hackett T-L, Walters H, Sohal SS, 'ABNORMAL M1/M2 MACROPHAGE PHENOTYPE SWITCHING OCCURS DIFFERENTIALLY IN THE SMALL AIRWAY WALL AND LUMEN IN SMOKERS AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)', RESPIROLOGY (2017)
2017 Rutting S, Xenaki D, Ge Q, Wood L, Hansbro P, Oliver B, 'DIETARY OMEGA-6, BUT NOT OMEGA-3 POLYUNSATURATED OR SATURATED FATTY ACIDS INCREASE INFLAMMATION IN HUMAN PULMONARY FIBROBLASTS', RESPIROLOGY (2017)
Co-authors Lisa Wood
2017 Pinkerton J, Kim R, Mayall J, Ali MK, Starkey M, Robertson A, et al., 'HIGH FAT DIET-INDUCED OBESITY PROMOTES STEROID-RESISTANT ASTHMA THROUGH AN NLRP3 INFLAMMASOME-DEPENDENT MECHANISM', RESPIROLOGY (2017)
Co-authors Jay Horvat
2017 Horvat J, Pinkerton J, Rae B, Mayall J, Brown A, Ali MK, et al., 'IMPAIRED INDUCTION OF SLC26A4 PROMOTES RESPIRATORY ACIDOSIS AND SEVERE, STEROID-INSENSITIVE ASTHMA', RESPIROLOGY (2017)
Co-authors Jay Horvat
2016 Hansbro PM, Liu G, Cooley MA, Jarnicki AG, Hsu AC, Nair PM, et al., 'Fibulin-1 Plays Critical Roles In The Pathogenesis Of Pulmonary Diseases', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, San Francisco, CA (2016)
Co-authors Gang Liu, Michael Fricker, Alan Hsu, Peter Wark, Darryl Knight, Jay Horvat
2016 Jones B, Harrison C, Waters D, Dua K, Starkey M, Jarnicki A, et al., 'BROMODOMAIN INHIBITORS REVERSE THE DISEASE FEATURES IN EXPERIMENTAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE', RESPIROLOGY (2016)
Citations Web of Science - 1
Co-authors Peter Wark, Darryl Knight
2016 Horvat J, Kim R, Pinkerton J, Rae B, Starkey M, Essilfie A, et al., 'IDENTIFICATION OF NOVEL THERAPEUTIC TARGETS FOR STEROID-INSENSITIVE ASTHMA USING MODELS THAT REPRESENT DIFFERENT CLINICAL SUBTYPES OF DISEASE', RESPIROLOGY (2016)
Co-authors Jay Horvat, Joerg Mattes, Simon Keely
2016 Gellatly S, Dennis P, Jarnicki A, Lachner N, Wood D, Fricker M, et al., 'HEALTHY GUT MICROBIOTA AMELIORATES EXPERIMENTAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE', RESPIROLOGY (2016)
Co-authors Simon Keely, Michael Fricker, Gang Liu
2016 Hansbro P, Nair P, Starkey M, Haw T, Liu G, Clark A, Ammit A, 'TRISTETRAPROLIN PROTECTS MICE AGAINST CIGARETTE-SMOKE INDUCED EXPERIMENTAL COPD', RESPIROLOGY (2016)
Co-authors Gang Liu
2016 Moheimani F, Koops J, Williams T, Reid AT, Hansbro PM, Wark PA, Knight DA, 'ABNORMAL MICRORNAS EXPRESSION IN EPITHELIAL CELLS OF SEVERE ASTHMATICS', RESPIROLOGY (2016)
Co-authors Andrew Reid, Peter Wark, Darryl Knight, Fatemeh Moheimani
2016 Kim RY, Pinkerton JW, Essilfie A-T, Robertson AA, Baines KJ, Mayall JR, et al., 'Nlrp3 Inflammasome-Mediated, Il-1 beta-Dependent Inflammatory Responses Drive Severe, Steroid-Insensitive Asthma', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, San Francisco, CA (2016)
Co-authors Malcolm Starkey, Katherine Baines, Peter Wark, Peter Gibson, Jay Horvat
2016 Mangan N, Mielke L, De Geus E, Gould J, Cumming H, Woodhouse I, et al., 'Type I interferons in the regulation of mucosal immune responses in the female reproductive tract', EUROPEAN JOURNAL OF IMMUNOLOGY, Melbourne, AUSTRALIA (2016)
2016 Horvat J, Kim R, Pinkerton J, Rae B, Starkey M, Essilfie A-T, et al., 'Identification of therapeutic targets for steroid-insensitive asthma using models that represent different clinical subtypes of disease', EUROPEAN RESPIRATORY JOURNAL (2016)
DOI 10.1183/13993003.congress-2016.PA563
Co-authors Paul Foster, Jay Horvat, Simon Keely
2016 Starkey M, Nguyen D, Kim R, Haw T, Nair P, Essilfie A, et al., 'EARLY-LIFE RESPIRATORY BACTERIAL INFECTION-INDUCED CHRONIC LUNG DISEASE IS DRIVEN BY A NOVEL TLR2/IL-13/MIR-21/PI3K SIGNALLING PATHWAY', RESPIROLOGY (2016)
Co-authors Jay Horvat
2016 Kim R, Pinkerton J, Essilfie A, Robertson A, Baines K, Mayall J, et al., 'NLRP3 INFLAMMASOME- MEDIATED, IL-1 beta-DEPENDENT INFLAMMATORY RESPONSES DRIVE SEVERE, STEROID-INSENSITIVE ASTHMA', RESPIROLOGY (2016)
Co-authors Jay Horvat, Peter Gibson, Peter Wark
2016 Hansbro P, Brown A, Essilfie A, Beckett E, Thorburn A, Hansbro N, et al., 'PROGRAMMED DEATH-1 (PD-1) PREDISPOSES TO RESPIRATORY VIRAL INFECTION-INDUCED SECONDARY BACTERIAL PNEUMONIA', RESPIROLOGY (2016)
Co-authors Jay Horvat
2016 Starkey M, Haw T, Pavlidis S, Nair MP, Liu G, Hanish I, et al., 'TOLL-LIKE RECEPTOR 7 PROMOTES CIGARETTE-SMOKE INDUCED EMPHYSEMA-LIKE ALVEOLAR ENLARGEMENT IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE', RESPIROLOGY (2016)
Co-authors Jay Horvat, Gang Liu
2016 Pinkerton J, Kim R, Essilfie A, Rae B, Mayall J, Ali M, et al., 'TARGETING OXIDATIVE STRESS FOR THE SUPPRESSION OF SEVERE, STEROID-INSENSITIVE ASTHMA', RESPIROLOGY (2016)
Co-authors Jay Horvat
2016 Hansbro P, Sunkara K, Jarnicki A, Kim R, Haw T, Wark P, et al., 'ROLE OF MIR-21 IN THE PATHOGENESIS OF EXPERIMENTAL COPD', RESPIROLOGY (2016)
Co-authors Peter Wark, Jay Horvat
2016 Tay H, Yang M, Hsu A, Nguyen T-H, Plank M, Maltby S, et al., 'Role of interleukin-36 gamma in regulating lung inflammation', EUROPEAN JOURNAL OF IMMUNOLOGY, Melbourne, AUSTRALIA (2016)
Co-authors Ming Yang, Steven Maltby, Nathan Bartlett, Alan Hsu
2016 Mayall J, Mangan N, Chevalier A, Kim R, Rae B, Hertzog P, et al., 'Interferon-epsilon- regulated gene expression patterns in protection against female reproductive tract infection', EUROPEAN JOURNAL OF IMMUNOLOGY, Melbourne, AUSTRALIA (2016)
Co-authors Jay Horvat
2016 Starkey MR, Dua K, Hsu AC, Nair PM, Haw TJ, Nguyen DH, et al., 'Interleukin-13 predisposes to more severe influenza infection in mice and human epithelial cells by suppressing interferon responses and activating the microRNA-21/PI3K signaling pathway', EUROPEAN JOURNAL OF IMMUNOLOGY, Melbourne, AUSTRALIA (2016)
Co-authors Paul Foster, Peter Wark, Alan Hsu, Jay Horvat, Malcolm Starkey
2016 Starkey MR, Nguyen DH, Kim RY, Haw TJ, Nair PM, Essilfie AT, et al., 'Early-life respiratory bacterial infection-induced chronic lung disease is driven by a novel TLR2/IL-13/miR-21/PI3K signaling pathway', EUROPEAN JOURNAL OF IMMUNOLOGY, Melbourne, AUSTRALIA (2016)
Co-authors Malcolm Starkey, Jay Horvat, Paul Foster
2016 Collison A, Sokulsky LA, Starkey MR, Nightingale S, Le Fevre A, Percival E, et al., 'TRAIL regulates egg-allergen induced eosinophilic oesophagitis', EUROPEAN JOURNAL OF IMMUNOLOGY, Melbourne, AUSTRALIA (2016)
Co-authors Malcolm Starkey, Joerg Mattes, Paul Foster, Adam Collison
2016 Hsu A, Starkey M, Hansbro P, Wark P, 'Micro-RNA-125a/b target A20 and MAVS to promote inflammatory and impair antiviral responses in chronic obstructive pulmonary disease', EUROPEAN JOURNAL OF IMMUNOLOGY, Melbourne, AUSTRALIA (2016)
Co-authors Peter Wark, Alan Hsu
2016 Brown AC, Essilfie AT, Beckett EL, Thorburn AN, Hansbro NG, Jarnicki AG, et al., 'The role of CD8 T-cells during anti-PD1 treatment of viral infection-induced secondary bacterial pneumonia', EUROPEAN JOURNAL OF IMMUNOLOGY, Melbourne, AUSTRALIA (2016)
Co-authors Jay Horvat, Nicole Hansbro, Peter Wark, Paul Foster
2016 Kim R, Pinkerton J, Essilfie A-T, Robertson A, Baines K, Mayall J, et al., 'NLRP3 inflammasome-mediated, IL-1 beta-dependent inflammatory responses drive severe, steroid-resistant asthma', EUROPEAN JOURNAL OF IMMUNOLOGY, Melbourne, AUSTRALIA (2016)
Co-authors Peter Gibson, Jay Horvat, Peter Wark
2016 Jones B, Harrison C, Dua K, Hsu A, Starkey M, Jarnicki A, et al., 'Bromodomain inhibitors reverse inflammation and disease features in experimental chronic obstructive pulmonary disease', EUROPEAN JOURNAL OF IMMUNOLOGY, Melbourne, AUSTRALIA (2016)
Co-authors Peter Wark, Darryl Knight, Alan Hsu
2016 Pathinayake PS, Hsu AC-Y, Parsons K, Loo S-L, Fricker M, Wood LG, et al., 'Effect of oxidative stress and rhinovirus infection on mitochondrial/endoplasmic reticular function in human primary bronchial epithelial cells', EUROPEAN JOURNAL OF IMMUNOLOGY, Melbourne, AUSTRALIA (2016)
Co-authors Peter Wark, Lisa Wood, Alan Hsu, Michael Fricker
2016 Steptoe R, Al-Kouba J, Coleman M, Jessup C, Starkey M, Overgaard N, et al., 'Ablation of pathogenic memory T-cell responses by bone marrow-mediated gene therapy under immune-preserving conditions', EUROPEAN JOURNAL OF IMMUNOLOGY, Melbourne, AUSTRALIA (2016)
Co-authors Jay Horvat
2015 Jones B, Jarnicki A, Smithers N, Knight D, Wark P, Adcock I, Hansbro P, 'EPIGENETIC CHANGES IN HATS AND HDACS DRIVE PATHOGENESIS THAT CAN BE REVERSED USING BET INHIBITORS IN EXPERIMENTAL COPD', RESPIROLOGY, Queensland, AUSTRALIA (2015) [E3]
Co-authors Peter Wark, Darryl Knight
2015 Tang F, Hansbro P, Burgess J, Baines K, Oliver B, 'NEUTROPHILS DISPLAY IMMUNOREGULATORY ROLES IN RHINOVIRUS INFECTIONS', RESPIROLOGY, Queensland, AUSTRALIA (2015) [E3]
Co-authors Katherine Baines
2015 Wark P, Tolosa J, Parsons K, Hansbro P, Smith R, 'THE PLACENTAL PROTEIN SYNCYTIN-1 IMPAIRS ANTIVIRAL RESPONSES AND EXAGGERATES INFLAMMATORY RESPONSES TO INFLUENZA', RESPIROLOGY, Queensland, AUSTRALIA (2015) [E3]
Co-authors Roger Smith, Peter Wark
2015 Kim R, Horvat J, Pinkerton J, Starkey M, Essilfie A, Mayall J, et al., 'INFECTION-INDUCED MICRORNA-21 DRIVES SEVERE, STEROID-INSENSITIVE EXPERIMENTAL ASTHMA BY AMPLIFYING PI3K-MEDIATED SUPPRESSION OF HDAC2', RESPIROLOGY, Queensland, AUSTRALIA (2015) [E3]
Co-authors Paul Foster, Simon Keely, Joerg Mattes, Malcolm Starkey, Jay Horvat
2015 Tay H, Kaiko G, Plank M, Li J, Essilfie A, Maltby S, et al., 'THE ROLE OF MIR-328 IN RESPIRATORY DISEASES', RESPIROLOGY, Queensland, AUSTRALIA (2015) [E3]
Co-authors Gerard Kaiko, Ming Yang, Joerg Mattes, Paul Foster, Steven Maltby
2015 Hsu A, Parsons K, Hansbro P, Wark P, 'ENHANCED PI3K ACTIVITY LEADS TO DECREASED INTERFERON-beta RESPONSE TO INFLUENZA INFECTION IN COPD', RESPIROLOGY, Queensland, AUSTRALIA (2015) [E3]
Co-authors Peter Wark, Alan Hsu
2015 Moheimani F, Roth H, Cross J, Reid A, Shaheen F, Warner S, et al., 'SUPPRESSION OF beta-CATENIN/CBP SIGNALING INHIBITS EPITHELIAL-MESENCHYMAL TRANSITION AND MIGRATION OF HUMAN AIRWAY EPITHELIUM', RESPIROLOGY, Queensland, AUSTRALIA (2015) [E3]
Co-authors Darryl Knight, Fatemeh Moheimani, Andrew Reid
2015 Loo S, Hsu A, Hansbro P, Wark P, 'THE ROLE OF PI3 KINASE IN INFLUENZA H1N1 AND RHINOVIRUS VIRAL ENTRY INTO PRIMARY BRONCHIAL EPITHELIAL CELLS', RESPIROLOGY, Queensland, AUSTRALIA (2015) [E3]
Co-authors Peter Wark, Alan Hsu
2015 Jones B, Jarnicki AG, Smithers N, Knight DA, Wark PA, Adcock IM, Hansbro PM, 'Epigenetic Changes In Hats And Hdacs Drive Pathogenesis That Can Be Reversed Using Bet Inhibitors In Experimental COPD', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Denver, CO (2015)
Co-authors Peter Wark, Darryl Knight
2015 Mateer S, Marks E, Maltby S, Goggins B, Horvat J, Hansbro P, Keely S, 'Pulmonary retention of PMN attracts primed intestinal lymphocytes in a mouse model of inflammatory bowel disease', FASEB JOURNAL (2015) [E3]
Co-authors Jay Horvat, Simon Keely, Steven Maltby
2015 Hansbro P, Kim R, Pinkerton J, Starkey M, Essilfie A-T, Mayall J, et al., 'MicroRNA-21 drives severe, steroid-insensitive experimental asthma by amplifying PI3K-mediated suppression of HDAC2', JOURNAL OF IMMUNOLOGY, New Orleans, LA (2015)
Co-authors Jay Horvat, Joerg Mattes, Paul Foster, Simon Keely
2015 Essilfie A-T, Horvat J, Kim R, Mayall J, Pinkerton J, Beckett E, et al., 'Macrolide therapy suppresses key features of experimental steroid-sensitive and steroid insensitive asthma', JOURNAL OF IMMUNOLOGY, New Orleans, LA (2015)
Co-authors Jay Horvat, Jodie Simpson, Peter Gibson, Paul Foster
2015 Tay H, Kaiko G, Mattes J, Hansbro P, Foster P, 'The role of miR-328 in respiratory diseases', JOURNAL OF IMMUNOLOGY, New Orleans, LA (2015)
Co-authors Paul Foster, Gerard Kaiko, Joerg Mattes
2015 Hansbro P, Haw T, Nair P, Hanish I, Nguyen D, Liu G, et al., 'Tumour necrosis factor-related apoptosis inducing ligand promotes the development of experimental chronic obstructive pulmonary disease', JOURNAL OF IMMUNOLOGY, New Orleans, LA (2015)
Co-authors Joerg Mattes, Adam Collison, Gang Liu, Darryl Knight, Jay Horvat
2015 Hansbro P, Mayall J, Mangan N, Starkey M, Kim R, Hertzog P, Horvat J, 'Role of NK cells in IFN-epsilon-mediated protection against female reproductive tract infection', JOURNAL OF IMMUNOLOGY, New Orleans, LA (2015)
Co-authors Jay Horvat
2015 Harrison C, Essilfee A-T, Jones B, Waters D, Jarnicki A, Hansbro P, 'DEVELOPING A NOVEL MOUSE MODEL OF LUNG CANCER', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
2015 Tang F, Hansbro P, Burgess J, Baines K, Oliver B, 'A novel immunoregulatory role of neutrophils in viral infections', American Journal of Respiratory and Critical Care Medicine, Denver, CO (2015) [E3]
Co-authors Katherine Baines
2015 Hansbro PM, Kim RY, Pinkerton JW, Starkey MR, Essilfie AT, Mayall JR, et al., 'Infection-Induced Microrna-21 Drives Severe, Steroid-Insensitive Experimental Asthma By Amplifying PhosphoINOSitide-3-Kinase (pi3k)-Mediated Suppression Of Histone Deacetylase (hdac)2', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Denver, CO (2015)
Co-authors Malcolm Starkey, Simon Keely, Jay Horvat, Joerg Mattes, Paul Foster
2014 Schilter H, Buson A, Cock T-A, Deodhar M, Findlay AD, Foot JS, et al., 'Inhibition Of Loxl2: Pharmaxis' Small Molecule Approach To Treat Fibrosis', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2014)
Citations Web of Science - 2
2014 Hansbro PM, Horvat JC, Kim RY, Mayall JR, Pinkerton JW, Essilfie A-T, et al., 'Antioxidant Treatment Suppresses The Progression Of Early-Life Infection-Induced Severe Asthma And Pathology In Later-Life', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2014)
Citations Web of Science - 1
Co-authors Lisa Wood, Malcolm Starkey, Jay Horvat
2014 Mateer S, Maltby S, Marks E, Goggins B, Horvat J, Hansbro P, Keely S, 'Immune cell mis-homing drives secondary organ inflammation in inflammatory bowel disease; a focus on the respiratory system', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2014) [E3]
Co-authors Jay Horvat, Steven Maltby, Simon Keely
2014 Hsu A, Parsons K, Fujita T, Hansbro P, Wark P, 'Critical role of PKR in antiviral stress granule and IFN-beta enhanceosome formation, and is impaired in chronic obstructive pulmonary disease', CYTOKINE, Melbourne, AUSTRALIA (2014) [E3]
DOI 10.1016/j.cyto.2014.07.088
Citations Web of Science - 1
Co-authors Peter Wark, Alan Hsu
2014 Hsu A, Parsons K, Hansbro P, Wark P, 'Enhanced PI3K activity leads to decreased IFN-beta response to influenza infection in chronic obstructive pulmonary disease', CYTOKINE, Melbourne, AUSTRALIA (2014) [E3]
DOI 10.1016/j.cyto.2014.07.089
Co-authors Alan Hsu, Peter Wark
2014 Starkey M, Hanish I, Dua K, Nair P, Haw T, Hsu A, et al., 'Interleukin-13 predisposes mice to more severe influenza infection by suppressing interferon responses and activating microRNA-21/PI3K', CYTOKINE, Melbourne, AUSTRALIA (2014) [E3]
DOI 10.1016/j.cyto.2014.07.182
Citations Web of Science - 2
Co-authors Jay Horvat, Malcolm Starkey, Paul Foster, Alan Hsu, Peter Wark, Darryl Knight
2014 Horvat J, Kim R, Mayall J, Pinkerton J, Starkey M, Essilfie A, et al., 'ANTIOXIDANT-BASED THERAPY FOR THE SUPPRESSION OF EARLY- LIFE INFECTION-INDUCED SEVERE ASTHMA', RESPIROLOGY (2014) [E3]
DOI 10.1111/resp.12263_2
Co-authors Malcolm Starkey, Lisa Wood, Jay Horvat
2014 Jones B, Hansbro P, 'THE INVOLVEMENT OF HISTONE ACETYLATION ENZYMES IN A MOUSE MODEL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE', RESPIROLOGY (2014) [E3]
2014 Girkin J, Sokulsky L, Hatchwell L, Starkey M, Collison A, Hansbro P, Mattes J, 'IDENTIFICATION OF A NOVEL INTERLEUKIN-13 SIGNALLING PATHWAY', RESPIROLOGY (2014) [E3]
Co-authors Malcolm Starkey, Adam Collison, Joerg Mattes
2014 Hsu A, Parsons K, Hansbro P, Wark P, Wark P, 'IMPAIRED FORMATION OF ANTIVIRAL STRESS GRANULE AND INTERFERON-BETA ENHANCEOSOME LEADS TO REDUCED ANTIVIRAL RESPONSES TO INFLUENZA IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE', RESPIROLOGY (2014) [E3]
Co-authors Alan Hsu, Peter Wark
2014 Starkey MR, Hanish I, Dua K, Hsu A, Monogar P, Foster PS, et al., 'Interleukin-13 Predisposes Mice To More Severe Influenza Infection And Exacerbated Allergic Airways Disease', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2014)
Co-authors Darryl Knight, Alan Hsu, Paul Foster, Peter Wark, Malcolm Starkey
2014 Hirota JA, Gold MJ, Hiebert P, Le A, Park H, Stefanowicz D, et al., 'Identification Of A Novel Uric Acid Transport System In Human Airway Epithelial Cells That Contributes To Innate And Adaptive Immune Responses', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2014)
Co-authors Darryl Knight
2013 Rehaume L, Mondot S, de Carcer DA, Velasco J, Benham H, Hasnain S, et al., 'Host Genetic Background Disrupts The Relationship Between Microbiota and Gut Mucosal Tolerance Leading To Spondyloarthritis and Ileitis After a Dectin-1 Trigger.', ARTHRITIS AND RHEUMATISM, San Diego, CA (2013) [E3]
2013 Hansbro PM, Horvat JC, Essilfie A-T, Kim RY, Mayall J, Starkey MR, et al., 'Immunomodulatory Effects Of Macrolide Treatment On Experimental Models Of Steroid-Sensitive And Steroid-Resistant Asthma', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
Co-authors Jay Horvat, Malcolm Starkey, Paul Foster
2013 Kim RY, Horvat JC, Starkey MR, Essilfie A, Foster PS, Hansbro PM, 'Inhibition Of Early-Life Chlamydia Lung Infection-Induced Micrornas Prevents Infection-Induced Lung Pathologies In Later Life', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
Co-authors Jay Horvat, Malcolm Starkey, Paul Foster
2013 Tay H, Kaiko G, Hansbro P, Foster P, 'The role of miRNA in regulating bacterial clearance', JOURNAL OF IMMUNOLOGY, Honolulu, HI (2013) [E3]
Citations Web of Science - 1
Co-authors Paul Foster, Hock Tay, Gerard Kaiko
2013 Hansbro P, Beckett E, Stevens R, Jarnicki A, Kim R, Hanish I, et al., 'A short-term model of COPD identifies a role for mast cell tryptase', JOURNAL OF IMMUNOLOGY, Honolulu, HI (2013) [E3]
Co-authors Nicole Hansbro, Emma Beckett, Peter Wark, Paul Foster, Jay Horvat, Simon Keely, Ming Yang
2013 Hansbro P, Horvat J, Essilfie A-T, Kim R, Mayall J, Starkey M, Foster P, 'Macrolides suppress key features of experimental steroid-sensitive and steroid-resistant asthma', JOURNAL OF IMMUNOLOGY, Honolulu, HI (2013) [E3]
Co-authors Emma Beckett, Paul Foster, Malcolm Starkey, Jay Horvat
2013 Kim RY, Horvat JC, Starkey MR, Essilfie A-T, Foster PS, Hansbro PM, 'MICRORNA INHIBITION IN NEONATAL CHLAMYDIA LUNG INFECTION PREVENTS INFECTION-INDUCED LUNG PATHOLOGY IN LATER LIFE', RESPIROLOGY (2013) [E3]
Citations Web of Science - 1
Co-authors Paul Foster, Jay Horvat, Malcolm Starkey
2013 Horvat JC, Essilfie A-T, Kim RY, Mayall JR, Starkey MR, Beckett EL, et al., 'MACROLIDES SUPPRESS KEY FEATURES OF EXPERIMENTAL STEROID-SENSITIVE AND STEROID-RESISTANT ASTHMA', RESPIROLOGY (2013) [E3]
Co-authors Jodie Simpson, Peter Gibson, Malcolm Starkey, Jay Horvat, Paul Foster, Emma Beckett
2012 Sobinoff AP, Beckett EL, Nixon B, Roman SD, Hansbro PM, McLaughlin EA, 'The impact of maternal cigarette smoke exposure on the male germline', Abstracts. The Annual Scientific Meeting of the Endocrine Society of Australia and the Society for Reproductive Biology 2012, Gold Coast, QLD (2012) [E3]
Co-authors Eileen Mclaughlin, Brett Nixon, Emma Beckett, Shaun Roman
2012 Stifter SA, Fung K, Horvat JC, Hansbro PM, De Weerd NA, Hertzog PJ, 'Expression, purification and biological characterisation of a novel type I interferon, IFN epsilon', Immunology, Glasgow, Scotland (2012) [E3]
Co-authors Jay Horvat
2012 Kaiko GE, Tay HL, Plank MW, Hansbro PM, Foster PS, 'MicroRNA regulate bacterial phagocytosis in the lung', Immunology: Abstracts of the European Congress of Immunology, Glasgow, Scotland (2012) [E3]
Co-authors Paul Foster, Gerard Kaiko
2012 Starkey M, Kim R, Horvat J, Essilfie A-T, Beagley K, Mattes J, et al., 'Constitutive IL-13 promotes respiratory chlamydial infection and infection-induced chronic airway hyper-responsiveness', JOURNAL OF IMMUNOLOGY, Boston, MA (2012) [E3]
Co-authors Paul Foster, Joerg Mattes, Jay Horvat
2012 Mateer S, Hansbro PM, Nolan GM, Chaney C, Minahan KL, Keely S, 'Development of pulmonary inflammation and altered lung function in a mouse model of colitis', Journal of Gastroenterology and Hepatology, Adelaide, S.A. (2012) [E3]
Co-authors Simon Keely
2012 Horvat JC, Essilfie A-T, Kim RY, Mayall JR, Starkey MR, Beckett EL, et al., 'Efficacy of antibiotic-based therapeutic strategies for the treatment of infection-induced, steroid-resistant allergic airways disease', Respirology, Canberra, ACT (2012) [E3]
Co-authors Paul Foster, Malcolm Starkey, Jay Horvat, Emma Beckett
2012 Hsu A, Parsons KS, Barr I, Hansbro PM, Wark PA, 'Deficient antiviral responses to influenza in primary bronchial epithelial cells of chronic obstructive pulmonary disease', Respirology, Canberra, ACT (2012) [E3]
Co-authors Peter Wark, Alan Hsu
2012 Plank MW, Kaiko GE, Luck H, Li J, Mattes J, Hansbro PM, Foster PS, 'The role of micrornas in CD4 T cell function', Respirology, Canberra, ACT (2012) [E3]
Co-authors Joerg Mattes, Gerard Kaiko, Paul Foster
2012 See HV, Simpson JL, Hansbro PM, Wark PA, 'Stable COPD patients have less rhinovirus-induced intracellular innate cytokines detected in PBMCS compared to healthy adults', Respirology, Canberra, ACT (2012) [E3]
Co-authors Jodie Simpson, Peter Wark
2012 Starkey MR, Kim RY, Horvat JC, Essilfie A-T, Beagley KW, Mattes J, et al., 'Constitutive IL-13 promotes respiratory chlamydial infection-induced chronic airway hyperresponsiveness', Respirology, Canberra, ACT (2012) [E3]
Co-authors Paul Foster, Malcolm Starkey, Jay Horvat, Joerg Mattes
2012 Tay HL, Kaiko GE, Plank MW, Mattes J, Hansbro PM, Foster PS, 'MiRNAs regulate bacterial infection in lungs', Respirology, Canberra, ACT (2012) [E3]
Co-authors Paul Foster, Hock Tay, Gerard Kaiko, Joerg Mattes
2012 Keely S, Baird A, Kominsky D, McNamee EN, Hansbro PM, Shalwitz RA, Colgan SP, 'Immune modulation by prolyl hydroxylase inhibition contributes to the prevention of endotoxemia in a murine model of inflammatory bowel disease', FASEB Journal, San Diego, California (2012) [E3]
Co-authors Simon Keely
2011 O'Reilly M, Hansbro PM, Horvat JC, Sozo F, Harding R, 'Inhalation of hyperoxic gas in the neonatal period has long-term effects on the pulmonary airways', Journal of Developmental Origins of Health and Disease, Portland, Oregon (2011) [E3]
Co-authors Jay Horvat
2011 Foster P, Li J, Wang W, Baines K, Bowden N, Hansbro P, et al., 'IL-27 underpins steroid resistant airway hyperresponsiveness via MyD88 dependent pathways', ALLERGY, Istanbul, TURKEY (2011) [E3]
Co-authors Peter Gibson, Ming Yang, Nikola Bowden
2011 Wynnea O, Horvat JC, Kim RY, Ong LK, Smith R, Hansbro PM, et al., 'Sex differences in the effect of neonatal infection and adult re-infection on hippocampal corticosterone receptors and stress response outcomes', Brain, Behavior, and Immunity, Chicago, Illinois (2011) [E3]
Co-authors Deborah Hodgson, Roger Smith, Linkooi Ong, Jay Horvat
2011 O'Reilly M, Harding R, Hansbro PM, Sozo F, 'Exposure to hyperoxic gas in the neonatal period can cause long-term changes in lung function', Journal of Paediatrics and Child Health, Hobart, Tasmania (2011) [E3]
2011 Foster PS, Tay HL, Kaiko GE, Plank MW, Mattes J, Hansbro PM, 'MiRNA and its roles in regulating bacterial infection in lungs', American Journal of Respiratory and Critical Care Medicine, Denver, CO (2011) [E3]
Co-authors Gerard Kaiko, Hock Tay, Joerg Mattes, Paul Foster
2011 Hansbro PM, Horvat JC, Essilfie A-T, Kim RY, Simpson JL, Dunkley ML, et al., 'Infection-induced neutrophilic allergic airways disease is resistant to steroid treatment', American Journal of Respiratory and Critical Care Medicine, Denver, CO (2011) [E3]
Co-authors Margaret Dunkley, Jay Horvat, Jodie Simpson, Paul Foster, Peter Gibson
2011 Horvat JC, Essilfie A-T, Kim RY, Simpson JL, Dunkley ML, Beagley KW, et al., 'Investigation of infection-induced steroid resistant asthma', Respirology, Perth, WA (2011) [E3]
Co-authors Paul Foster, Jodie Simpson, Margaret Dunkley, Jay Horvat, Peter Gibson
2011 Oreo K, Baines KJ, Gibson PG, Hansbro PM, 'Pro-inflammatory cytokine production is impaired in response to TLR2 activation in healthy ageing and COPD', Respirology, Perth, WA (2011) [E3]
Co-authors Peter Gibson, Katherine Baines
2011 See HV, Simpson JL, Hansbro PM, Wark PA, 'COPD patients PBMCS have an impaired immune response to phinovirus-infected bronchial epithelium', Respirology, Perth, WA (2011) [E3]
Co-authors Peter Wark, Jodie Simpson
2010 Hansbro PM, Essilfie A-T, Simpson JL, Dunkley ML, Horvat JC, Gibson PG, Foster PS, 'Haemophilus influenzae induces IL-17-mediated neutrophilic allergic airways disease', American Journal of Respiratory and Critical Care Medicine, New Orleans (2010) [E3]
Citations Scopus - 69Web of Science - 64
Co-authors Jay Horvat, Paul Foster, Jodie Simpson, Peter Gibson, Margaret Dunkley
2010 Thorburn AN, Foster PS, Gibson PG, Hansbro PM, 'Development of a streptococcus pneumoniae-based immunoregulatory therapy for asthma', American Journal of Respiratory and Critical Care Medicine, New Orleans (2010) [E3]
Co-authors Paul Foster, Peter Gibson
2010 Thorburn AN, Foster PS, Gibson PG, Hansbro PM, 'Streptococcus pneumoniae vaccine, prevenar, induces regulatory T cells and prevents allergic airways disease', American Journal of Respiratory and Critical Care Medicine, New Orleans (2010) [E3]
Co-authors Paul Foster, Peter Gibson
2010 O'Reilly M, Harding R, Beckett EL, Horvat JC, Hansbro PM, Sozo F, 'Exposure of the immature mouse lung to hyperoxic gas: do structural changes in the lung cause long-term changes in lung function?', 24th Fetal and Neonatal Physiology Workshop of Australia and New Zealand. Program and Abstracts, Wellington, NZ (2010) [E3]
Co-authors Emma Beckett, Jay Horvat
2010 Fung K, Cumming H, Mangan N, Horvat JC, Hansbro PM, Hertzog P, 'Interferon epsilon regulates reproductive tract immunity to Chlamydia infection', Journal of Reproductive Immunology, Palm Cove, QLD (2010) [E3]
Co-authors Jay Horvat
2010 Lam CE, Foo A, Essilfie A-T, Hansbro PM, Matthaei KI, Foster PS, Phipps S, 'Chemerin derived peptide reduces LPS and haemophilus influenza-induced emphysema in mice', Respirology, Brisbane, QLD (2010) [E3]
Co-authors Paul Foster
2009 Fung KY, Cumming H, Mangan N, Stifter S, Horvat JC, Hansbro PM, Hertzog PJ, 'Characterisation of a novel, constitutive cytokine that regulates mucosal immunity in the reproductive tract', Cytokine, Lisbon, Portugal (2009) [E3]
DOI 10.1016/j.cyto.2009.07.324
Co-authors Jay Horvat
2009 Hansbro PM, Starkey MR, Horvat JC, Kim RY, Phipps S, Gibson PG, Foster PS, 'Early life chlamydial infection enhances allergic airways disease through age-dependent differences in immunopathology', Journal of Immunology, Seattle, WASH. (2009) [E3]
DOI 10.1016/j.jaci.2009.10.018
Co-authors Malcolm Starkey, Jay Horvat, Peter Gibson, Paul Foster
2009 Hansbro PM, Thorburn AN, Foster PS, Gibson PG, 'Streptococcus pneumoniae vaccine, Prevenar, utilises Tregs to suppress asthma', Journal of Immunology, Seattle, WASH. (2009) [E3]
Co-authors Peter Gibson, Paul Foster
2009 Horvat JC, Starkey MR, Beagley KW, Gibson PG, Foster PS, Hansbro PM, 'Chlamydial respiratory infection predisposes to neutrophil dominated allergic airways disease (AAD)', Journal of Immunology, Seattle, WASH. (2009) [E3]
Co-authors Paul Foster, Peter Gibson, Malcolm Starkey, Jay Horvat
2009 Wark PA, Hsu A, Hansbro PM, 'Innate immune response of bronchial epithelial cells to infection with influenza', Journal of Immunology, Seattle, WASH. (2009) [E3]
Co-authors Alan Hsu, Peter Wark
2009 Wark PA, See HV, Simpson JL, Vanders RL, Hansbro PM, 'Peripheral blood monocytes (PBMCs) display innate antiviral response to rhinovirus (RV) infected bronchial epithelial cells', Journal of Immunology, Seattle, WASH. (2009) [E3]
Co-authors Jodie Simpson, Peter Wark
2009 Oldham RA, Simpson JL, Hansbro PM, Gibson PG, 'Increased bacterial load and colonisation in COPD', Respirology, Darwin, NT (2009) [E3]
DOI 10.1111/j.1440-1843.2009.01503_1.x
Co-authors Peter Gibson, Jodie Simpson
2009 Parsons KS, Gangireddy SR, Hansbro PM, Barr I, Wark PA, 'Response of primary bronchial epithelial cells to infection with human influenza virus', Respirology, Darwin, NT (2009) [E3]
DOI 10.1111/j.1440-1843.2009.01502_7.x
Co-authors Peter Wark
2009 Thorburn AN, O'Sullivan B, Thomas R, Foster PS, Gibson PG, Hansbro PM, 'Prevenar suppresses allergic airways disease through the expansion of regulatory T cells', Respirology, Darwin, NT (2009) [E3]
DOI 10.1111/j.1440-1843.2009.01503_1.x
Co-authors Peter Gibson, Paul Foster
2009 Oreo K, Baines KJ, Gibson PG, Hansbro PM, Simpson JL, 'Toll-like receptor agonists stimulate cytokine release from blood but not airway cells', Respirology, Darwin, NT (2009) [E3]
DOI 10.1111/j.1440-1843.2009.01503_1.x
Co-authors Katherine Baines, Peter Gibson, Jodie Simpson
2009 Essilfie A-T, Simpson JL, Dunkley ML, Foster PS, Gibson PG, Hansbro PM, 'Haemophilus influenzae infection induces features of neutrophilic asthma', Respirology, Darwin, NT (2009) [E3]
DOI 10.1111/j.1440-1843.2009.01503_1.x
Co-authors Peter Gibson, Jodie Simpson, Paul Foster, Margaret Dunkley
2009 Horvat JC, Starkey MR, Beagley KW, Preston JA, Gibson PG, Foster PS, Hansbro PM, 'Neutrophil influx during chlamydial lung infection determines the phenotype of allergic airways disease (AAD)', Respirology, Darwin, NT (2009) [E3]
DOI 10.1111/j.1440-1843.2009.01503_1.x
Co-authors Peter Gibson, Paul Foster, Malcolm Starkey, Jay Horvat
2009 Starkey MR, Horvat JC, Kim RY, Phipps S, Gibson PG, Beagley KW, et al., 'Early life chlamydial lung infection enhances allergic airways disease through age-dependent differences in immunopathology', Respirology, Darwin, NT (2009) [E3]
DOI 10.1016/j.jaci.2009.10.018
Citations Scopus - 66Web of Science - 64
Co-authors Jay Horvat, Paul Foster, Peter Gibson, Malcolm Starkey
2009 Hsu A, Hansbro PM, Barr I, Wark PA, 'Innate immune response of bronchial epithelial cells to human and avian influenza virus', Respirology, Darwin, NT (2009) [E3]
Co-authors Alan Hsu, Peter Wark
2009 Weckmann M, Lau J, Grafton K, Oliver B, Hansbro NG, Foster PS, et al., 'Tumstatin: A non-collagenous domain of collagen IV: Effects on inflammation and angiogenesis', Respirology, Darwin, NT (2009) [E3]
Co-authors Paul Foster, Nicole Hansbro
2009 Schilter HC, Shum B, Shim D, Maslowski K, Tsai L, Kim R, et al., 'Fatty acid binding proteins: A link between metabolism and airway inflammation?', Respirology, Darwin, NT (2009) [E3]
Co-authors Nicole Hansbro
2008 Wynne OL, Horvat JC, Smith R, Hansbro PM, Clifton VL, Hodgson DM, 'Impact of neonatal infection on adult hippocampal glucocorticoid receptor, mineralocorticoid receptor and corticotrophin releasing hormone mRNA abundance', Proceedings of the Australian Neuroscience Society, Hobart, TAS (2008) [E3]
Co-authors Roger Smith, Olivia Wynne, Deborah Hodgson, Jay Horvat
2008 Burgess JK, Boustany S, Oliver BG, Moir LM, Baraket M, Hansbro PM, et al., 'The absence of tumstatin in asthma may lead to angiogenesis and airway hyperresponsiveness', American Journal of Respiratory and Critical Care Medicine, Toronto, ONT (2008) [E3]
Co-authors Paul Foster, Nicole Hansbro
2008 Hansbro PM, Essilfie A-T, Foster PS, Gibson PG, 'Haemophilus influenzae (Hi) infection in asthma may drive the development of neutrophilic asthma (NA)', American Journal of Respiratory and Critical Care Medicine, Toronto, ONT (2008) [E3]
Co-authors Peter Gibson, Paul Foster
2008 Hansbro PM, Horvat JC, Beagley KW, Gibson PG, Foster PS, 'Neutrophil influx during chlamydial lung infection determines the phenotype of allergic airways disease', American Journal of Respiratory and Critical Care Medicine, Toronto, ONT (2008) [E3]
Co-authors Paul Foster, Peter Gibson, Jay Horvat
2008 Hansbro PM, Thorburn AN, Foster PS, Gibson PG, 'Streptococcus Pneumoniae vaccine prevenar: A potential therapy for the suppression of asthma', American Journal of Respiratory and Critical Care Medicine, Toronto, ONT (2008) [E3]
Co-authors Paul Foster, Peter Gibson
2008 Simpson JL, Hansbro PM, McDonald VM, Gibson PG, 'Age and disease related changes in airway inflammation and inflammatory subtype in older people with COPD', American Journal of Respiratory and Critical Care Medicine, Toronto, ONT (2008) [E3]
Co-authors Jodie Simpson, Peter Gibson, Vanessa Mcdonald
2008 Thorburn AN, Foster PS, Gibson PG, Hansbro PM, 'Streptococcus pneumoniae vaccine prevenar: A potential therapy for the suppression of asthma', Respirology, Melbourne, VIC (2008) [E3]
DOI 10.1111/j.1440-1843.2008.01252.x
Co-authors Peter Gibson, Paul Foster
2008 Horvat JC, Beagley KW, Gibson PG, Foster PS, Hansbro PM, 'Neutrophil influx during chlamydial lung infection determines the phenotype of allergic airways disease', Respirology, Melbourne, VIC (2008) [E3]
DOI 10.1111/j.1440-1843.2008.01252.x
Co-authors Jay Horvat, Peter Gibson, Paul Foster
2008 Essilfie A-T, Preston JA, Horvat JC, Dunkley ML, Foster PS, Gibson PG, et al., 'Haemophilus influenzae (Hi) infection in asthma may drive the development of neutrophilic asthma (NA)', Respirology, Melbourne, VIC (2008) [E3]
DOI 10.1111/j.1440-1843.2008.01252.x
Co-authors Margaret Dunkley, Jay Horvat, Peter Gibson, Jodie Simpson, Paul Foster
2008 Hansbro NG, Boustany S, Oliver B, Burgess J, Black J, Rosenberg H, et al., 'Early life pneumoviral infection induces the development of pulmonary angiogenesis', Respirology, Melbourne, VIC (2008) [E3]
DOI 10.1111/j.1440-1843.2008.01252.x
Co-authors Nicole Hansbro, Paul Foster
2008 Simpson JL, Hansbro PM, McDonald VM, Gibson PG, 'Age and disease related changes in airway inflammation in older people with COPD', Respirology, Melbourne, VIC (2008) [E3]
DOI 10.1111/j.1440-1843.2008.01252.x
Co-authors Vanessa Mcdonald, Jodie Simpson, Peter Gibson
2008 Boustany S, Oliver BG, Moir LM, Black JL, Hansbro PM, Hansbro NG, et al., 'Tumstatin, an angiogenic inhibitor, modulates airway angiogenesis', Respirology, Melbourne, VIC (2008) [E3]
DOI 10.1111/j.1440-1843.2008.01252_4.x
Co-authors Paul Foster, Nicole Hansbro
2008 Wynne OL, Horvat JC, Smith R, Hansbro PM, Clifton VL, Hodgson DM, 'Impact of neonatal infection on adult hippocampal glucocorticoid receptor and mineralocorticoid receptor abundance', 15th Annual Meeting of the Psychoneuroimmunology Research Society: Program, Madison, WISC (2008) [E3]
Co-authors Roger Smith, Deborah Hodgson, Jay Horvat, Olivia Wynne
2008 Hansbro PM, Essilfie A-T, Simpson JL, Dunkley ML, Gibson PG, Foster PS, 'Haemophilus influenzae (HI) infection induces features of neutrophilic asthma', Australasian Society for Immunology 38th Annual Scientific Meeting: Delegate Book, Canberra, ACT (2008) [E3]
Co-authors Margaret Dunkley, Peter Gibson, Jodie Simpson, Paul Foster
2008 Hazelwood L, Wood LG, Hansbro PM, Foster PS, 'High fat diet reduces eosinophilic lung inflammation via nicotinic acetylcholine-dependent signaling', Australasian Society for Immunology 38th Annual Scientific Meeting: Delegate Book, Canberra, ACT (2008) [E3]
Co-authors Lisa Wood, Paul Foster
2008 Schilter H, Shim D, Maslowski K, Tsai L, Shum B, Kim RY, et al., 'A role for fatty acid binding proteins in respiratory inflammation', Australasian Society for Immunology 38th Annual Scientific Meeting: Delegate Book, Canberra, ACT (2008) [E3]
Co-authors Nicole Hansbro
2008 Starkey MR, Horvat JC, Kim RY, Phipps S, Gibson PG, Beagley KW, et al., 'Early life chlamydial lung infection enhances allergic airways disease through age-dependent differences in immunopathology', Australasian Society for Immunology 38th Annual Scientific Meeting: Delegate Book, Canberra, ACT (2008) [E3]
Co-authors Paul Foster, Malcolm Starkey, Peter Gibson, Jay Horvat
2008 Thorburn AN, O'Sullivan BJ, Thomas R, Foster PS, Gibson PG, Hansbro PM, 'Suppression of allergic airways disease by the Streptococcus pneumoniae vaccine prevenar through the induction of regulatory T cells', Australasian Society for Immunology 38th Annual Scientific Meeting: Delegate Book, Canberra, ACT (2008) [E3]
Co-authors Peter Gibson, Paul Foster
2008 Schilter HC, Shum BOV, Maslowski K, Sewell WA, Hotamisligil GS, Rolph MS, et al., 'Crucial role for fatty acid binding proteins in airway mediated immune responses', Final Programme and Abstracts: World Immune Regulation Meeting II, Davos, Switzerland (2008) [E3]
2008 Hsu A, Hansbro PM, Wark PA, 'Innate immune response of bronchial epithelial cells to human and avian influenza virus', The 4th Congress of the Federation of Immunology Societies of Asia-Oceania: Conference Program, Taipei, Taiwan (2008) [E3]
Co-authors Alan Hsu, Peter Wark
2008 Asquith KL, Ramshaw H, Lopez A, Foster PS, 'The IL-3/IL-5/GM-CSF Common beta Receptor Plays a Pivotal Role in Regulating Th2 Immunity and Allergic Airway Inflammation', FASEB JOURNAL (2008) [E3]
Co-authors Kelly Asquith, Paul Foster
2007 Horvat JC, Preston JA, Gibson PG, Beagley KW, Foster PS, Hansbro PM, 'Development of allergic airways disease (AAD) is differentially affected by the timing of chlamydial infection relative to allergic sensitization', American Journal of Respiratory and Critical Care Medicine, San Francisco, Calif. (2007) [E3]
Co-authors Peter Gibson, Paul Foster, Jay Horvat
2007 Horvat JC, Garside CG, Wade MA, Preston JA, Hansbro NG, Gibson PG, et al., 'Development of allergic airways disease is differentially affected by chlamydial respiratory infection at different ages', American Journal of Respiratory and Critical Care Medicine, San Francisco, Calif. (2007) [E3]
Co-authors Jay Horvat, Paul Foster, Peter Gibson, Nicole Hansbro
2007 Hansbro PM, 'Chlamydia pneumoniae and asthma', 2007 National Chlamydia Conference. Program, Brisbane, QLD (2007) [E3]
2007 Wark PA, See HV, Oldham R, Timmins N, Gibson PG, Hansbro PM, 'Response by peripheral blood monocytes (PBMCs) to rhinovirus (RV) is greater in cells exposed to infected epithelium in coculture than exposed to RV alone', American Journal of Respiratory and Critical Care Medicine (American Thoracic Society 2007 International Conference Abstracts), San Francisco (2007) [E3]
Co-authors Peter Wark, Peter Gibson
2007 Wynne OL, Horvat JC, Smith R, Hansbro PM, Clifton VL, Hodgson DM, 'Impact of neonatal infection on adult hippocampal corticosterone receptor abundance and circulating corticosterone', Early Human Development, Perth (2007) [E3]
Co-authors Deborah Hodgson, Jay Horvat, Roger Smith, Olivia Wynne
2007 Wynne OL, Horvat JC, Hansbro PM, Clifton VL, Hodgson DM, 'Impact of postnatal stress on neuroendocrine development and function in adulthood in the mouse', Fetal & Neonatal Workshop of Australia and New Zealand 21st Annual Meeting. Abstracts, Melbourne, VIC (2007) [E3]
Co-authors Olivia Wynne, Jay Horvat, Deborah Hodgson
2007 Hansbro NG, Boustany S, Oliver BG, Burgess JK, Black JL, Hansbro PM, Foster PS, 'Viral-induced angiogenesis', Immuno 2007: 13th International Congress of Immunology. Abstracts and Posters, Rio de Janeiro, Brazil (2007) [E3]
Co-authors Nicole Hansbro, Paul Foster
2007 Essiflie A, Preston JA, Horvat JC, Dunkley ML, Foster PS, Gibson PG, et al., 'Elucidating the association between Haemophilus influenzae infection and neutrophilic allergic airways disease using mouse models', Immuno 2007: 13th International Congress of Immunology. Abstracts and Posters, Rio de Janeiro, Brazil (2007) [E3]
Co-authors Margaret Dunkley, Peter Gibson, Jay Horvat, Paul Foster, Jodie Simpson
2007 Ferguson AL, Beagley KW, Hansbro PM, Foster PS, 'CD4+ T-cell programming by adult and neonatal bacterial infections inhibit the development of allergic airway inflammation in later life', Immuno 2007: 13th International Congress on Immunology. Abstracts and Posters, Rio de Janeiro, Brazil (2007) [E3]
Co-authors Paul Foster
2007 Horvat JC, Moller CG, Wade MA, Preston JA, Hansbro NG, Gibson PG, et al., 'Allergic airways disease (AAD) is differentially affected by chlamydial lung infection at different stages of life', Respirology (TSANZ Abstracts-Posters), Auckland (2007) [E3]
DOI 10.1111/j.1440-1843.2007.001050.x
Co-authors Paul Foster, Peter Gibson, Nicole Hansbro, Jay Horvat
2007 Horvat JC, Preston JA, Gibson PG, Beagley KW, Foster PS, Hansbro PM, 'Timing of chlamydial infection relative to allergen exposure differentially affects allergic airways disease', Respirology (TSANZ Abstracts-Posters), Auckland (2007) [E3]
Co-authors Paul Foster, Jay Horvat, Peter Gibson
2007 See H, Oldham R, Timmins N, Hansbro PM, Wark PA, Gibson PG, 'Rhinovirus (RV) induced inflammatory response in mononuclear cells is enhanced by coculture with airway epithelium', Respirology (TSANZ Abstracts-Posters), Auckland (2007) [E3]
DOI 10.1111/j.1440-1843.2007.001050.x
Co-authors Peter Gibson, Peter Wark
2007 Simpson JL, Hansbro PM, Kenyon ME, Gibson PG, 'Remodelled asthma in the elderly: is asthma turning into COPD?', Respirology (TSANZ Abstracts-Posters), Auckland (2007) [E3]
Co-authors Jodie Simpson, Peter Gibson
2007 Hansbro PM, Warner S, Hurt A, Curran J, 'Carriage of avian influenza viruses by shorebirds in Australia', Sixth Australasian Shorebird Conference 2007: Program and Abstracts, Newcastle, N.S.W. (2007) [E3]
2006 Horvat JC, Preston JA, Gibson PG, Beagley KW, Foster PS, Hansbro PM, 'Exacerbation of Allergic Airways Disease (AAD) by Chlamydia is Differentially Affected by the Timing of Infection Relative to Allergen Exposure', Immunology and Cell Biology, Auckland, NZ (2006) [E3]
Co-authors Jay Horvat, Peter Gibson, Paul Foster
2006 Preston JA, Horvat JC, Beagley KW, Foster PS, Gibson PG, Hansbro PM, 'Streptococcus pneumoniae (SPN) lung infection suppresses hallmark features of a mouse model of asthma', Immunology and Cell Biology, Auckland, NZ (2006) [E3]
Co-authors Paul Foster, Peter Gibson, Jay Horvat
2006 Horvat JC, Moller CG, Wade MA, Preston JA, Hansbro NG, Gibson PG, et al., 'The development of allergic airways disease (AAD) is differently affected by chlamydial lung infection at different stages of life', Immunology and Cell Biology, Auckland, NZ (2006) [E3]
Co-authors Jay Horvat, Paul Foster, Peter Gibson, Nicole Hansbro
2006 Horvat JC, Wade MA, Preston JA, Hansbro NG, Gibson PG, Beagley KW, et al., 'Early life chlamydial lung infection enhances allergic airways disease (AAD)', Respirology, Canberra (2006) [E3]
Co-authors Jay Horvat, Paul Foster, Peter Gibson, Nicole Hansbro
2006 Preston JA, Horvat JC, Wade MA, Beagley KW, Foster PS, Gibson PG, Hansbro PM, 'Inhibition of allergic lung disease by respiratory streptococcus pneumoniae infection', Respirology, Canberra (2006) [E3]
Co-authors Jay Horvat, Paul Foster, Peter Gibson
2006 Horvat JC, Wade MA, Preston JA, Hansbro NG, Gibson PG, Beagley KW, et al., 'Neonatal chlamydial infection exacerbates allergic airways disease', Abstracts ATS 2006 International Conference, San Diego, California (2006) [E3]
Co-authors Peter Gibson, Paul Foster, Nicole Hansbro, Jay Horvat
2006 Preston JA, Horvat JC, Beagley KW, Foster PS, Gibson PG, Hansbro PM, 'Respiratory Streptococcus pneumoniae infection decreases key inflammatory responses in a mouse model of asthma', Abstracts ATS 2006 International Conference, San Diego, California (2006) [E3]
Co-authors Jay Horvat, Paul Foster, Peter Gibson
2006 Gadil E, Morris PS, Beissbarth J, Chang A, Gibson PG, Hare K, et al., 'Use of ototopical antibiotic treatment on chronic suppurative otitis media: A randomized placebo controlled trial and feasibility study', 5th International Symposim on Pneumoccoci and Pneumococcal Diseases, Alice Springs (2006) [E3]
Co-authors Peter Gibson
2006 Preston JA, Horvat JC, Wade MA, Beagley KW, Foster PS, Gibson PG, Hansbro PM, 'Inhibition of allergic lung disease by respiratory Streptococcus pneumoniae infection', 5th International Symposium on Pneumococci and Pneumococcal Diseases, Alice Springs (2006) [E3]
Co-authors Peter Gibson, Paul Foster, Jay Horvat
2006 Preston JA, Horvat JC, Wade MA, Beagley KW, Foster PS, Gibson PG, Hansbro PM, 'The influence of allergic airways disease on the immune response to respiratory Streptococcus pneumoniae infection', 5th International Symposium on Pneumococci and Pneumococcal Diseases, Alice Springs (2006) [E3]
Co-authors Paul Foster, Peter Gibson, Jay Horvat
2005 Preston JA, Horvat JC, Wade MA, Beagley KW, Foster PS, Gibson PG, Hansbro PM, 'Respiratory streptococcus pneumoniae infection decreases key inflammatory responses in a mouse model of asthma', TISSUE ANTIGENS, Melbourne, AUSTRALIA (2005)
Co-authors Paul Foster, Peter Gibson, Jay Horvat
2005 Horvat JC, Wade MA, Preston JA, Newcombe N, Ferguson AL, Kaiko G, et al., 'Neonatal But Not Adult Chlamydial Infection Induces the Development of Allergic Airways Disease Through Novel Mechanisms Involving Inflammation of Mixed Phenotype', Tissue Antigens, Melbourne, Australia (2005) [E3]
Citations Web of Science - 1
Co-authors Gerard Kaiko, Paul Foster, Jay Horvat, Peter Gibson
2005 Horvat JC, Preston JA, Hansbro NG, Ferguson AL, Gibson PG, Beagley KW, et al., 'Neonatal chlamydial infection inhibits the development of allergic airway inflammation in adult mice', Inflammation Research, Melbourne, Australia (2005) [E3]
Co-authors Peter Gibson, Paul Foster, Jay Horvat, Nicole Hansbro
2005 Wynne OL, Clifton VL, Murphy VE, Hodyl NA, Krivanek K, Smith D, et al., 'The Effects of Prenatal Endotoxin Exposure on Placental 11-HSD2 Activity and the Developing HPA Axis in the Fischer 344 Rat', Australian Neuroscience Society: Proceedings of the 25th Annual, Perth, Australia (2005) [E3]
Co-authors Deborah Hodgson, Vanessa Murphy, Olivia Wynne
2005 Preston JA, Horvat JC, Beagley KW, Foster PS, Gibson PG, Hansbro PM, 'Timing of Streptococcus Pneumoniae (pnc) infection determines the magnitute of the effect on allergic airways inflammation (AAI) in a mouse model of asthma', Respirology, Perth Convention Exhibition Centre (2005) [E3]
Co-authors Jay Horvat, Peter Gibson, Paul Foster
2005 Preston JA, Horvat JC, Beagley KW, Foster PS, Gibson PG, Hansbro PM, 'Respiratory Streptococcus Pneumoniae Infection Decreases Eosinophilia and Mucus Cell Hyperplasia in a Mouse Model of Asthma', Respirology, Perth Convention Exhibition Centre (2005) [E3]
Co-authors Jay Horvat, Peter Gibson, Paul Foster
2005 Hurt AC, Hansbro PM, Selleck P, Olsen B, Barr IG, Hampson AW, 'Isolation of Avian Influenza Viruses from two different Transhemispheric migratory shorebird Species in Australia', Australian Virology Group, Phillip Island, Australia (2005) [E3]
2005 Skelding KA, Hickey DK, Horvat JC, Hansbro PM, Bao S, Beagley KW, 'Combined transcutaneous and intranasal immunisation protects against genital tract Chlamydial infection', Proceedings of the Twelfth International Congress of Mucosal Immunology, Boston, Massachusetts, USA. (2005) [E3]
Co-authors Jay Horvat, Kathryn Skelding
2005 Skelding KA, Hickey DK, Horvat JC, Hansbro PM, Bao S, Beagley KW, 'Comparison of intranasal and transcutaneous immunisation for the protection against Chlamydial pneumonia', Proceedings of the Twelfth International Congress of Mucosal Immunology, Boston, Massachusetts (2005) [E3]
Co-authors Kathryn Skelding, Jay Horvat
2003 Berry L, Hickey DK, Skelding KA, Bao S, Hansbro PM, Beagley KW, 'Transcutaneous immunisation prevents Chlamydia muridarum genital tract infection', American Journal of Reproductive Immunology, - (2003) [E3]
Co-authors Kathryn Skelding
Show 189 more conferences

Patent (3 outputs)

Year Citation Altmetrics Link
2008 Hansbro PM, Gibson PG, Vaccine compositions (2008) [I3]
Co-authors Peter Gibson
2007 Gibson PG, Hansbro PM, Treatment and prevention of allergic airways diseases (2007) [I3]
Co-authors Peter Gibson
2001 Hanniffy SB, Hansbro PM, Wells JM, Le Page RW, Lactococcal expression of exported protein-based discovery of Streptococcus pneumoniae genes encoding surface proteins. (2001) [I1]

Report (1 outputs)

Year Citation Altmetrics Link
2008 Kirkland PD, Arzey KE, Tracey J, Hansbro PM, Rose K, 'Surveillance of wild birds in NSW for avian influenze viruses. Report to the Department of Agriculture, Fisheries and Forestry', NSW Department of Primary Industries, 15 (2008) [R2]
Edit

Grants and Funding

Summary

Number of grants 179
Total funding $26,201,667

Click on a grant title below to expand the full details for that specific grant.


20191 grants / $412,192

***Temporary CI of HOS as Dr Caitlin Gillis will be appointed to UON once G number is active*** Apoptotic cell clearance: from basic biology to new therapeutic strategies for chronic respiratory disea$412,192

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Darryl Knight, Doctor Caitlin Gillis, Professor Phil Hansbro, Professor Kodi Ravichandran
Scheme Early Career Fellowships
Role Investigator
Funding Start 2019
Funding Finish 2022
GNo G1800195
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

201811 grants / $2,545,719

Elucidating the role and potential for therapeutic targeting of TLR7 in emphysema and COPD$938,742

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Phil Hansbro, Conjoint Professor Peter Wark, Prof Ian Adcock, Professor Kensuke Miyake
Scheme Project Grant
Role Lead
Funding Start 2018
Funding Finish 2021
GNo G1700045
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Defining the roles and targeting interferon-epsilon as a new therapy for influenza in asthma and COPD$918,588

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Phil Hansbro, Conjoint Professor Peter Wark, Associate Professor Jay Horvat, Associate Professor Aeron Hurt
Scheme Project Grant
Role Lead
Funding Start 2018
Funding Finish 2021
GNo G1700046
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Discovery of efficient and accurate early stage biomarkers is crucial towards the treatment of early stage lung cancer$314,151

Funding body: IASLC International Association for the Study of Lung Cancer

Funding body IASLC International Association for the Study of Lung Cancer
Project Team Doctor Atiqur Rahman, Professor Phil Hansbro
Scheme Prevent Cancer Foundation/IASLC Joint Research Grant
Role Investigator
Funding Start 2018
Funding Finish 2020
GNo G1701236
Type Of Funding C3212 - International Not for profit
Category 3212
UON Y

Switching tristetraprolin on to turn off inflammation in COPD$160,738

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Alaina Ammit, Professor Andrew Clark, Doctor Nikki Verrills, Professor Phil Hansbro, Associate Professor Jonathan Morris, Professor Christine Jenkins
Scheme Project Grant
Role Investigator
Funding Start 2018
Funding Finish 2020
GNo G1800321
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Testing treatments for asthma$50,000

Funding body: Inflazome Limited

Funding body Inflazome Limited
Project Team Professor Phil Hansbro, Associate Professor Jay Horvat
Scheme Research Project
Role Lead
Funding Start 2018
Funding Finish 2018
GNo G1801017
Type Of Funding C3211 - International For profit
Category 3211
UON Y

The Role of Olfactory Receptor in Allergic Inflammation of Respiratory System$45,500

Funding body: Valentine Badham

Funding body Valentine Badham
Project Team Doctor He Wang, Professor Phil Hansbro, Miss Pu Wang
Scheme Valentine Badham PhD Scholarship Project Funds
Role Investigator
Funding Start 2018
Funding Finish 2021
GNo G1800956
Type Of Funding C3120 - Aust Philanthropy
Category 3120
UON Y

Genetic modelling to advance kidney stone and cystinuria treatments$38,000

Funding body: Kiriwina Investment Company Pty Ltd

Funding body Kiriwina Investment Company Pty Ltd
Project Team Doctor Malcolm Starkey, Doctor Aniruddh Deshpande, Professor Phil Hansbro, Dr Simon Jiang
Scheme Research Funding
Role Investigator
Funding Start 2018
Funding Finish 2018
GNo G1800435
Type Of Funding C3120 - Aust Philanthropy
Category 3120
UON Y

Understanding how group 2 innate lymphoid cells in early-life regulate postnatal lung development and susceptibility to chronic lung diseases$20,000

Funding body: Thoracic Society of Australia and New Zealand

Funding body Thoracic Society of Australia and New Zealand
Project Team Doctor Malcolm Starkey, Professor Phil Hansbro
Scheme Lungs for Life Research Award
Role Investigator
Funding Start 2018
Funding Finish 2018
GNo G1800627
Type Of Funding C3112 - Aust Not for profit
Category 3112
UON Y

Cell free microRNA: potential biomarkers for the early detection of lung cancer$20,000

Funding body: Thoracic Society of Australia and New Zealand

Funding body Thoracic Society of Australia and New Zealand
Project Team Professor Phil Hansbro
Scheme Lungs for Life Research Award
Role Lead
Funding Start 2018
Funding Finish 2018
GNo G1800687
Type Of Funding C3112 - Aust Not for profit
Category 3112
UON Y

The role of extracellular matrix protein 1 (ECM1) in cardiac fibrosis$20,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Mr Sean Hardy, Professor Andrew Boyle, Professor Phil Hansbro, Professor Peter Rainer
Scheme Emlyn and Jennie Thomas Postgraduate Medical Research Scholarship
Role Investigator
Funding Start 2018
Funding Finish 2019
GNo G1800696
Type Of Funding C3120 - Aust Philanthropy
Category 3120
UON Y

Investigating the Genetics of the Development of Lung Cancer$20,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Miss Vrushali Chimankar, Professor Phil Hansbro, Doctor Chantal Donovan
Scheme Emlyn and Jennie Thomas Postgraduate Medical Research Scholarship
Role Lead
Funding Start 2018
Funding Finish 2019
GNo G1800717
Type Of Funding C3120 - Aust Philanthropy
Category 3120
UON Y

201721 grants / $2,243,172

Elucidating the roles and mechanisms of activation of NLRP3 inflammasomes and developing therapeutic interventions for severe steroid-resistant asthma$707,853

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Phil Hansbro, Conjoint Professor Peter Gibson, Professor Matthew Cooper, Professor Luke O'Neill
Scheme Project Grant
Role Lead
Funding Start 2017
Funding Finish 2019
GNo G1600076
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Novel NLRP3 Inhibitors for Steroid Resistant Asthma$420,076

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Phil Hansbro, Professor Matthew Cooper
Scheme Development Grants
Role Lead
Funding Start 2017
Funding Finish 2019
GNo G1601329
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Treatments for COPD exacerbations$202,168

Funding body: Genentech Inc

Funding body Genentech Inc
Project Team Professor Phil Hansbro
Scheme Research Contract
Role Lead
Funding Start 2017
Funding Finish 2018
GNo G1700845
Type Of Funding C3211 - International For profit
Category 3211
UON Y

Characterising the epidemiological and biological effects of particulate matter exposures in coal mining to protect and improve the health of workers$171,061

Funding body: Coal Services Health and Safety Trust

Funding body Coal Services Health and Safety Trust
Project Team Professor Phil Hansbro, Associate Professor Jay Horvat, Associate Professor Kenneth Williams, Doctor Dusan Ilic, Associate Professor Carole James
Scheme Research Project
Role Lead
Funding Start 2017
Funding Finish 2019
GNo G1700782
Type Of Funding C3112 - Aust Not for profit
Category 3112
UON Y

Asthma treatments$120,000

Funding body: AstraZeneca

Funding body AstraZeneca
Project Team Professor Phil Hansbro, Doctor Nicole Hansbro, Associate Professor Jay Horvat
Scheme Research Grant
Role Lead
Funding Start 2017
Funding Finish 2017
GNo G1700098
Type Of Funding C3211 - International For profit
Category 3211
UON Y

PhD Scholarship for Daniel Hampsey$90,000

Funding body: Hunter New England Local Health District

Funding body Hunter New England Local Health District
Project Team Professor Phil Hansbro, Mr Daniel Hampsey
Scheme Scholarship
Role Lead
Funding Start 2017
Funding Finish 2017
GNo G1700554
Type Of Funding C2220 - Aust StateTerritoryLocal - Other
Category 2220
UON Y

Australian Cystic Fibrosis Research Trust 2017 Innovation Grant$80,000

Funding body: Thoracic Society of Australia and New Zealand

Funding body Thoracic Society of Australia and New Zealand
Project Team Associate Professor Jay Horvat, Professor Phil Hansbro, Conjoint Professor Peter Wark
Scheme Australian Cystic Fibrosis Trust Innovation Grant
Role Investigator
Funding Start 2017
Funding Finish 2017
GNo G1700984
Type Of Funding C3112 - Aust Not for profit
Category 3112
UON Y

IASLC International Association of the Study of Lung Cancer/IASLC Fellowship$64,298

Funding body: IASLC International Association for the Study of Lung Cancer

Funding body IASLC International Association for the Study of Lung Cancer
Project Team Doctor Atiqur Rahman, Professor Phil Hansbro
Scheme IASLC Fellowship
Role Investigator
Funding Start 2017
Funding Finish 2017
GNo G1700300
Type Of Funding C3212 - International Not for profit
Category 3212
UON Y

Assessment of new therapies for COPD in a smoking model$60,000

Funding body: AusBio Limited

Funding body AusBio Limited
Project Team Professor Phil Hansbro
Scheme Entrepreneurs' Programme: Innovation Connections
Role Lead
Funding Start 2017
Funding Finish 2017
GNo G1701510
Type Of Funding C3111 - Aust For profit
Category 3111
UON Y

Assessment of new therapies for COPD in a smoking model$50,000

Funding body: Department of Industry, Innovation and Science

Funding body Department of Industry, Innovation and Science
Project Team Professor Phil Hansbro
Scheme Entrepreneurs' Programme: Innovation Connections
Role Lead
Funding Start 2017
Funding Finish 2017
GNo G1701554
Type Of Funding C2110 - Aust Commonwealth - Own Purpose
Category 2110
UON Y

UON 2017 Researcher Equipment Grant $49,545

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Phil Hansbro
Scheme Researcher Equipment Grants
Role Lead
Funding Start 2017
Funding Finish 2017
GNo G1701159
Type Of Funding Internal
Category INTE
UON Y

Elucidating and targeting genomic and epigenetic changes in the development and progression of lung cancer$45,000

Funding body: Lung Foundation Australia

Funding body Lung Foundation Australia
Project Team Professor Phil Hansbro, Miss Vrushali Chimankar
Scheme PhD Scholarship in Lung Cancer Research
Role Lead
Funding Start 2017
Funding Finish 2019
GNo G1600585
Type Of Funding C3112 - Aust Not for profit
Category 3112
UON Y

MD990 and murine smoking model$40,000

Funding body: AusBio Limited

Funding body AusBio Limited
Project Team Professor Phil Hansbro, Doctor Nicole Hansbro
Scheme Entrepreneurs' Programme: Innovation Connections
Role Lead
Funding Start 2017
Funding Finish 2017
GNo G1700108
Type Of Funding C3111 - Aust For profit
Category 3111
UON Y

MD990 and murine smoking model$40,000

Funding body: Department of Industry, Innovation and Science

Funding body Department of Industry, Innovation and Science
Project Team Professor Phil Hansbro, Doctor Nicole Hansbro
Scheme Entrepreneurs' Programme: Innovation Connections
Role Lead
Funding Start 2017
Funding Finish 2017
GNo G1701037
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

Pharmaxis pilot study to test if novel PXS compounds can reduce inflammation in the lung.$35,000

Funding body: Pharmaxis Ltd

Funding body Pharmaxis Ltd
Project Team Professor Phil Hansbro
Scheme Research Grant
Role Lead
Funding Start 2017
Funding Finish 2018
GNo G1701505
Type Of Funding C3111 - Aust For profit
Category 3111
UON Y

Influenza virus surveillance in wild birds in NSW$29,289

Funding body: NSW Department of Primary Industries

Funding body NSW Department of Primary Industries
Project Team Professor Phil Hansbro
Scheme Research Grant
Role Lead
Funding Start 2017
Funding Finish 2018
GNo G1800549
Type Of Funding C2220 - Aust StateTerritoryLocal - Other
Category 2220
UON Y

Mast cell proteases as therapeutic targets for stroke$22,000

Funding body: Markey Insurance

Funding body Markey Insurance
Project Team Doctor Michael Fricker, Professor Phil Hansbro, Associate Professor Rohan Walker
Scheme Research Funding
Role Investigator
Funding Start 2017
Funding Finish 2017
GNo G1700861
Type Of Funding C3120 - Aust Philanthropy
Category 3120
UON Y

Mast cell and epithelial cell proteins in experimental CKD$8,500

Funding body: Harvard Club of Australia Foundation

Funding body Harvard Club of Australia Foundation
Project Team Professor Richard Stevens, Professor Phil Hansbro
Scheme Monday Club Research Support
Role Investigator
Funding Start 2017
Funding Finish 2017
GNo G1700168
Type Of Funding C3120 - Aust Philanthropy
Category 3120
UON Y

Utilisation of microbial products as novel therapies for COPD$5,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Professor Phil Hansbro, Doctor Shaan Gellatly, Doctor Michael Fricker, Mr Kurtis Budden
Scheme Greaves Family Postgraduate Top Up Scholarship in Medical Research
Role Lead
Funding Start 2017
Funding Finish 2017
GNo G1700348
Type Of Funding C3120 - Aust Philanthropy
Category 3120
UON Y

Jennie Thomas Medical Research Travel Grant$3,381

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Mr David Skerrett-Byrne, Professor Phil Hansbro, Doctor Matt Dun
Scheme Jennie Thomas Medical Research Travel Grant
Role Investigator
Funding Start 2017
Funding Finish 2017
GNo G1701070
Type Of Funding C3120 - Aust Philanthropy
Category 3120
UON Y

Surveillance of wild birds for avian influenza viruses in NSW$1

Funding body: Department of Agriculture, Fisheries and Forestry Australia

Funding body Department of Agriculture, Fisheries and Forestry Australia
Project Team Dr Peter Kirkland, Professor Phil Hansbro
Scheme New Industries Development Programme
Role Lead
Funding Start 2017
Funding Finish 2017
GNo G1601402
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

20169 grants / $2,123,923

Role and potential for therapeutic targeting of dysfunction, oxidative stress and altered metabolism in mitochondria in the pathogenesis of COPD$733,962

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Phil Hansbro, Conjoint Professor Peter Wark, Prof Ian Adcock, Professor Luke O'Neill
Scheme Project Grant
Role Lead
Funding Start 2016
Funding Finish 2019
GNo G1500070
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Identification of genomic mutations associated with the development and progression of lung cancer for use in early diagnosis$360,000

Funding body: Cancer Council NSW

Funding body Cancer Council NSW
Project Team Professor Phil Hansbro, Conjoint Professor Peter Wark, Professor David Watkins, Dr Warren Kaplan
Scheme Research Grant
Role Lead
Funding Start 2016
Funding Finish 2019
GNo G1500465
Type Of Funding C3112 - Aust Not for profit
Category 3112
UON Y

Investigation and therapeutic targeting of the immune mechanisms that predispose to and increase the severity of influenza in pregnancy$320,964

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Doctor Rebecca Vanders, Professor Phil Hansbro
Scheme Early Career Fellowships
Role Investigator
Funding Start 2016
Funding Finish 2021
GNo G1400642
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Investigate the role of mast cells in disease$300,000

Funding body: St George & Sutherland Medical Research Foundation

Funding body St George & Sutherland Medical Research Foundation
Project Team Professor Phil Hansbro, Professor Richard Stevens, Professor Steven Krilis
Scheme Capacity Building Grant
Role Lead
Funding Start 2016
Funding Finish 2017
GNo G1501132
Type Of Funding C3112 - Aust Not for profit
Category 3112
UON Y

The pneumococcal vaccine Prevenar 13 as a new asthma therapy$147,273

Funding body: Asthma Australia

Funding body Asthma Australia
Project Team Conjoint Professor Peter Gibson, Professor Phil Hansbro
Scheme National Research Program
Role Investigator
Funding Start 2016
Funding Finish 2017
GNo G1500725
Type Of Funding C3111 - Aust For profit
Category 3111
UON Y

Elucidating and targeting genomic and epigenetic changes in the development and progression of lung cancer$140,000

Funding body: Lung Foundation Australia

Funding body Lung Foundation Australia
Project Team Professor Phil Hansbro, Doctor Atiqur Rahman, Fellowship
Scheme Early Career Fellowship for Lung Cancer Research
Role Lead
Funding Start 2016
Funding Finish 2018
GNo G1600599
Type Of Funding C3112 - Aust Not for profit
Category 3112
UON Y

COPD treatments$68,724

Funding body: PharmAkea Inc

Funding body PharmAkea Inc
Project Team Professor Phil Hansbro, Doctor Nicole Hansbro
Scheme Research Project
Role Lead
Funding Start 2016
Funding Finish 2016
GNo G1601160
Type Of Funding C3211 - International For profit
Category 3211
UON Y

MD990 Respiratory Project$48,000

Funding body: AusBio Limited

Funding body AusBio Limited
Project Team Professor Phil Hansbro, Doctor Nicole Hansbro
Scheme Research Project
Role Lead
Funding Start 2016
Funding Finish 2016
GNo G1600515
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Targeting to Fibulin-1 as a novel therapeutic option for IPF$5,000

Funding body: Lung Foundation Australia

Funding body Lung Foundation Australia
Project Team Professor Phil Hansbro, Mr Gang Liu
Scheme Research Award
Role Lead
Funding Start 2016
Funding Finish 2016
GNo G1600702
Type Of Funding C3112 - Aust Not for profit
Category 3112
UON Y

20159 grants / $2,557,234

Modifying epigenetics as a novel treatment in COPD$1,110,137

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Phil Hansbro, Professor Darryl Knight, Conjoint Professor Peter Wark, Prof Ian Adcock
Scheme Project Grant
Role Lead
Funding Start 2015
Funding Finish 2019
GNo G1400006
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Development of new therapies for respiratory diseases and infection$841,074

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Phil Hansbro
Scheme Research Fellowships
Role Lead
Funding Start 2015
Funding Finish 2019
GNo G1400019
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Elucidating the post-transcriptional regulation of mast cell proteases$459,265

Funding body: ARC (Australian Research Council)

Funding body ARC (Australian Research Council)
Project Team Professor Phil Hansbro, Professor Richard Stevens, Professor Paul Hertzog
Scheme Discovery Projects
Role Lead
Funding Start 2015
Funding Finish 2017
GNo G1400517
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Nose only inhalation smoke exposure system for mice$54,698

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Phil Hansbro, Laureate Professor Paul Foster, Associate Professor Jay Horvat, Doctor Janet Bristow, Doctor Malcolm Starkey, Doctor Rebecca Vanders, University Staff
Scheme Equipment Grant
Role Lead
Funding Start 2015
Funding Finish 2015
GNo G1501551
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

Characterising the airway and gut microbiome in severe asthma$25,222

Funding body: John Hunter Hospital Charitable Trust

Funding body John Hunter Hospital Charitable Trust
Project Team Professor Jodie Simpson, Conjoint Associate Professor Nick Saltos, Professor Phil Hansbro
Scheme Research Grant
Role Investigator
Funding Start 2015
Funding Finish 2015
GNo G1500009
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

Investigation of the progression of Alzheimers Disease: Identification of potential drivers of disease$20,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Associate Professor Jay Horvat, Associate Professor Liz Milward, Professor Phil Hansbro, Dr Daniel Johnstone
Scheme Project Grant
Role Investigator
Funding Start 2015
Funding Finish 2015
GNo G1500589
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

How oxidative stress makes severe asthmatics susceptible to infection with Rhinovirus$20,000

Funding body: National Clinical CRE in Severe Asthma

Funding body National Clinical CRE in Severe Asthma
Project Team Conjoint Professor Peter Wark, Professor Lisa Wood, Professor Phil Hansbro, Mr Prabuddha Pathinayake
Scheme Seed Research Project
Role Investigator
Funding Start 2015
Funding Finish 2015
GNo G1600355
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Assessing the potential of a new therapeutic for COPD$16,838

Funding body: Boston University

Funding body Boston University
Project Team Professor Phil Hansbro, Dr Avi Spira, Spira, Avi
Scheme Research Grant
Role Lead
Funding Start 2015
Funding Finish 2015
GNo G1501125
Type Of Funding C3212 - International Not for profit
Category 3212
UON Y

Greaves Family Postgraduate Scholarship in Medical Research$10,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Associate Professor Jay Horvat, Doctor Richard Kim, Mr James Pinkerton, Professor Phil Hansbro
Scheme Postgraduate Research Scholarship
Role Investigator
Funding Start 2015
Funding Finish 2015
GNo G1501396
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

201412 grants / $3,667,619

Altering the microbiome to treat COPD$1,226,338

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Phil Hansbro, Professor Philip Hugenhotlz, Professor Matthew Cooper
Scheme Project Grant
Role Lead
Funding Start 2014
Funding Finish 2017
GNo G1300064
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Investigating the role of microbiomes in COPD$822,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Professor Phil Hansbro
Scheme Project Grant
Role Lead
Funding Start 2014
Funding Finish 2020
GNo G1400891
Type Of Funding C3120 - Aust Philanthropy
Category 3120
UON Y

Interferon epsilon for Chlamydia RTIs $750,487

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Phil Hansbro, Associate Professor Jay Horvat, Professor Paul Hertzog
Scheme Project Grant
Role Lead
Funding Start 2014
Funding Finish 2017
GNo G1300071
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

A novel approach to understanding Asthma: Focus on the epithelium $633,228

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Darryl Knight, Professor Phil Hansbro, Professor Stephen Stick, Dr Anthony Kicic
Scheme Project Grant
Role Investigator
Funding Start 2014
Funding Finish 2017
GNo G1300212
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

The Nanostring nCounter System$75,000

Funding body: Ramaciotti Foundations

Funding body Ramaciotti Foundations
Project Team Professor Darryl Knight, Professor Phil Hansbro, Laureate Professor Paul Foster, Laureate Professor Rodney Scott, Conjoint Professor Peter Gibson, Professor Michael Nilsson
Scheme Major Equipment Award
Role Investigator
Funding Start 2014
Funding Finish 2014
GNo G1300853
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

High Throughput Cell Genomics Centre$50,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Paul Hertzog, Professor James Whisstock, Professor Fabienne Mackay, Professor William Charman, Dr Jose Polo, Professor Elizabeth Hartland, Professor Martin Pera, Professor Phil Hansbro
Scheme Equipment Grant
Role Lead
Funding Start 2014
Funding Finish 2014
GNo G1300642
Type Of Funding Internal
Category INTE
UON Y

The Nanostring nCounter System$40,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Professor Darryl Knight, Professor Phil Hansbro, Laureate Professor Paul Foster, Laureate Professor Rodney Scott, Conjoint Professor Peter Gibson, Professor Michael Nilsson
Scheme Equipment Grant
Role Investigator
Funding Start 2014
Funding Finish 2014
GNo G1301083
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

Miltenyi Biotec GentleMACS Octo Dissociator with Heaters $23,566

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Phil Hansbro, Laureate Professor Paul Foster, Professor Darryl Knight, Professor Dirk Van Helden, Professor Joerg Mattes, Professor Jodie Simpson, Professor Lisa Wood, Associate Professor Liz Milward, Dr NATHAN Bartlett, Associate Professor Simon Keely, Doctor Steven Maltby, Doctor Andrew Jarnicki, Doctor Malcolm Starkey, Doctor Adam Collison, Doctor Shaan Gellatly
Scheme Equipment Grant
Role Lead
Funding Start 2014
Funding Finish 2014
GNo G1500861
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

The Nanostring nCounter System$20,000

Funding body: John Hunter Hospital Charitable Trust

Funding body John Hunter Hospital Charitable Trust
Project Team Professor Darryl Knight, Professor Phil Hansbro, Laureate Professor Paul Foster, Laureate Professor Rodney Scott, Conjoint Professor Peter Gibson, Professor Michael Nilsson
Scheme Research Grant
Role Investigator
Funding Start 2014
Funding Finish 2014
GNo G1301084
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

HMRI Award for Research Excellence$15,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Professor Phil Hansbro
Scheme Sparke Helmore/NBN Television Corporate Triathlon Award for Research Excellence
Role Lead
Funding Start 2014
Funding Finish 2014
GNo G1301343
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

2014 International Visitor from Imperial College London, UK$10,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Phil Hansbro, Prof Ian Adcock
Scheme International Research Visiting Fellowship
Role Lead
Funding Start 2014
Funding Finish 2014
GNo G1400869
Type Of Funding Internal
Category INTE
UON Y

American Thoracic Society, San Diego USA, 17-21 May 2014$2,000

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding body University of Newcastle - Faculty of Health and Medicine
Project Team Professor Phil Hansbro
Scheme Travel Grant
Role Lead
Funding Start 2014
Funding Finish 2014
GNo G1400567
Type Of Funding Internal
Category INTE
UON Y

20135 grants / $558,552

Enhancing innate immune responses to influenza in chronic obstructive pulmonary disease$504,552

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Conjoint Professor Peter Wark, Professor Phil Hansbro, Professor James Mahony
Scheme Project Grant
Role Investigator
Funding Start 2013
Funding Finish 2015
GNo G1200206
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Protecting Pregnant Women from Death during influenza epidemics$25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Laureate Professor Roger Smith, Professor Phil Hansbro, Conjoint Professor Peter Wark
Scheme Project Grant
Role Investigator
Funding Start 2013
Funding Finish 2013
GNo G1301181
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

DP73 Digital colour and monochrome camera + cellSens software + Xcite120 fluorescence lamp illuminator$20,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Laureate Professor Paul Foster, Doctor Alan Hsu, Professor Phil Hansbro, Professor Joerg Mattes, Doctor Katie Baines, Professor Jodie Simpson, Professor Rakesh Kumar, Doctor Nicole Hansbro, Doctor Steven Maltby, Doctor Ming Yang, Doctor Gerard Kaiko, Associate Professor Jay Horvat, Associate Professor Simon Keely, Doctor Andrew Jarnicki, Doctor Michael Fricker
Scheme Equipment Grant
Role Investigator
Funding Start 2013
Funding Finish 2013
GNo G1201186
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

Australia-Harvard Fellowship$7,000

Funding body: Harvard Club of Australia Foundation

Funding body Harvard Club of Australia Foundation
Project Team Professor Phil Hansbro
Scheme Australia-Harvard Fellowships
Role Lead
Funding Start 2013
Funding Finish 2013
GNo G1300903
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

International Congress of Immunology European Respiratory Society. 22-27 Aug 13 & 7-11 Sep 13$2,000

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding body University of Newcastle - Faculty of Health and Medicine
Project Team Professor Phil Hansbro
Scheme Travel Grant
Role Lead
Funding Start 2013
Funding Finish 2013
GNo G1300797
Type Of Funding Internal
Category INTE
UON Y

20127 grants / $786,879

Elucidating the role of mast cell tryptases in chronic obstructive pulmonary disease and Crohn's disease$609,879

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Phil Hansbro, Laureate Professor Nick Talley, A/Prof Brian Oliver
Scheme Project Grant
Role Lead
Funding Start 2012
Funding Finish 2014
GNo G1100239
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

SpectraMax M5e Multi-Mode Microplate Reader$50,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Laureate Professor Paul Foster, Professor Phil Hansbro, Professor Joerg Mattes, Professor Rakesh Kumar, Doctor Nicole Hansbro, Doctor Ming Yang, Associate Professor Jay Horvat, Associate Professor Simon Keely, Doctor Andrew Jarnicki, Doctor Linda Howland, Doctor Kelly Asquith
Scheme Equipment Grant
Role Investigator
Funding Start 2012
Funding Finish 2012
GNo G1100975
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

Emphysema Research$50,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Phil Hansbro
Scheme Special Project Grant
Role Lead
Funding Start 2012
Funding Finish 2012
GNo G1201088
Type Of Funding Internal
Category INTE
UON Y

Novel strategies to boost tristetraprolin function: a critical anti-inflammatory protein in asthma$30,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Alaina Ammit, Professor Andrew Clark, Professor Phil Hansbro
Scheme Project Grant
Role Lead
Funding Start 2012
Funding Finish 2014
GNo G1200372
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

COPD-induced systemic inflammation activates mast cell specific tryptases which lead to cardiovascular disease $25,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Professor Phil Hansbro, Doctor Andrew Jarnicki
Scheme Research Grant
Role Lead
Funding Start 2012
Funding Finish 2012
GNo G1200028
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Coordinated targeting of immune pathways to suppress infection-associated inflammatory diseases.$20,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Phil Hansbro, Professor Joerg Mattes
Scheme Near Miss Grant
Role Lead
Funding Start 2012
Funding Finish 2012
GNo G1200671
Type Of Funding Internal
Category INTE
UON Y

American Thoracic Society, San Francisco, 18 - 23 May 2012$2,000

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding body University of Newcastle - Faculty of Health and Medicine
Project Team Professor Phil Hansbro
Scheme Travel Grant
Role Lead
Funding Start 2012
Funding Finish 2012
GNo G1200498
Type Of Funding Internal
Category INTE
UON Y

201111 grants / $2,289,735

Identifying new therapeutic targets for preventing the induction and progression of COPD$626,732

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Phil Hansbro, Conjoint Professor Peter Wark
Scheme Project Grant
Role Lead
Funding Start 2011
Funding Finish 2013
GNo G1000252
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Understanding the mechanisms of respiratory viral infection- and COPD-induced predisposition to secondary bacterial pneumonia $573,390

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Phil Hansbro, Conjoint Professor Peter Wark
Scheme Project Grant
Role Lead
Funding Start 2011
Funding Finish 2013
GNo G1000248
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

A novel reproductive tract factor that protects against chlamydia$522,456

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Phil Hansbro, Professor Paul Hertzog
Scheme Project Grant
Role Lead
Funding Start 2011
Funding Finish 2013
GNo G1000251
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Development of microbial bioproducts for the suppression of inflammation$285,000

Funding body: ARC (Australian Research Council)

Funding body ARC (Australian Research Council)
Project Team Professor Phil Hansbro, Laureate Professor Paul Foster, Professor Rakesh Kumar
Scheme Discovery Projects
Role Lead
Funding Start 2011
Funding Finish 2013
GNo G1000021
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Research microscope, confocal ready nikon eclipse 90i microscope$69,157

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Laureate Professor Roger Smith, Conjoint Professor Tamas Zakar, Professor Jon Hirst, Doctor Kaushik Maiti, Doctor Gemma Madsen, Laureate Professor Rodney Scott, Conjoint Professor Peter Wark, Laureate Professor Paul Foster, Professor Phil Hansbro, Conjoint Professor Ian Wright
Scheme Equipment Grant
Role Investigator
Funding Start 2011
Funding Finish 2011
GNo G1100024
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

DVCR Special Equipment Grant 2011$66,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Phil Hansbro
Scheme Special Project (Equipment) Grant
Role Lead
Funding Start 2011
Funding Finish 2011
GNo G1101126
Type Of Funding Internal
Category INTE
UON Y

Maitland Cancer Appeal Committee Donation - Lung Cancer Mouse Model$50,000

Funding body: Maitland Cancer Appeal Committee

Funding body Maitland Cancer Appeal Committee
Project Team Professor Phil Hansbro, Laureate Professor Paul Foster, Doctor Gough Au
Scheme Research Project
Role Lead
Funding Start 2011
Funding Finish 2011
GNo G1100246
Type Of Funding Donation - Aust Non Government
Category 3AFD
UON Y

SCIREQ FlexiVentFX system + FlexiVentFX extension$45,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Phil Hansbro, Laureate Professor Paul Foster, Professor Joerg Mattes, Associate Professor Simon Keely, Associate Professor Jay Horvat, Doctor Nicole Hansbro, Doctor Ming Yang, Doctor Catherine Ptaschinski, Doctor Kelly Asquith, Doctor Gough Au, Conjoint Professor Peter Wark, Laureate Professor John Aitken, Conjoint Professor Keith Jones, Laureate Professor Roger Smith, Professor Judith Black, Professor Rakesh Kumar, Professor Paul Hertzog
Scheme Equipment Grant
Role Lead
Funding Start 2011
Funding Finish 2011
GNo G1100037
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

Streptococcus pneumoniae-based immunoregulatory therapy for asthma$35,000

Funding body: Asthma Foundation of New South Wales

Funding body Asthma Foundation of New South Wales
Project Team Professor Phil Hansbro
Scheme Innovation Grants
Role Lead
Funding Start 2011
Funding Finish 2011
GNo G1000788
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Antioxidant therapies for suppressing infection-induced asthma in children$15,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Associate Professor Jay Horvat, Professor Lisa Wood, Professor Phil Hansbro
Scheme Youth Research Project Grant
Role Investigator
Funding Start 2011
Funding Finish 2011
GNo G1001002
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

American Thoracic Society, Colorado Convention Centre, 15 - 18 May 2010$2,000

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding body University of Newcastle - Faculty of Health and Medicine
Project Team Professor Phil Hansbro
Scheme Travel Grant
Role Lead
Funding Start 2011
Funding Finish 2012
GNo G1100298
Type Of Funding Internal
Category INTE
UON Y

20104 grants / $107,500

Refining Streptococcus pneumoniae-based immunoregulatory therapy to suppress asthma$44,500

Funding body: Asthma Foundation of New South Wales

Funding body Asthma Foundation of New South Wales
Project Team Professor Phil Hansbro, Professor Rakesh Kumar
Scheme Research Grant
Role Lead
Funding Start 2010
Funding Finish 2010
GNo G0900076
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Buxco FinePointe software and FinePointe RC system for mice $39,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Laureate Professor Paul Foster, Professor Phil Hansbro, Professor Joerg Mattes, Doctor Nicole Hansbro, Doctor Simon Phipps, Doctor Ming Yang, Doctor Kelly Asquith, Doctor Catherine Ptaschinski, Professor Rakesh Kumar, Professor Judith Black
Scheme Equipment Grant
Role Investigator
Funding Start 2010
Funding Finish 2010
GNo G1000053
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

Targeting CXCR7 for fibrosis$22,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Phil Hansbro
Scheme Development Grants
Role Lead
Funding Start 2010
Funding Finish 2010
GNo G1000682
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

American Thoracic Society, New Orleans, 14 - 19th May 2010$2,000

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding body University of Newcastle - Faculty of Health and Medicine
Project Team Professor Phil Hansbro
Scheme Travel Grant
Role Lead
Funding Start 2010
Funding Finish 2011
GNo G1000126
Type Of Funding Internal
Category INTE
UON Y

20098 grants / $1,264,412

Mechanisms and treatment of early life chlamydial infection and associated asthma$592,125

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Phil Hansbro, Professor Kenneth Beagley, Professor Joerg Mattes
Scheme Project Grant
Role Lead
Funding Start 2009
Funding Finish 2011
GNo G0188845
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

The Development of New and Effective Immunotherapies for Asthma$45,455

Funding body: Asthma Foundation of New South Wales

Funding body Asthma Foundation of New South Wales
Project Team Professor Phil Hansbro
Scheme Asthma Research Sustainability Grant
Role Lead
Funding Start 2009
Funding Finish 2009
GNo G0189728
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

Coulter counter$41,150

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Laureate Professor Paul Foster, Professor Phil Hansbro, Professor Joerg Mattes, Doctor Simon Phipps, Doctor Ming Yang, Doctor Nicole Hansbro, Doctor Kelly Asquith
Scheme Equipment Grant
Role Investigator
Funding Start 2009
Funding Finish 2009
GNo G0189851
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

Prevention and treatment of asthma using streptococcus pneumoniae-based immunomododulatory therapy$20,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Phil Hansbro
Scheme Near Miss Grant
Role Lead
Funding Start 2009
Funding Finish 2009
GNo G0189815
Type Of Funding Internal
Category INTE
UON Y

Immunisation against chlamydia-associated asthma$18,182

Funding body: Rebecca L Cooper Medical Research Foundation Ltd

Funding body Rebecca L Cooper Medical Research Foundation Ltd
Project Team Associate Professor Jay Horvat, Professor Phil Hansbro, Laureate Professor Paul Foster
Scheme Research Grant
Role Investigator
Funding Start 2009
Funding Finish 2009
GNo G0189629
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

American Association of Immunologists and American Thoracic Society, Seattle USA, 8-12 May 2009$2,500

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding body University of Newcastle - Faculty of Health and Medicine
Project Team Professor Phil Hansbro
Scheme Travel Grant
Role Lead
Funding Start 2009
Funding Finish 2009
GNo G0189963
Type Of Funding Internal
Category INTE
UON Y

20085 grants / $502,150

The mechanisms of infection of bronchial epithelial cells by human & avian influenza viruses in chronic airways disease$379,650

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Conjoint Professor Peter Wark, Professor Phil Hansbro, Dr Ian Barr
Scheme Project Grant
Role Investigator
Funding Start 2008
Funding Finish 2010
GNo G0187593
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

The use of the components of the bacteria, streptococcus pneumoniae, as novel immunotherapies for asthma$50,000

Funding body: Asthma Foundation of New South Wales

Funding body Asthma Foundation of New South Wales
Project Team Professor Phil Hansbro, Professor Rakesh Kumar, Conjoint Professor Peter Wark
Scheme Research Grant
Role Lead
Funding Start 2008
Funding Finish 2008
GNo G0188434
Type Of Funding Donation - Aust Non Government
Category 3AFD
UON Y

Individually ventilated cages (IVC) and associated ventilator, holding boxes and water bottles$35,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Laureate Professor Paul Foster, Professor Phil Hansbro, Professor Joerg Mattes, Doctor Simon Phipps, Doctor Ming Yang, Doctor Nicole Hansbro, Doctor Kelly Asquith
Scheme Equipment Grant
Role Investigator
Funding Start 2008
Funding Finish 2008
GNo G0188541
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

Becton Dickinson high throughout sampler for the FACSCanto II cytometry system$35,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Conjoint Professor Peter Wark, Conjoint Professor Peter Gibson, Professor Jodie Simpson, Professor Lisa Wood, Doctor Vanessa Murphy, Professor Phil Hansbro
Scheme Equipment Grant
Role Investigator
Funding Start 2008
Funding Finish 2008
GNo G0188547
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

American Thoracic Society, Metro Toronto Convention Centre, 16/5/2008 - 21/5/2008$2,500

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Phil Hansbro
Scheme Travel Grant
Role Lead
Funding Start 2008
Funding Finish 2008
GNo G0188983
Type Of Funding Internal
Category INTE
UON Y

200720 grants / $1,254,050

Characterisation and Treatment of Innate Immune Dysfunction in Older People with Obstructive Airway Disease$416,875

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Jodie Simpson, Conjoint Professor Peter Gibson, Professor Phil Hansbro
Scheme Project Grant
Role Investigator
Funding Start 2007
Funding Finish 2009
GNo G0186426
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Viruses, Infection/Immunology, vaccines and Asthma, Hunter medical Research Institute$230,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team

P G Gibson

Scheme Research Infrastructure
Role Investigator
Funding Start 2007
Funding Finish 2007
GNo
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON N

Surveillance of wild birds for avian influenza viruses in NSW$172,524

Funding body: Department of Agriculture, Fisheries and Forestry Australia

Funding body Department of Agriculture, Fisheries and Forestry Australia
Project Team Dr Peter Kirkland, Professor Phil Hansbro
Scheme New Industries Development Programme
Role Lead
Funding Start 2007
Funding Finish 2016
GNo G0186812
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

Investigation of chlamydial infection and asthma$68,000

Funding body: Faculty of Health

Funding body Faculty of Health
Project Team

Phil Hansbro

Scheme Postdoctoral Award
Role Lead
Funding Start 2007
Funding Finish 2007
GNo
Type Of Funding Internal
Category INTE
UON N

In vitro response of bronchial epithelial cells and activation of lymphocytes to infection with rhinovirus$58,848

Funding body: John Hunter Hospital Charitable Trust

Funding body John Hunter Hospital Charitable Trust
Project Team Conjoint Professor Peter Wark, Professor Phil Hansbro, Professor Jodie Simpson
Scheme Research Grant
Role Investigator
Funding Start 2007
Funding Finish 2009
GNo G0188095
Type Of Funding Donation - Aust Non Government
Category 3AFD
UON Y

Prevention of heart disease by pneumococcal vaccination$50,000

Funding body: Pfizer Australia

Funding body Pfizer Australia
Project Team Professor Phil Hansbro, Dr Sukumaran Thambar, Professor John Attia, Associate Professor Mark McEvoy
Scheme Cardiovascular Lipid Research Grants
Role Lead
Funding Start 2007
Funding Finish 2007
GNo G0186642
Type Of Funding Aust Competitive - Non Commonwealth
Category 1NS
UON Y

Nitric Oxide Monitoring System (NIOX)$45,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Conjoint Professor Peter Gibson, Conjoint Associate Professor Vicki Clifton, Conjoint Professor Warwick Giles, Emeritus Professor Michael Hensley, Doctor Vanessa Murphy, Conjoint Professor Peter Wark, Professor Vanessa McDonald, Professor Jodie Simpson, Conjoint Associate Professor Bruce Whitehead, Laureate Professor Paul Foster, Professor Phil Hansbro, Professor Lisa Wood
Scheme Equipment Grant
Role Investigator
Funding Start 2007
Funding Finish 2007
GNo G0188193
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

In vitro response of bronchial epithelial cells and activation of lymphocytes from COPD patients by infection with rhinovirus, respiratory syncytial virus and haemophilus influenza$25,000

Funding body: GlaxoSmithKline Australia

Funding body GlaxoSmithKline Australia
Project Team Conjoint Professor Peter Wark, Professor Phil Hansbro, Professor Jodie Simpson
Scheme Support Grant
Role Investigator
Funding Start 2007
Funding Finish 2008
GNo G0188309
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Prevention and treatment of asthma by bacterial vaccination$22,500

Funding body: CRC for Asthma and Airways

Funding body CRC for Asthma and Airways
Project Team

Alison Thorburn

Scheme Unknown
Role Investigator
Funding Start 2007
Funding Finish 2007
GNo
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON N

Elucidation of the association between Haemophilus influenzae infection and neutrophilic asthma.$20,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Professor Phil Hansbro, Professor Jodie Simpson, Laureate Professor Paul Foster, Conjoint Professor Margaret Dunkley
Scheme Project Grant
Role Lead
Funding Start 2007
Funding Finish 2007
GNo G0187206
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

The role of tumstatin in angiogenesis and asthma$20,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Laureate Professor Paul Foster, Doctor Nicole Hansbro, Doctor Simon Phipps, Professor Phil Hansbro
Scheme Project Grant
Role Investigator
Funding Start 2007
Funding Finish 2007
GNo G0187238
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Hewlett Packard 7890 series gas chromatograph with accessories$20,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Lisa Wood, Conjoint Professor Peter Wark, Conjoint Professor Peter Gibson, Professor Jodie Simpson, Doctor Vanessa Murphy, Laureate Professor Paul Foster, Professor Phil Hansbro, Conjoint Associate Professor Vicki Clifton, Professor Clare Collins, Conjoint Professor Wayne Smith, Professor John Attia
Scheme Equipment Grant
Role Investigator
Funding Start 2007
Funding Finish 2007
GNo G0188191
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

Class II biohazard containment hood and carbon dioxide cell culture incubator$20,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Conjoint Professor Peter Wark, Conjoint Professor Peter Gibson, Professor Jodie Simpson, Doctor Vanessa Murphy, Professor Lisa Wood, Laureate Professor Paul Foster, Professor Phil Hansbro
Scheme Equipment Grant
Role Investigator
Funding Start 2007
Funding Finish 2007
GNo G0188192
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON Y

Prevention of asthma by antibiotic treatment/vaccination against chlamydia$20,000

Funding body: Rebecca L Cooper Medical Research Foundation Ltd

Funding body Rebecca L Cooper Medical Research Foundation Ltd
Project Team

Phil Hansbro

Scheme Research Award
Role Lead
Funding Start 2007
Funding Finish 2007
GNo
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON N

The prevention and treatment of Asthma with a diet high in seafood content$15,525

Funding body: Seafood Services Australia

Funding body Seafood Services Australia
Project Team Professor Phil Hansbro, Laureate Professor Paul Foster
Scheme Seafood Industry Development Fund
Role Lead
Funding Start 2007
Funding Finish 2007
GNo G0185404
Type Of Funding Aust Competitive - Non Commonwealth
Category 1NS
UON Y

Miccroarrays to identify novel therapeutic targets for bird flu$14,500

Funding body: John Hunter Hospital Charitable Trust

Funding body John Hunter Hospital Charitable Trust
Project Team Conjoint Professor Peter Wark, Professor Phil Hansbro
Scheme Research Grant
Role Investigator
Funding Start 2007
Funding Finish 2007
GNo G0187337
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

Microarrays to identify novel therapeutic targets for bird flu$14,500

Funding body: John Hunter Hospital Charitable Trust

Funding body John Hunter Hospital Charitable Trust
Project Team

Peter Wark

Scheme Research Award
Role Lead
Funding Start 2007
Funding Finish 2007
GNo
Type Of Funding Other Public Sector - Local
Category 2OPL
UON N

BioSafety Cabinet$10,778

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Professor Phil Hansbro
Scheme Equipment Grant
Role Lead
Funding Start 2007
Funding Finish 2007
GNo G0188049
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

The association between Chlamydial infection and asthma$7,500

Funding body: CRC for Asthma and Airways

Funding body CRC for Asthma and Airways
Project Team

Jay Horvat

Scheme Research Scholars Award
Role Investigator
Funding Start 2007
Funding Finish 2007
GNo
Type Of Funding Other Public Sector - Commonwealth
Category 2OPC
UON N

International Congress on Immunology, Riocentro, Rio de Janeiro, 20/8/2007 - 24/8/2007$2,500

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Phil Hansbro
Scheme Travel Grant
Role Lead
Funding Start 2007
Funding Finish 2007
GNo G0187944
Type Of Funding Internal
Category INTE
UON Y

200615 grants / $1,955,769

PRC Priority Research Centre for Asthma & Respiratory Diseases$524,282

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Laureate Professor Paul Foster, Conjoint Professor Peter Gibson, Conjoint Professor Kenneth Beagley, Emeritus Professor Michael Hensley, Professor Phil Hansbro, Professor Joerg Mattes, Professor Alistair Sim, Conjoint Professor Peter Wark
Scheme Priority Research Centre
Role Investigator
Funding Start 2006
Funding Finish 2013
GNo G0186914
Type Of Funding Internal
Category INTE
UON Y

Investigation of the association between chlamydial infection and asthma in different age groups$362,625

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Phil Hansbro, Conjoint Professor Kenneth Beagley, Conjoint Professor Peter Gibson
Scheme Project Grant
Role Lead
Funding Start 2006
Funding Finish 2008
GNo G0185145
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Surveillance and Analysis of Avian Influenza Viruses in Migratory Birds in Australia$249,625

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Phil Hansbro, Dr Ian Barr, Conjoint Professor Peter Wark, Dr Paul Selleck, Dr Simone Warner, Laureate Professor Paul Foster, Associate Professor Aeron Hurt, Dr Irene Peroulis, Dr John Curran, Conjoint Professor Peter Gibson
Scheme Potential Avian Influenza-Induced Pandemic
Role Lead
Funding Start 2006
Funding Finish 2006
GNo G0186000
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

The Newcastle Asthma Meeting (NAMe)$210,000

Funding body: Astra Zeneca

Funding body Astra Zeneca
Project Team

Phil hansbro

Scheme Conference support
Role Lead
Funding Start 2006
Funding Finish 2007
GNo
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON N

Characterisation of novel immune signals as targets for the treatment of asthma$160,000

Funding body: Commonwealth serum laboratories

Funding body Commonwealth serum laboratories
Project Team

Paul Foster

Scheme Unknown
Role Investigator
Funding Start 2006
Funding Finish 2006
GNo
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON N

Priority Research Centre for Asthma and Respiratory Disease$120,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team

Paul Foster/Peter Gibson

Scheme PRC
Role Investigator
Funding Start 2006
Funding Finish 2007
GNo
Type Of Funding Internal
Category INTE
UON N

Development of mouse models of angiogenesis$115,000

Funding body: CRC for Asthma and Airways

Funding body CRC for Asthma and Airways
Project Team

Phil Hansbro

Scheme Research Scholars Award
Role Lead
Funding Start 2006
Funding Finish 2007
GNo
Type Of Funding Internal
Category INTE
UON N

Prevention of heart disease by pneumococcal vaccination$55,000

Funding body: CVL - Pfiser

Funding body CVL - Pfiser
Project Team

Phil Hansbro

Scheme Unknown
Role Lead
Funding Start 2006
Funding Finish 2007
GNo
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON N

Surveillance for avian influenza viruses in wild birds in Australia$50,000

Funding body: Perpetual Limited

Funding body Perpetual Limited
Project Team Professor Phil Hansbro
Scheme Charitable Trusts and Foundations Project
Role Lead
Funding Start 2006
Funding Finish 2006
GNo G0186511
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Surveillance of microbial carriage by different feeding guilds of birds$30,000

Research council of SE Sweden & Swedish council for forestry & agriculture

Funding body: Research council of SE Sweden & Swedish council for forestry & agriculture

Funding body Research council of SE Sweden & Swedish council for forestry & agriculture
Project Team

Bjorn Olsen

Scheme Research council of SE Sweden & Swedish council for forestry & agriculture
Role Lead
Funding Start 2006
Funding Finish 2006
GNo
Type Of Funding International - Non Competitive
Category 3IFB
UON N

Identification of early-life signals induced in response to infection that predispose to asthma in later life$20,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Phil Hansbro, Laureate Professor Paul Foster, Conjoint Professor Kenneth Beagley, Professor Alistair Sim
Scheme Pilot Grant
Role Lead
Funding Start 2006
Funding Finish 2006
GNo G0186699
Type Of Funding Internal
Category INTE
UON Y

Characterisation of chronic bacterial colonisation and the innate immune response in patients with neutrophilic asthma.$20,000

Funding body: Asthma Foundation of New South Wales

Funding body Asthma Foundation of New South Wales
Project Team

Melanie Kenyon

Scheme Research Scholars Award
Role Investigator
Funding Start 2006
Funding Finish 2006
GNo
Type Of Funding Other Public Sector - State
Category 2OPS
UON N

Characterisation of chronic bacterial colonisation and innate immune response in patients with neutrophilic Asthma$18,837

Funding body: Asthma Foundation of New South Wales

Funding body Asthma Foundation of New South Wales
Project Team Mrs Melanie Forster, Professor Phil Hansbro
Scheme PhD Scholarships
Role Investigator
Funding Start 2006
Funding Finish 2006
GNo G0185993
Type Of Funding Donation - Aust Non Government
Category 3AFD
UON Y

-80¿C freezer$18,000

Funding body: Faculty of Health

Funding body Faculty of Health
Project Team

Phil hansbro

Scheme RIBG
Role Lead
Funding Start 2006
Funding Finish 2006
GNo
Type Of Funding Internal
Category INTE
UON N

American Thoracijavascript:closeProject();c Society 19-24 th of may 2006$2,400

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Phil Hansbro
Scheme Travel Grant
Role Lead
Funding Start 2006
Funding Finish 2006
GNo G0186495
Type Of Funding Internal
Category INTE
UON Y

200512 grants / $2,758,219

Drug targets from new animal models$2,030,948

Funding body: CRC for Asthma

Funding body CRC for Asthma
Project Team Laureate Professor Paul Foster, Professor Phil Hansbro, Professor Joerg Mattes, Doctor Ming Yang, Dr Simon Phipps
Scheme Research Grant
Role Investigator
Funding Start 2005
Funding Finish 2011
GNo G0185860
Type Of Funding CRC - Cooperative Research Centre
Category 4CRC
UON Y

Viruses, Infection/Immunology, vaccines and Asthma, Hunter medical Research Institute$321,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team

Ken Beagley

Scheme Research Infrastructure
Role Investigator
Funding Start 2005
Funding Finish 2007
GNo
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON N

CD4 T cell programming by neonatal and early-life infection$250,000

Funding body: ARC (Australian Research Council)

Funding body ARC (Australian Research Council)
Project Team Laureate Professor Paul Foster, Conjoint Professor Kenneth Beagley, Professor Phil Hansbro
Scheme Discovery Projects
Role Investigator
Funding Start 2005
Funding Finish 2007
GNo G0184398
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Modulation of inflammatory responses in the asthmatic lung by Chlamydial infection$50,000

Funding body: Asthma Foundation of New South Wales

Funding body Asthma Foundation of New South Wales
Project Team Professor Phil Hansbro, Laureate Professor Paul Foster, Conjoint Professor Kenneth Beagley
Scheme Research Grant
Role Lead
Funding Start 2005
Funding Finish 2005
GNo G0185208
Type Of Funding Donation - Aust Non Government
Category 3AFD
UON Y

Flexivent complete system solution for measurement of lung function$25,000

Funding body: Ramaciotti Foundations

Funding body Ramaciotti Foundations
Project Team Professor Phil Hansbro
Scheme Major Equipment Award
Role Lead
Funding Start 2005
Funding Finish 2005
GNo G0185625
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

2005 RIBG allocation$23,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Phil Hansbro
Scheme Research Infrastructure Block Grant (RIBG)
Role Lead
Funding Start 2005
Funding Finish 2005
GNo G0185803
Type Of Funding Internal
Category INTE
UON Y

CD4 T cell programming by neonatal and early life infection$18,837

Funding body: Asthma Foundation of New South Wales

Funding body Asthma Foundation of New South Wales
Project Team Professor Phil Hansbro
Scheme PhD Scholarships
Role Lead
Funding Start 2005
Funding Finish 2005
GNo G0184978
Type Of Funding Donation - Aust Non Government
Category 3AFD
UON Y

Chlamydia infection of dendritic cells drives the development of pro-asthmatic Th2 cells$15,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team

Beagley KW

Scheme Unknown
Role Investigator
Funding Start 2005
Funding Finish 2005
GNo
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON N

Prevention of asthma by immunisation with pneumococcal cell walls$10,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Phil Hansbro, Laureate Professor Paul Foster, Conjoint Professor Kenneth Beagley, Conjoint Professor Peter Gibson
Scheme Project Grant
Role Lead
Funding Start 2005
Funding Finish 2005
GNo G0184712
Type Of Funding Internal
Category INTE
UON Y

Efficacy of anti-microbial strategies$7,275

Funding body: Whiteley Corporation Pty Ltd

Funding body Whiteley Corporation Pty Ltd
Project Team Professor Phil Hansbro
Scheme Student Support Project
Role Lead
Funding Start 2005
Funding Finish 2005
GNo G0186017
Type Of Funding Not Known
Category UNKN
UON Y

The effect of maternal infection on predisposition towards asthma in adulthood$6,029

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Deborah Hodgson, Conjoint Associate Professor Vicki Clifton, Professor Phil Hansbro
Scheme Project Grant
Role Investigator
Funding Start 2005
Funding Finish 2005
GNo G0184735
Type Of Funding Internal
Category INTE
UON Y

World Inflammation Conference, 20-24 August 2005$1,130

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Phil Hansbro
Scheme Travel Grant
Role Lead
Funding Start 2005
Funding Finish 2005
GNo G0185614
Type Of Funding Internal
Category INTE
UON Y

20046 grants / $124,300

Modulation of Asthma by bacterial infection or vaccination in different age groups$60,000

Funding body: Rebecca L Cooper Medical Research Foundation Ltd

Funding body Rebecca L Cooper Medical Research Foundation Ltd
Project Team Professor Phil Hansbro, Laureate Professor Paul Foster, Conjoint Professor Kenneth Beagley
Scheme Research Grant
Role Lead
Funding Start 2004
Funding Finish 2006
GNo G0184154
Type Of Funding Donation - Aust Non Government
Category 3AFD
UON Y

ELISA reader/Fluorimeter/Luminometer$31,900

Funding body: Faculty of Health

Funding body Faculty of Health
Project Team

Darren Shafren

Scheme RIBG
Role Investigator
Funding Start 2004
Funding Finish 2004
GNo
Type Of Funding Internal
Category INTE
UON N

Modulation of immune responses in asthma by bacterial infections during early life.$15,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Phil Hansbro, Laureate Professor Paul Foster, Conjoint Professor Peter Gibson
Scheme Project Grant
Role Lead
Funding Start 2004
Funding Finish 2004
GNo G0183512
Type Of Funding Internal
Category INTE
UON Y

The effect of maternal inflammation on fetal development, placental function and neonatal immune competence: An animal model of asthma during pregnancy$10,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Deborah Hodgson, Conjoint Associate Professor Vicki Clifton, Professor Phil Hansbro
Scheme Project Grant
Role Investigator
Funding Start 2004
Funding Finish 2004
GNo G0183352
Type Of Funding Internal
Category INTE
UON Y

Modulation of asthma by chlamydial infection at different ages$5,000

Funding body: Asthma Foundation of New South Wales

Funding body Asthma Foundation of New South Wales
Project Team Associate Professor Jay Horvat, Professor Phil Hansbro, Conjoint Professor Kenneth Beagley
Scheme PhD Scholarships
Role Investigator
Funding Start 2004
Funding Finish 2004
GNo G0183717
Type Of Funding Donation - Aust Non Government
Category 3AFD
UON Y

International Symposium on the Pneumococcus & Pneumococcal Diseases, 9-13 May 2004$2,400

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Phil Hansbro
Scheme Travel Grant
Role Lead
Funding Start 2004
Funding Finish 2004
GNo G0183956
Type Of Funding Internal
Category INTE
UON Y

20034 grants / $404,000

Viruses, Infection/Immunology, vaccines and Asthma, Hunter medical Research Institute$321,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team

Ken Beagley

Scheme Research Infrastructure
Role Investigator
Funding Start 2003
Funding Finish 2005
GNo
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON N

Modulation of immune responses in the asthmatic lung by bacterial infections.$50,000

Funding body: Asthma Foundation of New South Wales

Funding body Asthma Foundation of New South Wales
Project Team Professor Phil Hansbro, Conjoint Professor Peter Gibson, Conjoint Professor Kenneth Beagley, Dr Paul Foster
Scheme Research Grant
Role Lead
Funding Start 2003
Funding Finish 2003
GNo G0183600
Type Of Funding Donation - Aust Non Government
Category 3AFD
UON Y

Treatment of asthma by vaccination with bacterial antigens.$17,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Professor Phil Hansbro, Conjoint Professor Peter Gibson, Conjoint Professor Kenneth Beagley
Scheme Research Grant
Role Lead
Funding Start 2003
Funding Finish 2003
GNo G0182627
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Prevention and treatment of asthma by immunisation with bacterial vaccines.$16,000

Funding body: Rebecca L Cooper Medical Research Foundation Ltd

Funding body Rebecca L Cooper Medical Research Foundation Ltd
Project Team Professor Phil Hansbro
Scheme Research Grant
Role Lead
Funding Start 2003
Funding Finish 2003
GNo G0183365
Type Of Funding Donation - Aust Non Government
Category 3AFD
UON Y

20027 grants / $113,309

Refrigerated Microfuge & Ultracentrifuge Buckets$40,967

Funding body: Faculty of Medicine and Health Sciences

Funding body Faculty of Medicine and Health Sciences
Project Team

Darren Shafren

Scheme RIBG
Role Investigator
Funding Start 2002
Funding Finish 2002
GNo
Type Of Funding Internal
Category INTE
UON N

Modulation of inflammatory responses in the asthmatic lung by bacterial infection and vaccination.$24,842

Funding body: Asthma Foundation of New South Wales

Funding body Asthma Foundation of New South Wales
Project Team Ms Julie Preston, Conjoint Professor Peter Gibson, Professor Phil Hansbro
Scheme PhD Scholarships
Role Investigator
Funding Start 2002
Funding Finish 2004
GNo G0181606
Type Of Funding Donation - Aust Non Government
Category 3AFD
UON Y

Development of new and improved pneumococcal vaccines.$16,000

Funding body: Rebecca L Cooper Medical Research Foundation Ltd

Funding body Rebecca L Cooper Medical Research Foundation Ltd
Project Team Professor Phil Hansbro
Scheme Research Grant
Role Lead
Funding Start 2002
Funding Finish 2002
GNo G0181997
Type Of Funding Donation - Aust Non Government
Category 3AFD
UON Y

Treatment of asthma by vaccination with bacterial antigens$12,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Phil Hansbro, Conjoint Professor Peter Gibson, Conjoint Professor Kenneth Beagley
Scheme Project Grant
Role Lead
Funding Start 2002
Funding Finish 2002
GNo G0181356
Type Of Funding Internal
Category INTE
UON Y

PCR machine$10,000

Funding body: Faculty of Health

Funding body Faculty of Health
Project Team

Darren Shafren

Scheme Equipment grant
Role Investigator
Funding Start 2002
Funding Finish 2002
GNo
Type Of Funding Internal
Category INTE
UON N

Treatment of asthma by vaccination with bacterial antigens$7,000

Funding body: John Hunter Hospital Charitable Trust

Funding body John Hunter Hospital Charitable Trust
Project Team

P G Gibson

Scheme Research Award
Role Investigator
Funding Start 2002
Funding Finish 2002
GNo
Type Of Funding Other Public Sector - Local
Category 2OPL
UON N

International Symposium on the Pneumococcus and Pneumococcal Diseases Anchorage, Alaska, 5 - 9 May, 2002$2,500

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Phil Hansbro
Scheme Travel Grant
Role Lead
Funding Start 2002
Funding Finish 2002
GNo G0181730
Type Of Funding Internal
Category INTE
UON Y

20017 grants / $323,811

Development of new generation vaccines including DNA vaccines, for mucosal disease Eg respiratory and reproductive tract infection$210,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team

Ken Beagley

Scheme Research Infrastructure
Role Investigator
Funding Start 2001
Funding Finish 2003
GNo
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON N

Development of an Elisa-based detection system for Listeria spp. and Listeria monocytogenes utilizing recombinant antibodies$45,000

Funding body: Tecra International Pty Ltd

Funding body Tecra International Pty Ltd
Project Team Professor Phil Hansbro, Professor Darren Shafren
Scheme University Grant Partner Funding
Role Lead
Funding Start 2001
Funding Finish 2003
GNo G0181526
Type Of Funding Contract - Aust Non Government
Category 3AFC
UON Y

Animal technician$38,045

Funding body: Faculty of Medicine and Health Sciences

Funding body Faculty of Medicine and Health Sciences
Project Team

Ken Beagley

Scheme RIBG
Role Investigator
Funding Start 2001
Funding Finish 2001
GNo
Type Of Funding Internal
Category INTE
UON N

Development of new and improved Pneumococcal vaccines.$12,000

Funding body: Ramaciotti Foundations

Funding body Ramaciotti Foundations
Project Team Professor Phil Hansbro
Scheme Research Grant
Role Lead
Funding Start 2001
Funding Finish 2001
GNo G0180651
Type Of Funding Aust Competitive - Non Commonwealth
Category 1NS
UON Y

Development of an Elisa-based detection system for Listeria spp. and Listeria monocytogenes utilizing recombinant antibodies$10,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Phil Hansbro, Professor Darren Shafren
Scheme Collaborative Research Grant
Role Lead
Funding Start 2001
Funding Finish 2001
GNo G0181525
Type Of Funding Internal
Category INTE
UON Y

Effects of infections by Streptococcus pneumoniae on eosinophilic immune responses$7,000

Funding body: John Hunter Hospital

Funding body John Hunter Hospital
Project Team

P M Hansbro

Scheme Respiratory SP&T Research Funds
Role Lead
Funding Start 2001
Funding Finish 2001
GNo
Type Of Funding Scheme excluded from IGS
Category EXCL
UON N

American Society for Microbiology, USA 20-24 May 2001$1,766

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Phil Hansbro
Scheme Travel Grant
Role Lead
Funding Start 2001
Funding Finish 2001
GNo G0180835
Type Of Funding Internal
Category INTE
UON Y

20005 grants / $209,122

Gene Pulser II Electroporator$160,000

Funding body: Faculty of Medicine and Health Sciences

Funding body Faculty of Medicine and Health Sciences
Project Team

Phil hansbro

Scheme Equipment grant
Role Lead
Funding Start 2000
Funding Finish 2000
GNo
Type Of Funding Internal
Category INTE
UON N

Gel Doc 2000 UV Flourescent Gel Documentation System$21,522

Funding body: Faculty of Medicine and Health Sciences

Funding body Faculty of Medicine and Health Sciences
Project Team

Phil Hansbro

Scheme Equipment grant
Role Lead
Funding Start 2000
Funding Finish 2000
GNo
Type Of Funding Internal
Category INTE
UON N

Development of new and improved pneumococcal vaccines$15,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team

P M Hansbro

Scheme Establishment grant
Role Lead
Funding Start 2000
Funding Finish 2000
GNo
Type Of Funding Scheme excluded from IGS
Category EXCL
UON N

Investigation of potential pneumococcal vaccine candidate antigens.$12,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Phil Hansbro
Scheme New Staff Grant
Role Lead
Funding Start 2000
Funding Finish 2000
GNo G0179329
Type Of Funding Internal
Category INTE
UON Y

Joint Annual Scientific Meeting & Exhibition of the Australian Society for Microbiology, Cairns QLD.$600

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Phil Hansbro
Scheme Travel Grant
Role Lead
Funding Start 2000
Funding Finish 2000
GNo G0180224
Type Of Funding Internal
Category INTE
UON Y
Edit

Research Supervision

Number of supervisions

Completed41
Current29

Current Supervision

Commenced Level of Study Research Title Program Supervisor Type
2018 PhD Understand the Roles and Therapeutic Targeting of Macrophages in COPD PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2018 PhD Investigating the Role of Inflammasomes in Female Reproductive Tract (FRT) Infections and Associated Disease PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2018 PhD Characterising the Epidemiological and Biological Effects of Particulate Matter Exposures in Coal Mining to Protect and Improve the Health of Workers PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2018 PhD Investigating Asthma-COPD Overlap Using Mouse Models PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2017 PhD Effects of Infection and Iron on Immune Responses and Pathology in The Central Nervous System PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2017 PhD Elucidating and Targeting Genomic and Epigenetic Changes in the Development and Progression of Lung Cancer PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2017 PhD Does Early Nutritional Content Induce the Development of Exploratory, Behaviourally Flexible Common (Indian) Mynas (Acridotheres Tristis) with High Range Expansion Potential? PhD (Psychology - Science), Faculty of Science, The University of Newcastle Co-Supervisor
2017 PhD Investigating the Development of New Treatments for Lung Cancer PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2017 PhD Beyond the Obvious: Risk Assessment of Contaminant Transformation Products and Metabolites PhD (Environment Remediation), Faculty of Science, The University of Newcastle Co-Supervisor
2017 PhD The Role of Olfactory Receptors in Inducing Allergic Inflammation PhD (Environ & Occupat Hlth), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2017 PhD Contaminant Induced Antimicrobial Resistance (CIAMR) - A Threat to Human and Animal Health PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2017 PhD Understanding the Molecular Basis of Chronic Respiratory Diseases through Multi-Omics Approaches PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2017 PhD Extracellular Matrix Protein 1 (ECM1) in the Ageing and Diseased Mammalian Heart PhD (Medicine), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2016 PhD Investigating the Genetics and Epigenetics of the Development of Lung Cancer PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2016 PhD Mechanisms and Therapeutic Targeting of Immunometabolism in Lung Disease PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2015 PhD Fatty Acids and Bronchodilator Responses PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2015 PhD Contribution of Cell Death to the Pathogenesis of Chronic Obstructive Pulmonary Disease (COPD) PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2015 PhD Investigation of Novel Immune Molecules in the Pathogenesis of Female Chlamydia Genital Tract Infections PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2015 PhD Generational Effects of Smoking in Pregnancy PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2015 PhD Characterization of physiological and neuronal alterations in Chlamydia reproductive tract infection PhD (Medical Biochemistry), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2015 PhD Neuropathological Effects of Putative Modifiers of Alzheimer's Disease Risk and Progression: Investigation in Mouse Models PhD (Medical Genetics), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2014 PhD Utilisation of Microbial Products as New Therapies for COPD/Emphysema PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2014 PhD Chronic Obstructive Pulmonary Disease (COPD) PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2013 PhD Investigating the Mechanisms that Underpin Early-Life Chlamydia Respiratory Infection-Induced Chronic Lung Disease PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2012 PhD Assessing the Epigenetic Involvement in the Development and Progression of Chronic Obstructive Pulmonary Disease (COPD) PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2007 Honours Chlamydia and asthma II Microbiology, University of Newcastle Co-Supervisor
2007 Honours Chlamydia and asthma Microbiology, University of Newcastle Principal Supervisor
2007 PhD Rhinoviruses and asthma Microbiology, University of Newcastle Co-Supervisor
2006 PhD Investigation of fatty acid binding proteins and asthma Microbiology, University of Sydney Co-Supervisor

Past Supervision

Year Level of Study Research Title Program Supervisor Type
2018 PhD Innate Anti-Viral Responses of Airway Epithelial Cells to Infection with Rhinovirus and Coronavirus PhD (Medicine), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2018 PhD Investigation of the Pathogenesis of Influenza Infection in Asthma and COPD; Potential Therapeutic Interventions PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2018 PhD Role of Iron in the Pathogenesis of Lung Disease PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2018 PhD Elucidating the Mechanisms of Steroid-Resistant Asthma PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2017 PhD The Role of Interferon Epsilon in Protection Against Chlamydial Reproductive Tract Infections PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2017 PhD Investigating the Mechanisms of Tobacco Cigarette Smoke Induced Lung Cancer PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2017 PhD Mechanisms of Predisposition to Secondary Bacterial Pneumonia PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2017 PhD Understanding the Mechanisms of Bacterial-Induced Exacerbation of Allergic Airways Disease in a Mouse Model PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2017 PhD The Role of Mast Cell Proteases in Respiratory Disease PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2017 PhD Modeling of Respiratory Syncytial Virus-induced Exacerbation of Allergic Airways Disease PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2017 PhD Mechanisms of Lung Inflammation Associated with Inflammatory Bowel Disease PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2017 PhD Identification of Novel Therapeutics for Chronic Obstructive Pulmonary Disease PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2016 PhD Investigation of Pathogenesis of Chronic Obstructive Pulmonary Disease PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2016 PhD Immunoregulatory Therapies for Inflammatory Diseases PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2016 PhD Role of Fibulin-1 in the Pathogenesis of Chronic Pulmonary Diseases PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2015 PhD Investigation of the Mechanisms of Respiratory Infection- Induced Lung Disease PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2015 PhD Characterising Innate Immune Responses and the Role of PD-1 in Patients with COPD PhD (Medicine), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2015 PhD Mechanisms of Increased Susceptibility to Influenza Infection in Mouse Models of Chronic Lung Diseases PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2014 PhD Immune Mechanisms that Underpin Early-Life Chlamydia Respiratory Infection-Induced Chronic Lung Disease PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2014 PhD The Role of microRNAs in Allergic Airways Disease and T Cell Biology PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2014 PhD The Role of MicroRNA in Regulating Anti-Bacterial Responses in Innate Immune Cells PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2013 PhD The Role of Early Life Infection on the Programming of CD4+ T-cells PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2012 PhD The Distribution, Abundance and Conservation of Avian Biodiversity in Yellow Sea Habitats in the Republic of Korea PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2012 PhD Modulation of Responses in Allergic Airways Disease by Haemophilus Influenzae Infection PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2011 PhD The Innate Immune Mechanisms Underlying the Interplay Between Respiratory Infections and Asthma PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2011 PhD A Streptococcus pneumoniae-based Immunoregulatory Therapy for Asthma PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2010 PhD Mechanism of Infection of Bronchial Epithelial Cells by Human and Avian Influenza Viruses PhD (Medicine), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2009 PhD Nutritional Modulation of Lung Inflammation PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2008 PhD Modulation of Responses in the Asthmatic Lung by Chlamydial Infection PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2007 Honours campylobacter carriage in birds Microbiology, University of Newcastle Principal Supervisor
2007 PhD Prevention and treatment of asthma using pneumococcal infection Microbiology, University of Newcastle Co-Supervisor
2007 PhD Modulation of Responses in the Asthmatic Lung by Streptococcus Pneumoniae PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2006 Honours Association of Haemophilus influenzae infection and asthma Accounting, University of Newcastle Principal Supervisor
2006 Honours Interaction of chlamydia with NOD proteins Accounting, University of Newcastle Co-Supervisor
2006 Honours Rhinoviruses and asthma Microbiology, University of Newcastle Co-Supervisor
2006 PhD Investigation of Surface Components of Listeria spp. by Phage Display PhD (Immunology & Microbiol), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2003 Honours Association of Chlamydia infection and asthma Accounting, University of Newcastle Principal Supervisor
2003 Honours Chlamydia in teh reproductive tract Microbiology, University of Newcastle Co-Supervisor
2001 Honours HIV infcetions Microbiology, University of Newcastle Co-Supervisor
2001 Honours Prevention of asthma by pneumococcal infection Microbiology, University of Newcastle Principal Supervisor
2001 PhD Identification of novel surface proteins of Streptococcus pneumoniae Microbiology, Unknown Principal Supervisor
Edit

Research Projects

Humira and Endothelial Function in Rheumatoid Arthritis 2 (HEART RA - 2) 2015 -

Hunter HEART-RA will answer many questions regarding cardiovascular disease in ACPA-positive RA. However, it will not evaluate ACPA-negative RA patient group and cannot answer the question of when, at which stage in the development of RA, cardiovascular risk becomes elevated and which inflammatory and non-inflammatory processes may be responsible. Hunter HEAT-RA-2 has been designed to investigate these questions in greater detail. 

Hunter HEART-RA-2 is an extension of Hunter HEART-RA consisting of 2 parts.

Part 1: Randomised Controlled Trial evaluating the Effect of the TNF-Inhibitor drug Humira (adalimumab) upon cardiovascular risk as measured by a platform of cardiovascular assessments. This second study will include ACPA-negative RA patients and more comprehensive assessments of cardiovascular function and inflammatory burden.

Part 2: Cross-Sectional Study evaluating cardiovascular risk in First Degree Relatives of patients with Rheumatoid Arthritis, Healthy Unrelated Controls and people with immunological markers of rheumatoid arthritis without clinical disease.  

In both parts of this study there will be a platform of assessments of articular inflammation, cardiovascular function and laboratory assessments. In addition to the routine assessments of inflammatory burden (clinical joint counts, ESR and CRP) musculoskeletal ultrasound will be used to detect subclinical joint inflammation.  The platform of cardiovascular assessments include endothelial function (EndoPAT), central arterial pressure indices, aortic stiffness (carotid-femoral pulse wave velocity) and carotid ultrasound (carotid intimal medial thickness and carotid plaque measurement). Participants will have a range of genetic and immunological tests and a sub-group will participate in studies of NETosis. 

Grants

Humira and Endothelial Function in Rheumatoid Arthritis - 2 (HEART-RA-2)

Funding body: Abbvie Pharmaceuticals

Funding body Abbvie Pharmaceuticals
Description

Interim analysis in Hunter HEART-RA-1 confirmed that endothelial function correlates inversely with inflammatory burden in patients with anti-CCP positive rheumatoid arthritis (RA). However, it appears that other disease-specific but non-inflammatory mechanisms may contribute to cardiovascular disease in RA. This might include genetic factors, abnormalities of lipid transport and newly described immune mechanisms such as NETosis. HEART-RA-1 also only evaluated patients with anti-CCP positive RA. 

HEART-RA-2 will consist of 2 parts:

Part 1, a randomised controlled trial will evaluate the effect of Humira upon endothelial function in anti-CCP antibody positive and anti-CCP antibody negative patients with RA. 

Part 2 will evaluate non-inflammatory mechanisms of cardiovascular disease by taking inflammation out of the equation. This will be done by studying people with Pre-RA i.e. who have evidence of RA on blood test of on ultrasound but no clinical evidence of RA.

Scheme Abbvie Investigator-Initiated Grant

Collaborators

Name Organisation
Professor John Richard Attia University of Newcastle
Professor Phil Michael Hansbro University of Newcastle

Edit

Research Collaborations

The map is a representation of a researchers co-authorship with collaborators across the globe. The map displays the number of publications against a country, where there is at least one co-author based in that country. Data is sourced from the University of Newcastle research publication management system (NURO) and may not fully represent the authors complete body of work.

Country Count of Publications
Australia 343
United Kingdom 41
United States 38
Canada 37
India 18
More...
Edit

News

Respiratory leader awarded TSANZ Fellowship

March 29, 2017

Professor Phil Hansbro has been awarded the title of Fellow of Thoracic Society of Australia and New Zealand

Protein implicated as key and common cause in respiratory illness

June 23, 2016

Hunter researchers have discovered a protein that induces both stiffening and inflammation in the airways of the lung, causing severe and chronic respiratory il

Newcastle Herald: Research links gut bacteria, disease treatment

September 21, 2015

A NEWCASTLE research team that’s used mice poo to treat asthmatic mice could be first in the world to show a link between gut bacteria and diseases throughout t

ARC Discovery Project funding success

November 19, 2014

Professor Phil Hansbro has been awarded more than $443,000 in ARC Discovery Project funding commencing in 2015 for his research project Elucidating the post-tra

NHMRC funding success

November 18, 2014

Professor Phil Hansbro and his team have been awarded over $1 million from the NHMRC to investigate modifying epigenetics as a novel treatment in COPD.

UON researcher awarded NHMRC Fellowship

September 2, 2014

UON researcher Professor Phil Hansbro received a prestigious NHMRC research fellowship for his project 'Development of new therapies for respiratory

‘transpoosion’ for a healthy gut

August 25, 2014

Professor Phil Hansbro's research on the devastating lung disease emphysema, and the role of the microbiome in the gut in this disease, was featured on the ABC'

Respiratory disease breakthrough

July 1, 2014

Researchers have discovered sinister specks of a molecule known as ASC that are exacerbating the biological inflammatory response in major airway diseases.

HMRI 2013 Awards Night

November 7, 2013

Respiratory researcher Prof Phil Hansbro has won the prestigious 2013 Award for Research Excellence

Newcastle researchers help in fight against STDs

March 1, 2013

Newcastle researchers have contributed to the discovery of a protein in the female reproductive tract that protects against sexually transmitted diseases

Professor Phil Hansbro

Position

Conjoint Professor
School of Biomedical Sciences and Pharmacy
Faculty of Health and Medicine

Focus area

Immunology and Microbiology

Contact Details

Email philip.hansbro@newcastle.edu.au
Phone (02) 4042 0187
Mobile 0427263084
Fax (02) 4042 0024

Office

Room HMRI 2406
Building HMRI Building
Location HMRI Building

,
Edit